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Abstract 
In recent years, there has been an upwelling in research into the aerosol systems 
projected for therapeutics that are conventionally not delivered via that route [1, 2]. 
The bioavailability of ibuprofen (IBP), a non-steroidal anti-inflammatory drug from 
the currently available dosage forms (oral and topical), is poor and these 
formulations are marketed with high dose which can produce significant adverse 
reactions in long term use [3-5]. This investigation aims to use IBP preparation by 
developing a controlled engineering method of producing fine (< 5 μm) crystals for 
pulmonary delivery from dry powder inhaler (DPI) formulation with very low dose. 
In the context of inhalation systems, IBP has been taken as a model drug.  
The techniques of producing respirable size (< 5 μm) particles for dry powder inhaler 
(DPI) formulations mostly involve crystallization followed by high energy input size 
reduction systems like milling and homogenization. Particles produced in such 
processes have a very high surface energy and poor flow property which restricts the 
efficient dispersal of the DPI in to the deep lungs.  
This investigation has used an anti-solvent precipitation crystallization (APC) 
method of producing fine IBP (< 5 μm) crystals for pulmonary delivery from DPI 
formulation with very low dose. In this process, the poorly water-soluble drug (IBP) 
was dissolved in a solvent (ethanol), and the solution was added into a miscible non-
solvent (water) with additives (HPMC, Pluronic F127, D-mannitol & L-leucine) 
under agitation. The crystallization method, solvent, anti-solvent and additives were 
selected based on the evidence reported in currently available literature.  
In the first phase of this dissertation, IBP solubility was investigated in the selected 
solvent-anti-solvent system, namely water-ethanol co-solvents at 10, 25 and 40 °C. It 
was found that the solubility of IBP increased considerably when ethanol contents 
were increased, and also increases with temperature. A correlation of fit of all 
measured data was established with published IBP solubility data at high aqueous 
ethanol (> 50 %). The experimental solubility data of IBP in the presence of 
additives as single component and in combination revealed the trend quantitatively.  
The results allowed calculation of the minimum amount of initial drug to be used to 
precipitate IBP and to determine the drug yield value after the precipitation 
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crystallization to produce fine (< 5 µm) IBP crystals for DPI formulations. The 
solubility investigation also revealed that Pluronic F127 and L-leucine enhance IBP 
solubility, whereas HPMC and mannitol show little or no effect. 
In the second phase of this research, the Plackett-Burman design revealed batch size, 
ultrasound and stirring speed as the significant process variables for particle size 
reduction in APC process. Optimised levels of temperature (25 °C), ultrasound (30 
minutes), stirring duration (> 20 minutes) and the additive concentrations HPMC 
(0.2%), Pl F127(1.3%), leucine (1.2%) and mannitol (8.6%) were determined to 
produce IBP particles with a volume median diameter of 3.9 ± 0.4 µm. 
In the third phase of this thesis, DPI formulations were prepared and characterized 
for density and flowability, size and aerodynamic diameter, crystallinity and drug 
dispersilibity in a twin stage impinger with respect to the composition, batch size and 
drug-additive concentrations. It was observed that the presence of leucine and 
mannitol in the formulation improved the flowability, lowered particle aerodynamic 
diameter and showed a higher percentage of FPF in the drug dispersibility test. 
Finally, all the formulation characterization results indicated that a high percentage 
of crystalline IBP phase in the formulation (by differential scanning calorimetry and 
X-ray diffraction) positively influenced the drug dispersibility in the in vitro 
aerosolization test. Surprisingly, the milled raw IBP powder dispersed a higher 
percentage of the drug due to the surface morphology (corrugated) than those of IBP 
particles produced in the APC process. 
The maximum drug release from milled pure IBP was 81 % after 90 minutes of 
dissolution, whereas from the prepared formulations F4, F6 and F10 were 100, 87% 
and 96% at 90, 60 and 60 minutes respectively. The dissolution profile indicated F4 
formulation achieves the 100% release of the drug and F6 formulation showed the 
faster dissolution which is 96% at 60 minutes comparing to other formulations. The 
outcomes of the dissolution test and the fine particle dose (FPD) of the prepared 
formulations (554 µg, 574.0 µg & 413.8 µg from the formulations F4, F6 and F10, 
respectively) indicated the future potential for inhalation to improve the IBP drug 
delivery by lowering the dose and increasing the bioavailability. Moreover, the faster 
dissolution performance of the prepared powder formulations will contribute to the 
development of other dosage form like tablet or capsule to achieve an improved 
bioavailability of IBP other than the currently marketed formulations.  
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 Introduction Chapter 1:
1.1 BACKGROUND 
The pulmonary delivery of drugs is an alternative to other dosage forms and it 
has been considered to be the most promising non-intrusive route of drug 
administration [6]. Pulmonary route has several distinct advantages such as direct 
drug delivery to the tracheobronchial tree followed by fast and predictable onset of 
action [7, 8]. As the gastrointestinal tract is avoided no degradation of the delivered 
dose occurs. Thus, lower dosages than by the oral route can be administered with 
similar efficacy which is expected to mitigate undesirable side effects [7, 8]. Finally, 
when two or more medications are administered alongside, pulmonary route can be 
adopted as an alternative to avoid the possible drug interaction [7, 8]. 
The lungs have a large surface area (100 m2), ultra – thin alveolar epithelium (0.1 - 
0.5 μm) and low-metabolic enzyme activity and therefore drug delivery via this route 
ensures rapid absorption and onset of action with a very low dose [9, 10]. Drug 
deposition in the lung is mainly controlled by the particle‘s aerodynamic diameter 
[11]. Particles larger than 5 μm are mostly caught by oropharyngeal deposition and 
are unable to reach the lungs while particles smaller than 1 μm are generally exhaled 
without deposition [12, 13]. To expedite successful delivery by a dry powder inhaler 
(DPI), nanoparticles are usually converted to nano-aggregates, having a larger 
geometric diameter (>10 μm) and low particle density (<1 g/cm3) due to their porous 
or hollow morphology, incorporating aerodynamic diameters within the 1–5 μm 
range [14, 15]. Alveolar or peripheral airways deposition of particles is critical 
because major drug absorption is possible in this region where the suitable particle 
size for deposition is 1-5 μm. So, the drug particles for deep lung delivery should 
have a narrow particle size distribution [16-18] in the range 1–5 μm. 
DPIs can be defined as the devices through which a dry powder formulation of an 
active drug is encapsulated and delivered for local or systemic effect through the 
respiratory tract. DPI formulations are basically categorized in two types.  In the first 
category, micronized drug particles with controlled flow property are formulated as 
loose agglomerates [19]. Another formulation type is the carrier-based interactive 
mixtures where micronized drug particles are adhered onto the surface of larger 
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carriers. This method is useful to increase the flow property of very cohesive 
micronized drug particles [19]. However, in case of carrier-based interactive 
mixtures, three main aspects are important for desired therapeutic effects. The  first 
step involves the detachment of drug particles from the surface of the large carriers. 
The second step is the dispersion of the detached drug particles during aerosolization 
by an inhalation device. Finally, resulting deposition of the drug particles in the 
lower airways of the lungs [20].  
In recent years, DPIs are taking over the arena in pulmonary drug delivery due to the 
apparent restrictions in metered dose inhalers (MDIs) and nebulizers. DPIs overcome 
the problems associated in the use of propellant gases and the requisite for 
coordination of inhalation and actuation in the use of MDIs. Moreover, DPIs are 
more handy and user friendly as spacers are not required [19]. The successful 
delivery of drug from DPI is comprised of the integration of drug formulations, 
design of the devices and patient‘s inhalation profile [16]. 
Most currently available carrier-based dry powder inhalers are comparatively 
inefficient, delivering of only 20 – 30% of the nominal dose to the lungs [21]. The 
sensitivity of the delivered dose at poor inhalation flow rates to particle adhesion and 
static charges are generally accountable for the low efficiency of the DPI 
formulations [22]. Subtle changes in powder characteristics such as size distribution, 
shape, surface roughness, surface energetic, electrostatics and other properties are 
suspected to be responsible for significant changes in powder cohesion/adhesion, 
mixing and flow [23-25]. This is the most challenging problems in pulmonary 
delivery. To overcome these problems direct controlled crystallization of the drug 
particle has been taken as a promising aspect. The challenge of particle size control 
in ibuprofen (IBP) crystallization techniques is that the product naturally tends to 
form relatively large crystals due to the advantage of growth over the nucleation 
mechanism [26].  
This study approaches to develop IBP microparticles (1 - 5μm) for DPI formulation 
produced by controlled crystallization process. The conventional micronization 
process (i.e. milling, homogenization) with high energy input incorporates 
undesirable particle shape, size, surface charge modifications, decreased crystallinity 
and possible degradation that limit the inhalation efficiency of DPI formulations 
[27]. It is expected that a controlled crystallization process free from high shear 
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milling using suitable additives would overcome limitations in producing IBP 
microcrystals suitable for DPI formulations. The drug particles produced by direct 
controlled crystallization are expected to be free flowing and of better surface 
properties and therefore will lead to a better inhalation efficiency profile from the 
DPI formulation.  
1.2 AIMS 
This project aims to develop an alternative functional and economic method of 
producing fine crystals (1–5μm) of the model drug IBP for pulmonary delivery from 
DPI formulations. The project has three objectives:  
 
 To investigate the IBP solubility profile in aqueous ethanol with the selected 
additives. 
 To manufacture IBP particles with a required size (< 5 μm) by using an 
optimized APC process. 
 To investigate the particle size, flow properties and surface morphology of 
the IBP particles produced and relate the outcome to the lung delivery of the 
drug.  
1.3 SIGNIFICANCE 
A crash precipitation crystallization technique mixing an organic solution of 
IBP with an aqueous solution containing additives (e.g. Pluronic F127 & HPMC) 
will produce nano/microcrystals [28]. The IBP recovery in this process is very high 
(near 100% of theoretical) which makes the process cheap and cost effective. 
However, the problem with this method is agglomeration of the crystals produced, 
giving a non-uniform and large particle size distribution. Though the use of additives 
addresses this problem to some extent, the problem has not been solved. The 
solubility of IBP in different compositions of the organic and aqueous phase with and 
without additives would provide the amount of IBP to be used and the degree of 
supersaturation for crystallization. IBP is very poorly soluble in aqueous media [29] 
and determining its solubility in highly aqueous ethanol solution will contribute to 
the knowledge. Figure 1.1 represents the overall project. 
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Figure 1.1 Steps in the project to develop the IBP dry powder inhaler formulation. 
The key objective of particle engineering is to integrate necessary characteristics for 
example required size range and narrow particle size distribution with an improved 
dispersibility. This study will use racemic IBP particles as a model drug, which will 
provide a unique opportunity to develop a novel DPI formulation for pulmonary 
delivery of IBP for better therapeutic applications. However, this technique could be 
used for other API to produce fine (~5 μm) particles of other drugs.  
Lately, inhalation therapy has remarked substantial bio-medical concern in the 
growth of innovative particle technologies for the dry powder inhaler (DPI) systems 
[22]. DPIs of the first generations, generally demonstrated a comparatively low 
efficacy (10-15%) in terms of the fine particle fraction (FPF) [30]. Many research 
efforts have looked to increase the percentage of fine particle fraction (%FPF) for 
DPI formulations of various drug products. No work has been done to make IBP DPI 
formulation with a one-step controlled crystallization technique to improve 
inhalation efficiency. This project results in the development of cost effective new 
DPI formulation strategies for lung delivery.  
Improvement in industrial crystallization knowledge is of great interest to the 
pharmaceutical API manufacturing industry, which is under pressure from the 
regulatory authorities to develop a much more scientific approach to pharmaceutical 
manufacture. Therefore, a one-step direct controlled crystallization technique is an 
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exciting prospect for producing drug particles with the required size (1–5 µm) for 
DPI formulation. 
1.4 THESIS OUTLINE 
 Outline of Chapter 2  1.4.1
This chapter reviews the literature on the anatomy of the pulmonary route of 
drug delivery, the mechanism of drug deposition into the deep lung, and different 
inhalation systems, and focuses on the lung delivery of drugs from a dry powder 
inhaler system. The existing particle engineering techniques and the challenges for 
dry powder inhaler formulations indicated that anti-solvent precipitation 
crystallization (APC) is promising, and its basic principles are demonstrated as the 
core methodology for this project. Then the selected additives used in this method 
are described in-depth in terms of their role in the particle manufacturing process. 
The chapter concludes with the justification for using IBP as the model drug in this 
project. 
 Outline of Chapter 3 1.4.2
This chapter describes the research methods used to achieve the aims and 
objectives stated in Chapter 1. IBP solubility was determined by the dissolution to 
equilibrium method, IBP concentration was determined by UV spectrophotometry, 
and the method of particle preparation suitable for inhalation was the APC process. 
Finally, the chapter describes the instruments and methodology used to characterize 
the prepared particles of the DPI formulation according to size, morphology, density, 
flow property, crystallinity and dispersibility in lungs. 
 Outline of Chapter 4 1.4.3
This chapter presents the initial investigation for the particle crystallization 
method development. The solubility of IBP was investigated in 0–50% of ethanol in 
water-ethanol co-solvents. The IBP solubility trend at three temperatures was 
determined and the correlations were compared with previous data at a higher 
ethanol range in previous work by Rashid [31]. Finally, the IBP solubility profile in 
water-ethanol co-solvents in the presence of selected additives (Pluronic F127, 
HPMC, L-leucine and mannitol) was determined and demonstrated. 
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 Outline of Chapter 5 1.4.4
Chapter 5 involves the investigation of variables affecting the size of the IBP 
particles from anti-solvent precipitation crystallization (APC). The chapter first 
describes the experimental set up of a Plackett-Burman design studying nine 
variables and screening out the most effective ones. Then the effect of individual 
excipients, Pluronic F127, HPMC, leucine and mannitol, on the particles‘ size is 
discussed. An optimised formulation for preparing IBP particles < 5 µm and the 
method validation was done by characterization of particle size in Malvern 
Mastersizer 3000, scanning electron microscope (SEM) and transmission electron 
microscope (TEM).  
 Outline of Chapter 6 1.4.5
Chapter 6 demonstrates the DPI formulation development and characterization 
for density and flowability, size and aerodynamic diameter, particle morphology, 
crystallinity and aerosol performance using the methods described in Chapter 3. The 
outcome of the characterization results was correlated with the effect of the batch 
size, additive composition and crystallinity on the aerosol and dissolution 
performance of the developed DPI formulations. 
 Outline of Chapter 7 1.4.6
Chapter 7 summarises all the outcomes obtained from the research work in 
Chapters 3, 4, 5 and 6. The significant research findings and analysis are specified. 
The benefits and importance of the proposed methods are summarised. Finally, 
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 Literature Review Chapter 2:
2.1 INTRODUCTION 
This chapter begins with the anatomy of the pulmonary route of drug delivery 
and the mechanism of drug deposition into the deep lung. Then the different 
inhalation systems are discussed with a focus on the lung delivery of drugs from a 
dry powder inhaler system. The literature review of the existing particle engineering 
techniques and the challenges for dry powder inhaler formulations are outlined in 
next section. The anti-solvent crystallization technique and its basic principles are 
demonstrated as the core methodology for this project. Then the selected additives 
used in this method are described in-depth in terms of their structural configuration, 
mechanism of action and role in the particle manufacturing process. The chapter 
concludes with the justification for using ibuprofen (IBP) as the model drug in this 
project. 
The pulmonary route of drug delivery is already a well-established route for treating 
respiratory diseases such as asthma and chronic obstructive pulmonary disease 
(COPD) [32]. More recently, this route of drug delivery is becoming attractive for 
commonly prescribed medications to reduce systemic exposure and decrease the 
associated side effects [33].  
Although promising, delivery of drugs to the respiratory tract is encountered by a 
number of anatomical and physiological challenges [34]. The process and 
development of  an inhalable formulation requires the knowledge of the 
physicochemical  properties  of the drug  formulation components and the biological 
features of the respiratory tract  [35]. So, this chapter will start with the mechanism 
of drug deposition into the deep lungs and its transport through the alveolar epithelia 
to the systemic circulation. 
2.2 BIOLOGICAL TRANSPORT MECHANISMS OF PARTICLES IN 
PULMONARY EPITHELIAL CELLS 
There are different particle uptake mechanisms in epithelial cells dependent 
upon the properties of cells and particles. Figure 2.1 shows the diagram of the 
transport mechanisms across bronchial and alveolar epithelial cells.  
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Figure 2.1 The mechanism of transport of microparticles after deposition on the (A) 
bronchial and (B) alveolar epithelium [35]. 
 
Before entering the epithelial cells, drug particles need to cross over the surfactant 
and mucus layers. The surfactant is the lung lining fluid comprising phospholipid and 
proteins. The mucus layer is a part of the mucociliary clearance system [36, 37]. This 
step is also aided by the alveolar macrophase and mucociliary escalator clearance 
systems. Alveolar macrophages act as the first-line host guard against the inhaled 
drug particles which are cleared from the alveoli to the bronchioles by the lining 
fluid and then by the mucociliary escalator [38]. The drug particle transport across 
these layers depends on the particle size, solubility, lipophilicity and charge [39, 40] 
which leads to the erosion and dissolution of the microparticles into the epithelial 
cells. 
The epithelial cells regulate the transport of compounds, retaining the structural role, 
barrier integrity and the cellular communications. There are multi-protein complexes 
known as tight junctions which tie the apical membrane of the epithelial cells. 
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Lipophilic compounds are believed to be absorbed through the cell membranes and 
hydrophilic molecules through the tight junctions by passive diffusion [41, 42]. 
Moreover, hydrophilic compounds like carbohydrates, amino acids, 
neurotransmitters and vitamins are also known to be transported by carrier-mediated 
processes.  
An active transport system uses cellular metabolic energy (e.g. sodium-potassium 
pump) and electrochemical gradient (coupled transport) to transport molecules across 
the cell membrane [43]. However, the active transporters in the lung‘s epithelial cells 
are believed to be responsible for affecting the residence time of drug molecules and 
uptake of drugs from the systemic circulations, causing pulmonary toxicity or the 
drug metabolism kinetics [44]. P-glycoprotein is considered to be the most notable 
transporter among the efflux transporters [35]. 
The receptor-mediated transport particularly involves the transcellular trafficking of 
biopharmaceuticals due to their large molecular size and poor permeability. 
Literature suggests that particles < 200 nm are mostly entrapped via clathrin-coated 
pits, while those > 200 nm are entrapped via caveolae-mediated endocytosis [45]. 
Macromolecules smaller than 40 kilodaltons in alveolar spaces are assumed to be 
absorbed through tight junctions and paracellular diffusion [46, 47]. 
The providence of an inhalation system is dependent on the physicochemical 
characteristics of the particle and anatomical structures of the pulmonary airways. 
Therefore, particle size plays  an important role to influence the depth of penetration, 
site of deposition and bioavailability of the drug in the respiratory tract [48]. The 
next section will discuss the effect of the particle size on its deposition mechanism 
within the respiratory tract. 
2.3 MECHANISMS OF PARTICLE DEPOSITION IN LUNGS 
Alveoli deposition of particles is critical, because major drug absorption is 
allowed in this region and the suitable particle size for alveolar (peripheral airways) 
deposition is 1-5 μm in aerodynamic diameter. So, the drug particles for deep lung 
delivery should have a narrow particle size distribution [16-18, 49, 50]. 
The particle deposition in the lungs can be defined in five different mechanisms. 
They are inertial impaction, sedimentation, diffusion, interception and electrostatic 
precipitation. The two last mechanisms are related to particle shape  and electrostatic 
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charges, respectively  [51, 52]. It is evident in the available literature that smaller 
particles delivered to the lungs are deposited in the smaller airways as opposed to the 
larger airways (Figure 2.2). 
 
Figure 2.2 The diagram represents particle deposition in the lungs according to 
different mechanisms related to particle size: inertial impaction, sedimentation and 
diffusion. [53]. 
 
The mechanisms of deposition directly (or inversely) related to particle size are 
presented in Figure 2.3, where, d: particle diameter; Stk: Stokes number; ρp: particle 
density; V: air velocity; η: air viscosity; R: airway radius; Vts: terminal settling 
velocity; ρa: air density; g: gravitational acceleration; Dif: diffusion coefficient; k: 
Boltzmann's constant; T: absolute temperature; dae: aerodynamic diameter; ρ0: unity 
density [49, 50]. 









Figure 2.3 The influence of particle size on deposition [50]. 
 
A recent study has shown that particle charge effects deposition substantially, 
especially for smaller sizes where the impaction mechanism of deposition is less 
dominant. An empirical dimensionless relation is suggested to predict average 
deposition in the mouth-throat that includes the three relevant dimensionless 
numbers: Stokes number, Reynolds number and induced charge number [54].  
The aerodynamic diameter, Dae is defined by the diameter of an equivalent volume 
sphere Deq of unit density with the same terminal settling velocity as the actual 
particle [55]. The following expression describes the relationship between these 
dimensions. 
       √
  
   
 
where ρp represents the particle density and ρₒ represents the unit density of the air 
where the particles are dispersed and χ is the dynamic shape factor. Any deviation 
from the sphericity is called the dynamic shape factor [50, 55]. Deq can be calculated 
using the volume mean diameter (D [4,3]) from the particle size distribution curves 
[56, 57]. 
In vitro determination of the aerodynamic size of inhaled medication can be done 
using cascade impactors or the twin stage impinger [58]. Usually, the aerosolization 
efficiency is evaluated in terms of different parameters, such as emitted dose (ED), 
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fine particle fraction (FPF), the geometric standard deviation (GSD) and mass 
median aerodynamic diameter (MMAD) [22]. 
MMAD is the median aerodynamic diameter (Dae) of the entrained particles based on 
mass [59, 60] and also refers to the particle size, in which 50% of the mass of the 
aerosol is smaller and 50% larger than the referred parameter [61, 62].  
2.4 PULMONARY DRUG DELIVERY SYSTEMS 
 The pulmonary drug delivery systems are commonly available in three dosage 
forms, the jet or ultrasonic nebulizer, metered–dose inhaler (MDI), and dry-powder 
inhaler (DPI). Nebulizers are not preferred for chronic drug treatment in the daily 
care of patients due to their administration and lack of portability. The pressurised 
MDIs were the most well-accepted inhalation system over decades due to the 
perceived ease of use [63]. But problems in the use of environmentally non-friendly 
propellant gases and the inherent difficulties in coordination of inhalation and 
actuation have created the need for developing new pulmonary drug delivery system 
to replace the propellant driven MDIs [64]. Dry powder inhalers (DPI) were 
premeditated with the aim of eliminating the limitations of MDI.  
2.5 DRY POWDER INHALER (DPI) SYSTEM 
DPIs deliver single doses of powder drug formulation contained in capsules 
that should be broken inside the device by patient‘s inspiratory flow before their 
administration [49]. They have several advantages over other pulmonary drug 
delivery systems; for example, direct delivery of the drug into the deep lungs 
utilising the patient‘s respiration [19], solid state stability of formulation, and no 
need to coordinate between inhalation and actuation. 
The main drawbacks of the DPI system are that patients perceive the drug entering 
the airway to a lesser degree. They should be kept in a dry atmosphere, as humidity 
instigates the powder agglomeration deterring the stability of the inhalation system 
[65].  
 Role of devices in inhalation efficiency of DPI system 2.5.1
The role of the device in DPI is to redisperse the interactive powder mixtures 
into fine drug particle fractions by aerodynamic means [64]. The function of the 
device can be altered by the resistance to airflow, that directly influences parameters 
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such as the peak inspiratory flow (PIF), flow increase rate (FIR), and the total 
inhalation time [66]. At present, a wide range of devices is available on the market, 
but the desired clinical efficacy has not been achieved yet. The future improvement 
on DPI devices will have to emphasis on simplicity of use, dependability, suitability 
for  products and doses variety, and most important on the cost-effectiveness  [64]. 
With increasing demand for the pulmonary delivery of the systemic drugs there is a 
potential scope for developing new DPI delivery devices [19]. 
 Role of patient’s inhalation profile in drug delivery efficiency of DPI 2.5.2
system 
The variability of the drug dosage to different age group patients, delivered by 
inhalation, is a key concern as an older patient‘s breathing capacity would be 
different to the younger ones. It has been found that older patients are unable to reach 
adequate inspiratory flow in devices with high resistance to airflow [67]. Therefore, 
the device–patient interface has been given special attention for pulmonary drug 
delivery, since the patients vary in their skill and training to use the inhalation 
product  [68, 69]. It has been demonstrated that, delivery of a drug either from DPI or 
MDI would be equally efficient if the inhalation technique is accurate [70].  
2.6 DRY POWDER INHALER FORMULATIONS AND CHALLENGES 
DPI products are formulated either as loose agglomerates of micronized drug 
particles with controlled flow property or as carrier-based interactive mixtures with 
micronized drug particles adhered onto the surface of large lactose carriers, which is 
used to increase the flow property of very cohesive micronized drug particles [19].  
Particle surfaces are key factors in particle interactions, stability, and ease of 
dispersion. Due the very small particle size (<5 μm) requirement of the inhalation 
system, the total surface area of the powder formulation is very large, which possess 
greater potential for charging, moisture uptake and influencing the van der Waals 
forces [55]. A small amount of moisture present will also bring about capillary forces 
[71]. These factors are mostly responsible for causing stability issues in a DPI 
system.  
 
In a study by Kaily et al. [72], it was found that carrier particles with higher 
elongation ratio (ER) can significantly increase the amounts of drug delivered to 
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lower airway regions [72]. They also found that, shape of carrier particles or the drug 
itself influenced the dynamics of drug dispersion and particles with different 
morphologies demonstrates different dispersive shear forces during the 
aerosolization [72]. 
The electrostatic charging behaviour of the drug product may also affect the dosing, 
aerosol performance and inhaler retention. So, a consistent charging of the drug in 
ambient conditions is desired from the dry powder inhaler preparation [54]. It is 
found that this electrostatic charging behaviour can be consistently maintained by the 
crystalline form rather than the amorphous form of the drug salbutamol sulphate, 
[73] and knowledge gained from the study may be useful for optimising the dry 
powder inhaler formulation development process. 
2.7 TECHNOLOGIES OF PARTICLE ENGINEERING FOR THE DPI 
SYSTEMS 
Most commercially available DPI formulations are shown to have low fine 
particle fraction (FPF), typically 10-30%, and research efforts have looked at 
conventional formations, particle properties and product performance to increase this 
low range of %FPF. The currently available mechanisms of preparing micronized 
particles for inhalation purposes are described in the following sections. 
 Drug micronization and powder blending limitations 2.7.1
Jet-milling micronization 
This is the most commonly used method to get particles with inhalable size for 
DPI formulations. Nevertheless, micronization by milling requires high energy,  
excess duration of time and may produce contamination [27]. It also results in 
undesirable particle shape, size, decreased crystallinity and resulting instabilities 
from degradation, and therefore could be unsuitable for some DPI formulations [74, 
75]. Moreover, during the milling micronization processs, the particles are not grown 
in natural process because it cleaves at the crystal face with little attachment energy 
on the surface [76]. A number of studies have been undertaken to investigate the 
influence of the primary crystallization and micronization of active pharmaceutical 
ingredients for dry powder inhaler formulations. The study by Kubavat et al. [77] 
shows that in different crystallization conditions the %FPF of budesonide was not 
more than 9.7 ± 0.3%, which is negligible in respect of dry powder inhalation 
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efficiency. So, it was concluded that mechanical micronization of the material after 
crystallization may affect their interfacial characteristics and dispersibility of the 
carrier based DPI formulations [77]. 
Air-jet micronization 
 Shur et. al. [78] used air-jet micronization to process anhydrous and 
monohydrate ipratropium bromide (IB) crystals and investigated the effects on the  
aerosolization performance in dry powder inhaler (DPI) formulations. The 
physicochemical and surface interfacial property data derived from the cohesive-
adhesive balance (CAB) approach were correlated to the in-vitro aerosolization 
performance. The percentage FPF of the monohydrate and anhydrous IB 
formulations was 22.6 ± 1.3% and 23.3 ± 0.8%, respectively [78]. Therefore, no 
improvement in the inhalation efficiency was found on subsequent micronization of 
anhydrous ipratropium bromide crystals produced by using supercritical fluid 
technology and ipratropium monohydrate crystals produced by seed crystallization. 
2.8 CONTROLLED CRYSTALLIZATION OF DRUG CARRIER TO 
IMPROVE THE INHALATION EFFICIENCY OF DPI 
To improve the flow property of the dry powder inhaler formulations, various 
strategies have been applied for the modification of the drug carrier particles as well 
as to increase the FPF. A number of studies have been undertaken on the drug 
salbutamol sulphate using different carrier molecules produced by different 
engineering techniques [79-81]. Likewise, conventional anti-solvent crystallization 
with mechanical agitation [82] was investigated for the crystallization of lactose and 
use of the crystals to improve the dispersion and disaggregation of salbutamol 
sulphate. But a respirable size was not obtained, due to the poor mixing which gave 
heterogeneous growth of crystals, and to variations in the particle size and 
morphological features; for example, prismatic, pyramidal and tomahawk-shaped 
crystals were observed. 
Unlike the lactose molecules or other sugar particles, surface modified biodegradable 
polymer microparticles of polycaprolactone (PCL) have been investigated as carriers 
for a dry powder inhaler formulation [60, 83]. This work explored the aerosolization 
profile of salbutamol sulphate (SS) from mixtures with polycaprolactone (PCL) 
microspheres and  polyvinyl alcohol (PVA) pre-coated with magnesium stearate and 
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leucine [83]. However, the overall improvement in the FPF was not sufficiently 
significant compared with conventional DPI formulations. 
The effect of particle size of an ideal carrier with uniform physical properties on the 
dry powder inhaler performance was investigated by Kaialy et al. [84] and it was 
concluded that if the carrier morphology, shape, true density and the solid carrier has 
a uniform spherical shape, the size of the carrier does not influence the dry powder 
inhaler performance significantly. 
2.9 CONTROLLED CRYSTALLIZATION OF THE DRUG TO IMPROVE 
THE INHALATION EFFICIENCY OF DPI 
At present micron-sized near-spherical particles in inhalable size are often 
prepared by spray-drying of a drug solution [85]. However, this technique can result 
in an amorphous product which is then thermodynamically unstable and could be 
susceptible to absorb moisture, to form agglomerates or to recrystallise on storage. 
An amorphous product may not flow well and eventually affects the FPF [85-87].  
On the other hand, when melt sonocrystallization [88] was used, the product was 
unsuitable for inhalation due its larger size (100 μm to 1.1 mm) and unsuitable 
hardness and density. The concept of micro crystallization [89, 90] has been used in 
producing α-lactalbumin, using PEG-8000 as a stabilizer to overcome milling 
induced problems. The roughly spherical microcrystals were between 1 to 2 μm. 
Tests in pulmonary delivery showed the highest deposition was 36.3%, which is still 
a low level of FPF.  
A seed zone crystallization method [90] was used for an insulin micro-crystallization 
process at pH 10.5, using an excess amount of seed in a supersaturated solution. But 
the crystals produced were too large (up to 20 μm) for pulmonary use. Microscystals 
of fluticasone propionate (FP) and salmeterol xinafoate (SX) from PEG solvents 
were prepared by aqueous crystallization. The highest FPF was 25.7 ±1.5%, which 
resulted from the formulation of fluticasone propionate (FP) microcrystals with the 
largest median diameter (FP PEG 400B: 6.1±0.2 mm), which is still considered to 
give a low efficiency of inhalation [91]. 
Rasenack et. al. [16, 92, 93] first introduced the direct controlled crystallization 
process for hydrophobic drugs to get respirable size range particles using antisolvent 
precipitation employing hydroxylpropylmethylcellulose (HPMC). The precipitated 
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drug crystals (budesonide, prednisolone, fluticasone and disodium cormatogycolate) 
exhibited a higher FPF than jet milled samples, for example: in the case of 
beclomethasone-17,21-dipropionate (BDP), the FPF of jet milled drugs was 9.5%, 
which increased to 25.6% by micro crystallization [94]. But the use of tailor made 
non-volatile additives can be highly restrictive due to toxicity issues, and the 
increased FPF was still not satisfactory. In addition, spherical agglomerates (200-300 
μm) were produced using a conventional anti-solvent crystallization technique 
without additives, so the particles were deagglomerated by mixing with lactose. The 
results showed that the FPF was increased 2-3 times more than that of micronised 
materials [95, 96]. However, depending on the drug molecules, spherical 
agglomerates might not deagglomerate properly and the final FPF might be affected. 
A reactive precipitation crystallization technique was used for the protein molecule, 
sumatriptan succinate, without additives and followed by spray drying, and it gave a 
FPF value over 50% [96, 97]. However, depending on the drug compounds, spray 
drying may produce powders that are amorphous and hence physically unstable. 
A spray drying method was applied to produce inhalable insulin powder suitable for 
dry powder formulation and it was capable of producing 83.6% FPF, [98] but the 
drug product is yet to be evaluated by the drug agency for market authorization.  
These methods, however, exhibit some key issues like the presence of polymeric 
stabilising excipients on the surface of the particles that contributes to its amorphous 
content [92]. Ragab et al. [99], prepared progesterone crystals by antisolvent 
precipitation/ combined cooling and antisolvent crystallization from a water-
isopropanol (IPA) mixture. He observed a significant effect of the antisolvent 
addition rate, initial drug concentration and the solvent composition of the 
crystallization process on the aerosol performance of progesterone microcrystals. 
Hence, the particle size for pulmonary deposition was possible to prepare and control 
by the process parameters alone. However, in the majority cases, the high size of the 
particles indicates a large portion would be unsuitable for pulmonary delivery [99]. 
In the case of the IBP crystallization, it was attempted to control the process 
parameters to achieve the desired narrow size distribution of particles (1-5 µm) in 
one step. 
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2.10 ANTISOLVENT PRECIPITATION CRYSTALLIZATION (APC) FOR 
DPI FORMULATION 
Conventional crystallization processes mostly produce larger particles (>10 
µm) which are not suitable for inhalation. As was discussed earlier, jet-milling 
micronization process requires high energy input that induces, several 
physicochemical instability of the product due to the contamination arising from the 
mechanical attrition during milling. Henceforth, a high-gravity precipitation (HGCP) 
technique has been used to produce salbutamol sulphate as a model anti-asthmatic 
drug, followed by spray drying [97]. The rotating packed bed (RPB) used in the 
HGCP method was the key component to producing particles within inhalable size 
range without using additives (Figure 2.4) [100]. 
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Figure 2.4 Schematic diagram of (a) the RPB and (b) the reactive HGCP process 
(re-drawn)[101]. 
 
A simple combination technology was used to prepare DPI formulation of 
salbutamol sulphate involving anti-solvent sonocrystallization followed by spray 
drying by Muhammad and co-workers (Figure 2.5) [102].  
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Figure 2.5 Schematic diagram of sonocrystallization technique (re-drawn) [102]. 
 
However, in both processes, spray drying was used for particle recovery which has 
been reported to produce amorphous powder leading to physical instabilities [97]. A 
limited number of studies report that the APC process has not been used so far to 
prepare a DPI formulation without involving a spray drying step. Moreover, 
according to recent reports, the method of particle recovery produced in the APC 
process by a suitable drying process is a challenge yet to overcome. 
2.11 CRYSTALLIZATION 
Crystallization is the process by which atoms, ions or molecules assemble to 
pack into an ordered three-dimensional arrangement under definite settings. 
Crystallization is driven by the excess concentration in solution above the solubility 
limit, which in solution equates to supersaturation. Hence it is necessary to know the 
solubility of a crystallising material in the solvent used.  
 Solubility and supersaturation 2.11.1
The solubility, C*, is defined as the amount of solute that can dissolve at 
equilibrium in the solvent to make a solution saturated at fixed conditions of 
temperature, pressure and pH. Supersaturation is a very important parameter in the 
crystallization processes. A supersaturated solution is one where the concentration of 
the dissolved solute exceeds the equilibrium. Supersaturation, which is the driving 
force for the nucleation and crystal growth processes, can be produced in a number 
of ways once a solvent is chosen. These include: 
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i) Solvent removal by evaporation or extraction. This is very useful 
when the solvent is non-aqueous and has a relatively high vapour 
pressure.  
ii) By cooling or heating the solution depending on the solubility change 
with temperature. However, in many cases, this technique does not 
work if the solubility of material changes very little over the 
temperature ranges of interest, or if the solubility remains high at low 
temperatures.  
iii)  Salting out, by changing the properties of the solvent by the addition 
of a salt, an acid/base or an anti-solvent. Very good mixing is required 
for this method.  
iv) Precipitation, when two soluble materials are mixed together in a 
solution that reacts quickly to form a product of low solubility. Since 
the solubility of the product is quickly surpassed, the solution reaches 
supersaturation and the material crystallizes [26].  
Figure 2.6 shows the phase diagrams from the different crystallization techniques. It 
also shows how supersaturation is created and the relation between concentration, 
solubility and supersaturation ratio S = c/c*. 
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Figure 2.6 The phase diagrams, solubility lines, and operating points for the 
different crystallization techniques: 
(a) evaporative crystallization; (b) cooling crystallization; (c) antisolvent 
crystallization; (d) precipitation [103]. 
 
 
 Anti-solvent (water) precipitation process of crystallization: 2.11.2
Basic principles 
Precipitation is comprised of a number of main steps: chemical reaction 
following supersaturation, nucleation, solute diffusion and particle growth [104]. The 
nucleation rate (dN/dt) can be correlated empirically with supersaturation as 
𝑑 
𝑑𝑡
   ( 𝑖 − 
 )       (2.1) 
 
where Kn is the solute nucleation constant, Ci and C
* are the solute concentration on 
the particle surface and saturation concentration, respectively.  
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The diffusion rate of solute to the particle surface is 
𝑑 
𝑑𝑡
  𝑑( −  𝑖)       (2.2) 
 
where Kd is the solute diffusion rate constant and C is the bulk solution 
concentration. The growth rate of particle is 
𝑑 
𝑑𝑡
   ( 𝑖 − 
 )       (2.3) 
 
where Kg is the particle growth rate constant. The value of ‗b‘ is usually between 1 
and 3, and usually increases with temperature [105]. 
Particles in the nano-size range can be obtained by rapid micro-mixing of reactants to 
enhance nucleation while minimising the time for particle growth.  
Eqs. (2.1) – (2.3) indicate that both the nucleation and particle growth depend on the 
level of supersaturation which needs to be controlled in various processes such as  
supercritical fluid, high-gravity, ultrasound, limited impacting jets or vortex mixing 
[105]. 
 Crystal structure of ibuprofen (IBP) 2.11.3
During crystal formation, growth units (molecules, atoms or ions) prefer to 
pack into a vacancy in the exposed crystal lattice rather than form a new lattice layer. 
So crystals generally have plane faces linked to the inherent crystal lattice directions. 
Due to the difference in the growth rates of these faces, the sizes of the faces may 
change, resulting in different shapes (morphologies) for the crystals, but the angles 
between these faces are unique. Therefore, crystals are usually classified into systems 
based on three unique bond angles (α, β, γ) and three relative distances a, b, c in the 
directions of the chosen x, y and z axes. The smallest repeating lattice unit is known 
as the unit cell [106, 107].  
Common racemic IBP contains an equal number of molecules of each enantiomer. 
But it is known the S(+) enantiomer has a different size of unit cell (cell dimensions 
a, b, c) and different space group from the racemic form [108]. The RS (±) racemic 
and S (+) form of IBP belong to the monoclinic system. Figure 2.4 illustrates 
molecular structure obtained from neutron diffraction refinement of X-Ray 
diffraction of single IBP crystal. The structural data are reported in Table 2.1 




Figure 2.7 The molecular structure of IBP [109]. 
Table 2.1 Crystal structure of racemic and S-(+) form of ibuprofen [108, 110-113] 
 
Parameter RS(±) ibuprofen S(+) ibuprofen 
Formula C13H18O2 C13H18O2 
Molecular weight 206.3 206.3 
Crystal system Monoclinic  Monoclinic  
Space group P21/c P21 
a[Å] 12.67 12.46 
b[Å] 7.88 8.03 
c [Å] 10.73 13.53 
ß[°] 99.3 112.95 
No. of molecules in the cell 4 4 
Density [g/cm3] 1.110 1.098 
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2.12 IBUPROFEN (IBP) CRYSTALLIZATION PREDICTION MODEL 
FROM HIGH ETHANOL SOLUTIONS 
A crystallization chart for IBP in aqueous ethanol at 25°C has been generated 
and shows all the major properties required for a crystallization study. It is based on 
the results found by Rashid [26]. For 25°C, it shows: (i) the solubility; (ii) the 
metastable limits (for selected induction times); (iii) the growth rates; and (iv) the 
nucleation rates. The following sections will explain how Figure 2.8 was prepared.        
 
 
Figure 2.8 Enlarged crystallization diagram for ibuprofen (I) – ethanol(E) – 
water(W) at 25°C, showing the solubility curve and secondary nucleation threshold 
(SNT) lines (for various times). Also shown are growth rates (in m/min) and 
nucleation rates (as #/min/g slurry). The nucleation rates are zero below the SNT. 
The lines ABCD correspond to a possible process for producing fine ibuprofen 
crystals. Water is added to a saturated solution of ibuprofen in ethanol (A) to give 
point B (above the nucleation limit) where nucleation (and growth) will occur. The 
supersaturation may fall a little (C) then ethanol is added to bring the solution back 
to a very low growth rate region (D). 
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The plot shows superimpositions on the phase diagram. This original plot from [26] 
has been enlarged to show details in the metastable zone. Also to put the new plot on 
a compatible basis for future work, the water concentration needed to be put on the 
same basis as the solubility. Now X’W = W/E is used instead of the previous XW = 
W/(W+E), where W is water and E is ethanol by weight. The range of X’W from 0 
to 0.3 was chosen as being the likely region for practical crystallizations. This 
allowed I/E (where I = ibuprofen) to run from 0.4 to 0.65 (Figure 2.8). Details of the 




The 25°C solubility data of [26] are shown as the points on the plot. This data has 
been fitted using TableCurve 2D and the selected equation is 
 
 ln(I*/E) = 4.576 – 5.362*( X‘W) – 5.208*exp(-X‘W)   [2.4] 
 
where I*/E is the solubility. This is the solubility curve shown in Figure 2.8. The 
three parameters of equation 2.4 have 95% uncertainties about ± 3%. The equation 
fits an estimated 95% of the I*/E data points within ± 0. 5%. 
 
ii. Secondary Nucleation Threshold (SNT) 
 
The 25°C SNT data of Rashid [26] has been refitted by exponentials to give the 
correlation 
 
 SNT  = 0.144*exp(-XW/0.117) * exp(-t/1.1)   [2.5] 
 
where SNT is the supersaturation [as (I/E) = (I/E)SNT – (I*/E)] at which a solution, 
containing water with a solvent concentration XW = W/(E+W), just nucleates at time 
t hours. The parameters have a 95% uncertainty of about ± 20% and the correlation 
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fits an estimated 95% of the data within ± 0.02 units of I/E. The fit of the correlation 
to the data is shown in Figure 2.8. SNT curves at selected induction times are shown 
in Figure 2.9 [26]. 
  
   
Figure 2.9 SNT supersaturation (on log supersaturation scale) against induction 
time, based on the data of Rashid [26]. The horizontal lines joining the pairs of 
experimental points have been omitted. 
 
iii. Growth rate 
Rashid [26] gives the following correlation for the growth rate at 25°C as a function 
of supersaturation s [as (I/E) = (I/E) – (I*/E)] and water content XW = W/(E+W) 
G = 9.657 * exp[1.95 * XW]* s    [2.6] 
where G is the growth rate of a volume median size crystal in m/min. The 
parameters have a 95% uncertainty of about ± 25% and the correlation fits an 
estimated 95% of the growth data within ± 40%. Rashid [26] showed that IBP 
crystallising from aqueous ethanol shows growth rate dispersion (GRD). For 
nucleated IBP crystals, the distribution is log normal in shape with a CVG (= standard 
deviation/ mean) of ~ 0.5. 
A procedure is needed for generating the constant growth rate lines (series of I/E vs. 
X‘W points) for Figure 2.8. An XW (i.e. X‘W) value can be chosen for a selected G 
value. From equation 2.6 the supersaturation s can be evaluated. From equation 4 the 
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solubility can be calculated and adding s to it gives the required solution I/E 
concentration. Lines of selected constant growth rate are shown in Figure 2.8. 
iv. Nucleation rates 
 
Rashid [26] gives the following correlation for the secondary nucleation rates at 25°C 
in a seeded suspension where the solution has a supersaturation s 
B = 1.73 × 105 *exp [-XW/0.12 ] *s  for s > sSNT    
B = 0    for s < sSNT   [2.7] 
 
where B is the nucleation rate in #/min/g of the slurry. The nucleation rates are low. 
Equation 2.7 is not a very well defined correlation. The parameters have a 95% 
uncertainty of about ± 80% and the correlation fits an estimated 95% of the measured 
B data within a factor of 3. 
The procedure for calculating curves of constant B is the same as that given above 
for G, except equation 2.7 is used instead of equation 2.6. The predicted nucleation 
curves for selected nucleation rates are shown in Figure 2.8. 
 Predicted crystal contents 2.12.1
The crystal content (mass of crystal per g of slurry) CC is calculated by 
 
CC =  /6 C N 3   [2.8] 
 
where C is the crystal density, N is the number of crystals present per g of slurry, 3 
is the third moment of the size distribution 3 =  L
3 F(L) dL, L is crystal size (as 
volume equivalent size) and f(L) is the number size distribution function. For the 
simplified processes considered, we will take N = B*t, where B is the nucleation 
rate, t the time the solution is held at that nucleating rate and 3 = Lm
3*F, Lm is the 
volume median size of the crystals and F (here taken as 2) a correction factor for the 
distribution shape.  
From the data in Figure 2.8, Figure 2.10 shows estimated crystal contents as a 
function of the selected water content of the solution. The parameter is the 
concentration of the initial solution (as w/w I/E) which does not have a great effect, 
except to allow operation at lower X’W values, giving higher nucleation rates. Values 
have been restricted to operation above the t=0 SNT curve and initial solutions below 
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the t = 60 min SNT curve, so solutions can be prepared without nucleation. Growth 
times are those required to give a 3 m volume median crystal size. 
  
 Figure 2.10. Predicted crystal contents from crystallization processes. 
The estimated CC values were ridiculously small (< 1 ppm, which would not even be 
observable). To get a viable process, nucleation rates will need to be at least three or 
four orders of magnitude larger. This model was developed to produce IBP crystals 
in inhalable size. However, the predicted crystal content model showed that the 
process is not suitable, as the yield value is below the practical range. Hence, this 
process established from the solubility data from Rashid [26] could not be used for 
this work. 
2.13 IBUPROFEN (IBP ) PARTICLE SIZE REDUCTION TECHNIQUES 
FROM CURRENT LITERATURE 
IBP has been used as a model drug to produce particles of micro and 
nanometer range by the rapid expansion of supercritical solutions (RESS) method, 
but critical conditions (temperature and pressure) and the complicated plant set up 
make it less suitable for bulk production [114]. Another combinative particle size 
reduction technology, based on solvent-antisolvent precipitation coupled high 
pressure homogenization (HPH), was adopted to produce IBP nanocrystals by Sinha 
and co-workers [115] in nanosuspension form. The generation of small crystals 
(nano-crystals) by crash nucleation of IBP has been proposed by Khan [28] with the 
use of the additives Pluronic F127 (Pl F127) and HPMC (hydroxypropyl 
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methylcellulose) respectively to restrict crystal growth and prevent agglomeration. 
Solvent diffusion and melt emulsification methods have also been used to produce 
IBP nanosuspension with polyvinylalcohol (PVA), polyvinylpyrrolidone (PVP) K25, 
Pluronic® F68, Tween 80 [116]. Verma and co-workers produced nanosuspension of 
IBP using sodium lauryl sulfate (SLS), PVP K30, Pluronic® F68, F127, Tween 80, 
HPMC in precipitation and microfluidization methods [117]. These studies focused 
on investigating the feasibility of the nanosuspension formulation for oral 
administration. IBP was also studied to develop the formulation for inhalation in 
aerosol suspension [118] and nebulizer dosage form [119]. However, it was 
evidenced in many reports that liquid dosage forms are very likely to show physical 
and chemical instability, caused by particle agglomeration and crystal growth in the 
Oswald ripening process [120]. In the case of pulmonary drug delivery, particle 
agglomeration could be a major issue, since it affects the amount of drug deposition 
in the site and thus the formulation efficacy [51]. Table 2.2 shows a summary of the 
recent literature for IBP nanoparticle preparations. 
 Chapter 2: Literature Review 31 
Table 2.2 Literature summary of IBP nanoparticle preparations. 
 







Solvent diffusion, melt 
emulsification 
NA Water Polyvinylalcohol (PVA), 
Polyvinylpyrrolidone (PVP) K25, 
Pluronic® F68, Tween 80 
Nanosuspension [116] 
Precipitation, microfluidization NA Water Sodium lauryl sulfate (SLS), PVP K30, 
Pluronic® F68, F127, Tween 80, HPMC 
Nanosuspension [117] 
Evaporation-condensation Inhalation Argon+vapor None Aerosol 
suspension 
[118] 
Self-nanoemulsufication Inhalation Oil-in-water Tween 80,Cremophor RH 40, Transcutol 
P, Capryol 90, Polyethylene glycol (PEG) 
400 
Nebulizer [119] 
Rapid expansion of supercritical 
solutions (RESS) 
NA Supercritical CO2 NA Precipitated 
powder 
[114] 
Supercritical Antisolvent (SAS) NA Supercritical CO2 Poly L-lactic acid (PLA), Eudragit L100 Precipitated 
powder 
[121] 
Anti-solvent precipitation  NA Aqueous ethanol Hydroxypropylmethylcellulose (HPMC), 
Pluronic F127 (Pl F127) 
Nanosuspension [28] 
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The literature in Table 2.2 shows that many researchers prepared IBP nanoparticles 
but none have investigated its feasibility as a dry powder inhaler formulation. Our 
research will attempt to produce IBP particles using an anti-solvent precipitation 
crystallization (APC) process by controlling particle size in the presence of additives. 
In most of the literature given in Table 2.2, the yield value of drug particles is very 
high (> 90%) in anti-solvent precipitation crystallization methods [18, 122, 123]. 
Moreover, Pl F127 and HPMC polymers have been successfully used as particle 
growth and agglomeration inhibitors in several formulation preparations [28, 117]. Pl 
F127 and HPMC polymeric additives were selected to control the IBP particle size in 
the anti-solvent precipitation crystallization process in the present work.  
 Precipitation techniques 2.13.1
Basically, in the antisolvent precipitation process, the solution of a poorly 
water-soluble drug, generally in an organic solvent is added into a miscible non-
solvent or an aqueous solvent under agitation. A rapid high supersaturation occurs 
resulting in fast nucleation and precipitation (Figure 2.11). This method simply takes 
advantage of the change in the solubility of the same drugs in different but miscible 
liquids. However, due to the agglomeration tendency of the drug particles, it is hard 
to inhibit growth, which brings problems in production. Stabilizers/additives need to 
be added to the solvent or non-solvent phases to limit the particle growth and 
produce stable drug particles with desired size by the adsorption of the stabilizer at 
the particle surface in a fixed orientation [122, 124]. An illustration of the driving 
mechanism for the antisolvent precipitation (AP) process is shown in Figure 2.11. 
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Figure 2.11. Representation of antisolvent precipitation (AP) of drug particles in the 
presence of amphiphilic stabilizers. Re-drawn from Matteucci et al. [122] 
 
Optimization of the stirring rate, solvent-antisolvent ratio, drug content and 
temperatures are  required to obtain uniform size nanoparticles in the AP process 
[125]. The drug precipitates as micro- or nanoparticles and the resulting dispersion is 
called a hydrosol [126]. A larger volume ratio of antisolvent to solvent leads to a 
higher supersaturation and rapid nucleation. But, a moderate drug content is 
considered, because a higher drug concentration will obstruct the diffusion process 
resulting a non-uniform supersaturation and also will increase the tendency of 
particle aggregation [127]. A lower temperature generally favours the decrease of 
particle size. This technique is cost-effective, avoids the use of high energy, increase 
the solubility and  also enhance the drug dissolution rate due to the formation of 
slightly amorphous state [128, 129].  
2.14 ROLE OF ADDITIVES IN CONTROLLING CRYSTAL GROWTH 
It was mentioned that uncontrolled crystal growth and the particle aggregation 
are significant drawbacks for the anti-solvent APC process. Different parameters like 
stirring rate, the volume ratio of anti-solvent to solvent, temperature, drug solution 
addition rate and so on may be optimised, but the desired particle properties may still 
be out of reach. Use of additional substances (additives) in the anti-solvent 
crystallization system has been successful in inhibiting crystal growth and alleviating 
particle aggregation [130].  
Additives can be classified into two types, tailor-made additives and polymeric 
additives where the first ones are not preferred due to their potential toxicities [131]. 
On the other hand, polymeric additives have been used conveniently in different 
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types of crystallization processes in different studies [123, 130, 132]. In the 
inhalation field, only excipients generally recognized as safe (GRAS) can be used 
[133]. The additives used in this work are already established as safe excipients for 
various pharmaceutical preparations, and Figure 2.12 presents the molecular 





n= degree of polymerization, R= -H; -CH3;  (CH2CH (CH3) O) H; or -





Figure 2.12 Molecular structures of additives used in this study a) Pluronic F127, b) 
HPMC, c) D-mannitol and d) L-leucine. (Drawn using Chemdraw Pro 11). 
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 Crystal growth inhibitor: Pluronic F127 (Pl F127) 2.14.1
Pluronic F127 (Pl F127) (Figure 2.12a) is a triblock copolymer containing a 
hydrophobic propylene oxide (PO) polymer unit in the middle of two hydrophilic 
ethylene oxide (EO) polymer units. Literature reports suggest that a larger molecular 
weight with a more hydrophobic group in the polymer chain is suitable for inhibiting 
the growth of non-polar surface drug molecules like IBP [134]. Moreover, the 
quantitative effect of the Pl F127 in the growth of IBP crystals in anti-solvent 
precipitation process was investigated by Vetter and co-workers [124]. It was 
observed that the growth mechanism was surface integration controlled and the 
presence of the surfactant polymer reduces IBP crystal growth by its surface active 
properties. It was seen that the polymeric additive adsorbs isotropically on the 
surface of the crystals which hinders the diffusion of solute molecules resulting a 
slower rate of crystal growth. It was also shown that the Pl F127 used in the 
crystallization process is not incorporated into the structure of the crystals [124]. It 
has been reported that a mixture of surfactant Pl F127 and HPMC had a dual action 
of enhancing dissolution rate and inhibiting crystallization of the poorly aqueous 
soluble drug felodipine [135]. IBP as solid dispersions with poloxamer 188, 
poloxamer 407 (Pl F127) [136] and in combination with HPMC is reported to have 
enhanced bioavailability [137]. A possible explanation of this is that IBP-Pl F127 
(1:10) solid dispersion systems might be completely miscible in the liquid state and 
immiscible in the solid state [138]. They crystallised out at once as micro-fine 
crystals from the liquid mixture, resulting in increased IBP surface area and 
enhanced dissolution rate [139, 140]. So, the improvement of solubility and the 
dissolution from the solid dispersions may be credited partially to the decrease in 
particle size in IBP crystalline state due to the presence of poloxamer 407 or Pl F127. 
In addition, a part of the drug might also have existed in a partial amorphous form 
[141]. Therefore, taking account of the evidences of solubility enhancement and 
growth inhibition role from available literature, Pl F127 was selected as a potential 
effective additive for the present study.  
 Agglomeration inhibitor and stabilizer: HPMC 2.14.2
 Hydroxy propyl methyl cellulose (HPMC) is a large molecular non-ionic 
stabilizer and can adsorb onto IBP particles due to the interaction of the hydrophobic 
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(methoxyl) and hydrophilic (hydroxypropyl) groups (present in the polymeric chains 
(Figure 2.12b)) with the IBP surface [117]. Growth inhibition occurs based on the 
presence of a hydrodynamic boundary layer surrounding the crystal and aniso-tropic 
adsorption of the polymer on the growing crystal faces. Moreover, the non-adsorbed 
polymer molecules are not washed away but gather at the boundary region (Figure 
2.13). Thus, provides higher resistance for drug molecules to diffuse through the 
barrier,  perhaps resulting the growth inhibition. HPMC contains a large number of 
hydrogen bonding functional groups which is assumed to inhibit the crystal growth 




Figure 2.13 Schematic diagram showing the mechanism of growth inhibition and 
habit modification of crystals by polymers [142].  
 
HPMC was successfully used as a stabilizer at a very low concentration (0.1%) 
dissolved in the anti-solvent phase due to its hydrogen bonding potential for IBP 
nanocrystal preparation in a cavi-precipitation process [115, 143]. Terebetski and co-
workers investigated the physical role of HPMC in nucleation and crystal growth of 
IBP sodium by the dissolution method to assess the degree and extent of 
supersaturation [134]. It was shown that intermolecular hydrogen bonding between 
IBP and HPMC was driving supersaturation by delaying nucleation and crystal 
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growth of the thermodynamically stable crystalline free acid [134]. Another poorly 
water soluble drug, naproxen, was stabilised by HPMC and nanosuspensions were 
prepared by an optimised precipitation-ultrasonication process [144]. However, an 
increase in particle size was observed with an increase in HPMC concentration due 
to the deposition of concentric layers of HPMC on the drug surface [144]. It was also 
reported that the enhanced viscosity of the solution hindered the ultrasonic energy 
and obstructed the diffusion between the solvent and anti-solvent during 
precipitation, resulting in larger particle formation due to Ostwald ripening [144]. 
Therefore, the optimum HPMC concentration for the proposed anti-solvent 
crystallization (APC) of IBP was important to achieve the desired particle growth 
and agglomeration inhibition in the process. 
 Cryoprotectant, carrier and bulking agent: D-mannitol 2.14.3
D-Mannitol (C6H8OH6) (Figure 2.12c), a hexahydric alcohol, has been largely 
used as a carrier and a bulking agent for freeze-dried pharmaceutical preparations 
[145]. Tee and Marriot, Steckel and Bolzen, and Saint-Lorant and Leterme reported 
its potential use as a carrier for aerosol delivery [146-148]. D-mannitol is also well 
known for its cryoprotective or lyoprotective properties [149] and as a bulking agent 
for the formulation, especially when the concentration of product for freeze drying is 
very low [150]. It has been chosen among other cryoprotectants because of its 
mucolytic property, as many lung diseases are characterised by the presence of thick 
stationary mucus in the airways [151]. Nanosuspension formulations or liquid 
dispersions have been converted to solid form by a lyophilization process. In order to 
protect the particles from freezing (cryoprotectants) or drying stress (lyoprotectants) 
[150], mannitol is incorporated at a constant concentration level (10%) [152] with 
liquid sample before freeze drying. The hypothesis of nanoparticle stabilization 
during the freezing step proposes that sugars isolate individual particles in the 
unfrozen fraction, thus avoiding aggregation for the period of freezing above glass 
transition temperature (Tg) [153]. The mechanism for stabilization of nanoparticles 
by lyoprotectants during the drying steps is explained by the water replacement 
hypothesis, which presumes the formation of hydrogen bonds between a 
lyoprotectant and the polar groups at the exterior of drug nanoparticles. These 
lyoprotectants preserve the intrinsic structures of nanoparticles by acting as water 
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replacements [154]. Figure 2.14 shows the nanosuspension samples freeze dried with 
and without mannitol. 
 
 
 Figure 2.14 Physical state of drugs nanosuspension after freeze drying without 
mannitol (a) and with mannitol (b) [152]. 
Freeze dried nanosuspensions without mannitol appeared as off-white, fluffy and 
sheet-like materials, and large agglomerates were observed. Nanosuspensions with 
mannitol formed a powder easily redispersible in phosphate buffer solution (PBS) 
after manual shaking. Hence, mannitol acts as a carrier which prevents nanoparticle 
aggregation during the freeze drying process [152]. Although mannitol crystallises in 
different polymorphic forms (α, β or δ) depending on the concentration (relative to 
other components in the formulation) and freezing rate, no evidence of any effect of 
these mannitol polymorphs on drying/processing characteristics or product stability 
has been reported so far [145, 155]. Mannitol has been used as a matrix material for 
controlled crystallization of a poorly water soluble drug (fenofibrate) [155] and a 
cryoprotectant for curcumin-chitosan nanoparticle complex preparation in a spray 
freeze drying (SFD) process [156]. It has also been used successfully as a carrier for 
the DPI formulations of nucleic acid produced by a spray freeze drying process 
[157], and a hydrophobic drug budesonide containing freeze dried mannitol [133] to 
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enhance its aerosolization behaviour. The findings from the above studies suggest 
that D-mannitol can be used as an additive to recover the IBP nanoparticles in a 
freeze drying process and also can act as a potential carrier in the DPI formulation. 
 Dispersive adjuvant: L-leucine 2.14.4
L-leucine (C6H13NO2) (Figure 2.12 d), a hydrophobic amino acid, has been 
used as a dispersive adjuvant for DPI formulations. It is used because amino acids 
are additives that have been found to improve aerosol efficiency [158, 159]. 
Enhanced aerosolization performance of several drugs from DPIs by using L-leucine 
as dispersive agent among other amino acids has also been recorded [160-162]. A 
recent study demonstrated the enhanced dispersion of conjugated chitosan 
nanoparticles was ascribed to the amphiphilic setting of the L-leucine conjugate and 
hydrophobic cross-links formed on the nanoparticles‘ surface [163]. Addition of 
leucine was found to improve the flow and aerosolization properties of freeze dried 
mannitol [133]. Another investigation found a notable surface modification and 
substantial improvement in the flow properties of fine IBP powder after dry coating 
with L-leucine to use in an oral dosage form [164].  
Feng and co-workers studied the effect of increasing L-leucine mass fraction in the 
DPI formulation of a model drug, specifically its effect on leucine crystallinity of 
microparticles, on powder density and on powder dispersibility [165].  L-leucine 
possess the ability to form hollow particles, and a change in particle morphology 
from solid spheres to hollow, rugose particles  leads to the formation of low density 
particles and enhanced dispersibility of the DPI formulations [159, 166-168]. Due to 
the surfactant nature, leucine can also reduce the interparticulate adhesive forces and 
lessen the aerodynamic particle size [169, 170]. A study of the poorly water soluble 
drug budesonide demonstrated that leucine can be used in ethanol-water co-solvent 
systems to develop inhalable particles with great dispersibility and better 
manufacturability [171]. Therefore, from the available literature, it was evident that 
L-leucine would be a useful additive to the process of developing IBP as a dry 
powder inhaler formulation. However, it is also reported that high concentrations of 
l-leucine (i.e. above 50% w/w) have a negative effect on the long term drug stability 
[169]. 
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2.15 MODEL DRUG: IBUPROFEN (IBP) 
Ibuprofen (IBP), which is (±)-2-(p-isobutyl phenyl) propionic acid, belongs to 
class II of the Biopharmaceutics Classification System (BCS) of drugs, also known 
as non-steroidal anti-inflammatory drugs or NSAIDs [172-174]. Figure 2.15 shows 
the molecular structure of IBP. 
 
Figure 2.15. The molecular structure of IBP [28](Drawn using Chemdraw Pro 11). 
 
IBP has a chiral carbon, and hence two different enantiomeric forms of IBP exist, 
with different biological effects. The S-enantiomer, which is the biologically active 
form, and the R-enantiomer, which has no biological activity, are partially converted 
into the S-form in the human organism [175] [176]. IBP is used in the therapy of 
rheumatism, dysmenorrhoea, headache, fever and arthritis. It is presented in a 
number of formulations such as oral suspensions, capsules, tablets, syrups, 
suppositories and creams, and transdermal patches are also under development [177].  
Among all these IBP preparation products, the first five are subject to oral dosage 
forms which undergo gastrointestinal digestion and absorption and liver 
detoxification, and after a series of functional roles in the blood, circulation then 
activates its anti-inflammatory effect. The required dosage for this effect in an adult 
is 20 mg ~ 30 mg, whereas the provided dose is about ten times of this amount [174]. 
Moreover, it is also found that long-term usage of higher doses of IBP has the 
potential to cause hypertension and myocardial infarction, and there is an elevated 
risk of cancer mortality [3-5]. It was also found that pulmonary administration of IBP 
nanoparticles in mice requires a dose three to five times less than that for oral 
administration and has the same analgesic effect [118]. It is also documented that the 
onset of analgesia occurs at IBP plasma concentration between 6.8 and 10.1 µg/ml 
[178]. Hence, most of the literature suggests that peak plasma level of IBP from a 
400 mg tablet lies between 17–36 µg/ml [179-182]. A nebulised oil-in-water 
nanoemulsion mist of IBP was developed with ideal properties for inhalation and 
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successful in-vitro drug release by the dissolution test [119]. However, in the case of 
both formulations, the cell toxicity tests revealed moderate effects from bio-
incompatibility at an increased level of delivered drug concentration. 
All types of oral dosage forms as well as oral formulations are associated with 
common adverse reactions. Some patients may also suffer from allergic nephritis, 
cystitis, kidney disease, renal papillary necrosis or renal failure, and bronchospasm 
[174]. In the case of topical products, there are no contra-indications or adverse 
reactions as for the oral medication, but poor sealing performance, production of 
secondary pollution and non-uniform administration cause tenderness as well as 
slowing the drug action [174]. Recently, research incorporating IBP in a gelatine 
based tissue adhesive found adverse effects on the bonding strength due to its 
reaction with the other adhesive components and increased crosslinking density 
[183]. 
As discussed earlier, the pulmonary route of administration is considered to be the 
most non-invasive route, because it bypasses the first stage of metabolism and is 
expected to eliminate most of the adverse drug reactions caused by oral drug 
administration. The route of drug delivery also offers the most efficacious drug 
action in the lowest dose (mostly 10–30 mg) and minimises the side effects caused 
by chronic use of higher drug doses. 
Despite the fact that the IBP is the most commonly used therapeutic medicine, its 
poor solubility in aqueous solutions lessens the dissolution and absorption rates into 
the blood circulation [173]. A study has shown that the bioavailability of IBP 
increases two fold on a decrease of particle size from 150 µm to 30 µm [184]. The 
particles in dry powder inhaler formulations are to be less than 5µm, and such a 
particle size reduction in the formulation substantially enhances the dissolution rate 
as well as the bioavailability [64]. 
2.16 SOLUBILITY OF IBUPROFEN (IBP) 
Ibuprofen (IBP) has poor water solubility and belongs to class II of the 
Biopharmaceutics Classification System (BCS). On the basis of their solubility and 
permeability through biological membranes, drugs can be categorized into four 
classes, as given by the Biopharmaceutical Classification System (BCS) (Figure 
2.16). 
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Figure 2.16 Biopharmaceutical classification (BCS) of drugs. 
 
It is identified that poorly water soluble drugs are typically hydrophobic, having a 
better affinity penetrating more rapidly towards the lipophilic intestinal membrane. 
In spite of this, absorption of these drugs from the GI tract is unpredictable due to 
their poor solubility in water. Therefore, enhancement of the drug solubility from any 
dosage formulation is connected with the application of auxiliary substances to 
advance new technological possibilities [185].  
Information on IBP solubility in aqueous solvents (especially low ethanol aqueous 
ones) is scarce, and results from the available studies are not in good agreement [116, 
186-190]. For example, Figure 2.17 shows the reported solubilities of IBP in pure 
water at 25°C arranged in order of increasing value. The value obtained in this study 
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Figure 2.17 Reported solubilities of IBP in water at 25°C. Note that the Bolten et al. 
result is at 27°C, that of Yalkowsky et al. [190]. at 30 °C and Watkinson et al.[189] 
at 32 °C. The Fini et al.[187] data was for the sodium salt in very dilute acid. 
 
The poor aqueous solubility of IBP causes difficulties to determine its accurate 
solubility value in water; such as melting point alteration and temperature change 
due to the long term vigorous agitation in dissolution method. In Figure 2.17 the 
methods for determining IBP aqueous solubilities were different in the reported 
works. The huge variability between the reported values are due to the errors 
associated with the differences in the adopted methods and conditions for the 
solubility determination. Manrique and Martinez [191],   Yalkowsky (30 °C) [190], 
Bhattamishra and Padhy (27 °C) [29] and Kocbek [116] used the dissolution to 
equilibrium method but temperature condition differed in some cases from 2-7 °C.  
Fini et. al. added the sodium salt of IBP in very diluted acid gradually into distilled 
water until it was saturated and equilibrium was achieved after a week of storage. 
Bhattamishra and Padhy [29], Jouyban [192] and Watkinson [189] used 
centrifugation to separate the IBP saturated solution sample for concentration 
determination.  Bolten [172] determined the IBP solubility in water at 27 °C and used 
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the IBP aqueous solubility at 32°C and used both HPLC and UV spectrophotometry 
for the concentration determination. Other researchers have used the UV 
spectrophotometry. Moreover, due to the very small amount of solute dissolving in 
aqueous solvents, the low solubility values show higher deviations in the derived 
data from other researchers. The variability in the available literature data for IBP 
solubility in pure water flag the need for extensive investigation on improving the 
current research in this area. 
Figure 2.18 shows the available literature data for IBP solubility in aqueous ethanol.  
 
 
Figure 2.18 Prior solubility data for IBP in aqueous ethanol. The Garzon & 
Martinez [193] data are for 25, 30, 35 and 40°C. 
 
The available solubility data in the low ethanol range was not sufficient to construct 
a phase diagram. Moreover, additives are to be used to control the particle size in the 
proposed method of precipitation crystallization. Hence, IBP solubility in the 
presence of the selected additives also needs to be investigated. 
The outcomes of this investigation will be used to design and optimise the APC 
process for producing IBP crystals in nano/micrometer range for developing an 
efficient dry powder inhaler formulation.  
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2.17 CONCLUSION 
This research proposes a new approach to developing IBP DPI formulation, 
using regular size particles produced by a controlled crystallization process. So far 
there is no work reported in the literature on IBP microcrystals to produce a DPI 
formulation, and thus it is anticipitated that the outcome of this project would be able 
to contribute to the development of a non-invasive DPI formulation with reduced 
cost and with better therapeutic benefit. 
The limited literature shows some attempts have been made at a direct crystallization 
technique, using additives for producing respirable size crystals, but it appears that 
this technique has never been applied successfully. The present PhD project proposes 
to develop a new method of a controlled crystallization process for producing IBP of 
small size (< 5 μm) crystals for pulmonary delivery. This proposed work is expected 
to be of interest to pharmaceutical companies. In addition, it is anticipated that this 
project could result in novel intellectual property and appropriate protection will be 
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 Research Methods Chapter 3:
3.1 INTRODUCTION 
The materials and methodologies adopted to achieve the aims for this project 
are described in this chapter. The materials‘ sources and specifications are given at 
the beginning of the chapter. The equipment calibrations (UV spectrophotometry), 
method development and validations (solubility and particle preparation), and 
instruments to measure the characteristics of the formulations are outlined and 
described with the detailed methods and implementation of the study. 
3.2 MATERIALS 
 Model drug 3.2.1
Ibuprofen (IBP) was used as the active pharmaceutical ingredient (API) in this 
study. USP grade IBP (Part no: 30-1192-1000GM) was purchased from Professional 
Compounding Chemists of Australia Pty Ltd (PCCA, Matraville, NSW 2036), as a 
high purity racemate of (R)/(S)-(±)-[2-(4-isobutyl-phenyl) propionic acid] with the 
empirical formula C13H18O2 and molecular weight 206.27. It was used without 
further purification. Figure 3.1 shows an SEM of the purchased IBP crystals with 
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Figure 3.1. SEM of purchased IBP crystals. 
 Additives 3.2.2
A formulation additive is any component other than the active ingredient of the 
formulation. Some pharmaceutical excipients/additives used in this study for making 
inhalable particles are as follows: 
Pluronic F127 (Pl F127) 
Pluronic F127 (Pl F127) (Figure 2.12a) is a surfactant copolymer comprising a 
hydrophobic propylene oxide (PO) polymer block in the middle of two hydrophilic 
ethylene oxide (EO) polymer blocks. Pl F127 (Poloxamer 407 NF, Part no: 302637-
500GM) was purchased from Professional Compounding Chemists of Australia Pty 
Ltd (PCCA, Matraville, NSW 2036). 
Hydroxy propyl methyl cellulose (HPMC)  
Hydroxy propy methyl cellulose (HPMC) (Figure 2.12 b) is a large molecular 
non-ionic stabilizer. It was purchased from Sigma-Aldrich (Part no: 09963-100 G, 
Lot no: BCBG6002V). 
 D-mannitol (C6H8OH6) 
Mannitol (Figure 2.12 c) is a hexahydric alcohol and has been largely used as a 
cryoprotectant and a bulking agent for freeze-dried pharmaceutical preparations 
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[145]. D-mannitol was purchased from Sigma-Aldrich (Part no: M4-125-500 g, Lot 
no: SLBJ5312V). 
L-Leucine (C6H13NO2)  
L-leucine (Figure 2.12 d), is a hydrophobic amino acid which has been used as 
dispersive adjuvant for DPI formulations [158]. L-leucine (Bioultra, ≥ 99.5%) was 
purchased from Sigma-Aldrich (Part no: 61819-100 G, Lot no: BCBM2322V). 
 Chemicals and Solvents 3.2.3
Spectrophotometric grade ethanol was purchased from Sigma-Aldrich and 
deionised/Millipore water is available in the laboratory. 
3.3 METHODOLOGIES 
3.4 UV SPECTROPHOTOMETRY 
UV/Vis spectrophotometers use the UV (ultra violet) and visible regions of the 
spectrum. A spectrophotometer quantitatively measures the fraction of light at a 
given wavelength that is absorbed by a given solution. 
According to the Beer-Lambert law, the absorbance Abs = ln (I0/Ii) = kS C , where Ii 
is the light intensity with the sample in the path and I0 with no sample (solvent only), 
C is the solute molar concentration, and kS is a co-efficient particular to each material 
and varies with the wavelength of the light and the cell path length. Thus it is 
necessary to select a suitable wavelength and path length and then determine the co-
efficient kS which can then be used to give the solute concentration in a solution. 
Concentrations units for this section on spectrophotometry are given as mass fraction 
IBP to total solution mass. 
 Wavelength selection in UV spectrophotometer 3.4.1
The wavelength was scanned by preparing different dilute IBP solutions in 
absolute ethanol. Though the scans showed maximum abs in 207 nm (Figure 3.2) 
and 262 nm (Figure 3.3), it was found in the literature that wavelengths of 221 [164, 
194] and 264 nm [29, 152, 187, 195] show a good response to the low to high IBP 
concentration. The calibration plots in Figure 3.4 for 264 nm & Figure 3.6 for 221 
nm have shown linear relationships (R2=1) of IBP concentration with the absorbance 
value. In the wavelength of 264 nm, calibrations were performed for each of the 
solvents used for the solubility investigations. At 221 nm the calibration was done in 
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duplicate trials using 35% aqueous ethanol. In all cases the responses were linear 
confirming the accuracy of the analysis in the selected wavelengths.   So, wavelength 
221 nm [164, 194] was chosen for IBP assay in the in vitro aerosolization tests in the 
twin stage impinger due to its high sensitivity to detecting a low amount (0.3- 21 
µg/mL) of the drug. The solubility measurement tests were done using 264 nm [29, 
152, 187, 195] to minimise the dilution number in order to keep drug concentration 
(50 to 1500 ppm) within the limit of detection (Figure 3.3). 
 
Figure 3.2 UV spectrophotometer wavelength scan with four different concentrations 
of IBP solutions in 35% w/w ethanol for identification at 221 nm. 
  
Figure 3.3. UV spectrophotometer wavelength scan with six different concentrations 





















































Working wavelength for solubility
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 Calibration Method 3.4.2
A Thermo Scientific Evolution Array UV-Visible spectrophotometer operated 
with VISIONcollect software (version 1.5, Build 7) was used in this study at a 
wavelength of 264 nm for the solubility tests. For IBP in aqueous ethanol, the 
concentration range of the spectrophotometer is 50 to 1500 ppm by wt. (mass 
fraction) IBP (absorbance from ~ 0.07 to 2). The spectrophotometer was calibrated 
against weighed solutions of ethanol (E), water (W) and IBP (I). All measurements 
were done using 10 mm square quartz cuvettes. 
The calibration curves are illustrated in Figure 3.4, which indicates the linearity of 
the Beer-Lambert relation. However, the slope of the lines (the Beer-Lambert 
constant, ks) varies with the ethanol content (Figure 3.5), showing some interaction 
of the added ethanol with the IBP structure. The large errors in the low ethanol 
solutions were due to the very low solubilities and the resultant difficulties in getting 
a wide range of test results. The slope varies linearly with the ethanol content and the 
correlating equation is shown on Figure 3.5 (with 95% uncertainties on the 
parameters). These slopes were used to determine the solubility of IBP in aqueous 
ethanol. The raw data is provided in Appendix A1 and Appendix A2. 
 
Figure 3.4 Linearity of Beer-Lambert law in calibration of the UV 
spectrophotometer. The data range for the 20% ethanol content is limited because of 
the low solubility. Values of R2 for the correlations are also shown. 
 
R² = 0.9983 
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Figure 3.5 Calibration of UV spectrophotometer. Variation of slope ks with ethanol 
content. 
 
Calibration at 221 nm for IBP DPI formulation assay after in vitro drug 
dispersibility test in Twin stage impinger: To determine the trace amount of drug 
content (< 1 µg) a calibration curve of IBP in 35% aqueous ethanol was constructed 
at 221 nm [164, 194] wavelength for its high sensitivity. The reproducible linear 
trends were established in the concentration range of 0.3- 21 µg/mL in volumetric 
method (Figure 3.6) from duplicate trials. The average slope (0.0405 ± <0.0001) of 
this calibration curves was used to determine the IBP drug content in the inhaler 
device, in stage 1 and stage 2 of the twin stage impinger (detailed in Section 3.16.1). 


























 Ethanol XE = E/(E+W), % w/w 
Slope  =  0.001475 (± 0.000010) - 4.38 10-6 (± 2.6 10-6)* XE 
 Chapter 3: Research Methods 53 
 
Figure 3.6 UV calibration curves for IBP concentration determination at 221 nm in 
35% w/w ethanol solutions from duplicate trials. Values of R2 for the correlations 
are also shown. 
3.5 MEASUREMENT OF SOLUBILITY 
Solubility studies were carried out by the dissolution of IBP particles to 
equilibrium into aqueous ethanol solvents in magnetically stirred Schott bottles in a 
water bath at constant temperature.  
The water bath temperature was kept constant within ± 0.1 ºC of the desired 
temperatures (10, 25 and 40 ºC) and was checked with a calibrated glass 
thermometer. For an experiment, an excess amount of IBP was mixed with ~ 20 g of 
aqueous ethanol solvents of different composition. The experimental set up is shown 
in Figure 3.7. 
 
Figure 3.7 Schott bottles on stirrer plate in thermostatic water bath. 
R² = 0.9999 
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Figure 3.8 and Figure 3.9 show the approach to equilibrium for several experiments 
(data is provided in Appendix A4 and A5). Equilibrium is reached within 30 minutes, 
so bottles were stirred with magnetic stirrers for at least 6 hours to ensure 
equilibrium. Then the bottles were left to settle in the bath and the supernatant from 
each bottle was filtered using preheated/pre-cooled syringes with 0.22 µm 
membranes, then diluted if necessary. 
 
Figure 3.8 Approach to equilibrium for the dissolution of IBP in water and aqueous 
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Figure 3.9 Investigation of equilibrium attainment for two dissolutions and one 
crystallization (falling curve) of IBP in aqueous ethanol with additives. The values 
for 10% E, 0.1% of each excipient (Pl F127 & HPMC)) have been multiplied by a 
factor of 6 to expand the scale for comparison. 
 
The effect of additives on IBP solubility was investigated at 25°C. The concentration 
ranges used were 0 to 2% w/w HPMC/ (E+W), 0 to 2% w/w Pl F127/ (E+W), 0-
1.6% w/w leucine/ (E+W), 0-18% w/w mannitol/(E+W), and 0 to 20% w/w 
E/(E+W). Unless otherwise indicated, concentrations are given as a mass ratio to the 
amount of solvent (E+W).  
The supernatant from each bottle was filtered and diluted as necessary for 
quantification purposes. The diluted samples along with an appropriated standard 
calibrations were analysed on the UV spectrophotometer working at a wavelength of 
264 nm [119, 152, 187, 195] and using 10 mm square UV quartz cuvettes [196]. 
Each experiment was done in triplicate. 
 Preparation of HPMC solutions 3.5.1
Solutions containing 5% w/w HPMC were prepared by adding HPMC powder 
to a weight of water required to make up to one tenth of the final weight. Vigorous 
agitation was used until the aggregates of powder were dissolved. The solutions was 
then refrigerated for 24 hours at 4°C to allow polymer hydration, made up to final 
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required concentration of additives were prepared by taking the weighed amount of 
Pl F127, leucine and mannitol powder, made up to the final weight with 
water/aqueous ethanol. They were magnetically stirred to dissolution. 
3.6 NEAR-INFRARED SPECTROSCOPY 
Near-infrared (NIR) spectroscopy is a technique with wide and varied 
applications in pharmaceutical analysis. The NIR spectral range extends from 
780 nm to 2500 nm (from 12800 cm-1 to 4000 cm-1) [198]. NIR spectroscopy has 
applications for chemical, physical and process analysis including the determination 
of absolute water content. In this work, a Cary series UV-Vis-NIR spectrophotometer 
(Cary 5000, Agilent technologies) was used for the determination of water in each 
phase after the phase separation of IBP in aqueous ethanol (>35% E/(E+W)) at 40°C. 
It is a double beam instrument operated by Cary WinUV software (version 
6.1.0.1568).  
3.7 PHASE SEPARATION  
IBP in aqueous ethanol shown two liquid phases at certain concentration 
((>35% E/(E+W)) at 40 °C [26]. This was checked using NIR in the present work. 
Excess amount of IBP was added in 40 and 50% E/ (E+W) solutions, stirred for 24 
hours and allowed to settle in a 40 °C temperature controlled bath for 72 hours. 
Samples were collected from each layer. The IBP concentration was determined by 
the UV spectrophotometer as per the method described in Section 3.3. The water 
content was determined using an NIR spectrophotometer (Section 3.6) after diluting 
with ethanol as required. The ethanol content for each layer was determined by 
subtracting the measured IBP and water content value [199]. 
 Wavelength Selection 3.7.1
The wavelength was scanned for eleven aqueous ethanol solvents (0-100% 
E/(E+W)) within the NIR spectral range using a quartz cuvette with a 1 mm optical 
path. Peaks were found in the wavelengths of 1446 nm, 1932 nm and 2310 nm (Scan 
spectrums shown in Appendix A6). The highest peak was typically shown at ~1932 
nm wavelength and was considered as the best wavelength for determining water 
content. Other peaks might have resulted from the –OH group present in ethanol. 
Absolute ethanol was used as the reference. 
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 Calibration Method 3.7.2
To determine the water content, 16 points were chosen to calibrate the NIR 
equipment. The calibration points were produced at a pre-determined concentration 
of water in ethanol (W/(E+W)), gravimetrically prepared on an analytical balance 
(with accuracy of ± 0.0001 g). The calibration curve is shown in Figure 3.10. The 
slope from this calibration line was used to calculate the water content using the 
Beer-Lambert relation. The raw data is given in Appendix A7. 
 
Figure 3.10 Calibration curve of NIR spectrophotometer at 1932 nm. Values of R2 
for the correlation is also shown. 
 
3.8 PREPARATION OF IBP MICROCRYSTALS FOR INHALATION 
This section will discuss the method of preparing IBP micro/nanocrystals for 
successful deep lung deposition. The method was the anti-solvent precipitation 
crystallization (APC) by co-solvent technique [28, 124, 152, 200, 201], optimized 
with respect to the significant variables identified from Plackett-Burman 
investigation (will be discussed in Chapter 5 Section 5.2).  
This technique involves mixing of two different phases (Figure 3.11). The first phase 
(solvent phase) is ethanol with dissolved IBP (30-200 mg/g). The second phase (anti-
solvent phase) where IBP is practically insoluble contains dissolved additives. The 
crystallizer is shown in Figure 3.12 and shows the ultrasonic bath (Soniclean 750 
HT), the cooler (Julabo, FT 200), the heating immersion circulator ED (Julabo) and 
the overhead stirrer (Lab Co.). 
y = 0.5623x 
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Figure 3.11 Anti-solvent precipitation crystallization (APC) process to make 
inhalable microparticles. 
 
The additive solution was prepared by taking the weighed amount of powder of Pl 
F127, L-leucine, D-mannitol and 5% HPMC solution (prepared as described in the 
Section 3.5.1) made up to the final weight with water to give the additives in the 
concentration range HPMC 0.1-0.8%, Pl F127 0-1.8%, leucine 0.9-1.3% and 
mannitol 4.4-9%. Mannitol acts as a carrier which prevents aggregation of particles 
during freeze drying [146-148, 152] and leucine is used for improving powder 
dispersibility [160-162].  
 
Figure 3.12 Crystallizer set up for anti-solvent precipitation crystallization (APC) 
preparing inhalable IBP particles. 
 
Various process parameters ( Table 3.1) including temperature, concentration and 
amount of polymers (HPMC and Pluronic F127), amount and concentration of 
mannitol, and stirring speed were varied to get the best size of the 
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micro/nanocrystals. These ranges were chosen based on the optimization 
experiments undertaken for each of the variables. The investigations for the optimum 
conditions are detailed in Chapter 5. The crystallization batch size range was chosen 
to be 10-50 g including the drug solution and the anti-solvent. The trial and error 
experiments showed that the particle size (< 5 µm) was better controlled in a small-
scale batch (10 g). But considering the productivity of the process, the large-scale 
batches (50 g) were prepared with a maximum particle size (D[v,0.5]) of 20 µm. The 
solvent-antisolvent ratio and the range of stirring speed were chosen from the 
precipitation method used by Khan et. al [28]. The temperature range was selected 
from a series of experiments (section 5.3.1) where the smallest particle size D[v,0.5] 
= 7.14 µm was obtained at 25 °C. However, due to the ultrasound power during the 
process the temperature of the bath was increased to 30 °C producing particles with 
D[v,0.5] = 9.77 µm. Thus, the temperature range was chosen from 25 - 30 °C. The 
ultrasound duration range was 30 - 60 minutes where size of the particles was 8.4 - 
6.4 µm (section 5.3.2 ). The minimum range (0.3 %) of drug concentration in organic 
phase was selected from Khan et. al [28] and the maximum range (2.0 %) was 
selected to get the maximum yield of particles. The maximum concentration of each 
additives were chosen based on their maximum solubility in the aqueous medium. 
The reason was to make sure they are in homogenous solution phase and not 
crystallizing out within the anti-solvent media. 
 Table 3.1 Anti-solvent precipitation crystallization (APC) process parameters and 
optimized range of conditions for preparing respirable IBP particles. 
 
Process parameters Condition 
Batch size 10 – 50 g 
Solvent-anti-solvent ratio (S/AS) 1 : 9 (fixed) 
Stirring speed, rpm 600 – 1200 
Temperature 25 - 30°C 
Ultrasound application 50/60 Hz, Pulse swept power 180W 
Duration of mixing 30 - 60 minutes 
Drug concentration in organic phase 0.3-2% 
Pl F127 concentration 0-1.8% 
HPMC concentration 0-0.8% 
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Process parameters Condition 
Leucine concentration 0-1.5% 
Mannitol concentration 0-9% 
 
The drug solution was added into the antisolvent solution approximately at 1ml/s rate 
(maintained manually by hand and time recorded using a stopwatch). Table 3.1 
shows that the drug solution was one tenth of the anti-solvent solution. The very 
small volume of the drug solution was easier to add at a relatively constant rate 
manually by hand compared to the volume of the anti-solvent.  Thus, the order of 
adding drug solution into the anti-solvent was chosen to maintain the addition rate 
relatively constant at all time. 
 Isolation of dried particles 3.8.1
The product of micro/nano crystal suspensions was centrifuged at 3500 rpm for 
60 minutes in falcon tubes to remove dissolved additives. The excess liquid was 
discarded and the remainder was frozen using a deep freezer at -75 ºC for 24 hours. 
These frozen semisolids were the solid particles of IBP microcrystals present in the 
10% aqueous ethanol crystallization media (<1ml, rationally containing HPMC, Pl 
F127, L-leucine and D-mannitol) which was converted into the semisolid state in a 
freezer at -75 ºC temperature, were freeze dried using a lyophilizer (Alpha 1-4 LD 
plus). The freeze drying was performed at a temperature of -55 °C and vacuum 1.0 
mbar absolute for 24 – 96 hours, depending on the sample volume [144]. The 
duration of freeze drying was finalized by weighing the samples (n=5) once daily for 
four days. After freeze drying, the samples were kept over dried silica gel in the glass 
desiccator. Two samples were weighed once daily for 13 days to monitor any 
changes due to the moisture contents in the silica gel glass desiccator.  
Figure 3.13 shows the weight variation plot of the samples in the freeze dryer 
(first four days) and silica gel glass desiccator (next eight days). The large error bars 
in the freeze dried samples are due to the batch-to-batch volume difference in five 
samples. The weight of the dried sample was stable after 36 hours of drying in the 
freeze dryer. The sample weight variation during storage in the silica gel glass 
desiccator remained within acceptable range (± 0.4 mg). The silica gel beads were 
freshly oven dried before using each time and replaced on time to make sure that the 
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humidity in the desiccator is maintained to approximately 0%. IBP melting point is 
about 75-77°C which was sensitive for an oven drying process. The melting process 
of IBP starts from 40-60°C for a normal oven drying process. Moreover, oven dried 
particles are found as hard solid cakes, which causes difficulties to get desired size 
particles for aerosolization. For the above reasons, the freeze drying process was 
chosen over the oven drying process. 
  
 
Figure 3.13 Sample weight variation on drying in freeze dryer and silica gel glass 
desiccator. 
3.9 PARTICLE SIZE ANALYSIS  
The particle size of the crystallized IBP was measured by the laser diffraction 
technique using a Malvern Mastersizer 3000 equipped with a small volume 
dispersion unit. Laser diffraction techniques are commonly used in crystallization 
studies, as they rapidly provide a volume based size distribution in terms of the 
convenient volume equivalent size of a particle. They determine particle sizes by 
measuring the intensities at different angles of forward light diffraction; smaller 
particles scatter at larger angles than larger ones do. Laser diffraction is a non-
intrusive fast method, is simple to use, and measures a wide range of particle sizes. It 
is estimated that the relative error in the volume median diameter (VMD) calculated 
by the Malvern Mastersizer 3000 is ± 2% [202, 203]. Particle size measurements for 
the nanocrystals were done using the Zetasizer (NanoZS 90, Malvern Instruments, 
UK).  
The suspending medium was saturated IBP solution prepared with equivalent 
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as the dispersant in the small volume (120 ml) dispersion unit stirring at 2000 rpm. 
Crystal suspensions were added dropwise until the obscuration reached the desired 
level.  
The mass median diameter (MMD, D[v,0.5]) and volume mean diameter (Dv[4,3]) 
determined from the output of the laser diffraction particle sizing were used as the 
major size parameter to characterize the particle size distributions (PSD). The 
particle size distribution data was presented in the appendices C1-8 by tabulating the 
D[v,0.1], D[v,0.5] & D[v,0.9] data values. The particle size distribution data of the 
final formulations were given in Chapter 6 Table 6.3. Measurements were taken from 
three replicates of each of the formulations. The refractive index for IBP in Table 3.2 
was collected from the Malvern mastersizer refractive index guide [204]. 
Table 3.2 The optical parameter settings for size measurement by laser diffraction. 
 
Material Refractive index Absorption index 
IBP 1.43 [204, 205] 1.2 
Dispersant 1.331[204] NA 
 
The absorption index was selected from the maximum value providing the lowest 
weighted residual (%). The trend of weighted residual vs absorption index simulated 
from calculations done by Mastersizer 3000 software (Mastersizer- v 3.10) is given 
in Figure 3.14. The selected value from the trend confirms the best suitability for the 
particle size distribution analysis. 
 
Figure 3.14 The trend of weighted residual vs absorbance index. The weighted 
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3.10 MILL MICRONIZING METHOD 
A McCrone Micronizing mill (serial no. 130803) was used to mill the raw IBP 
powder into inhalable size. Raw IBP powder was loaded (< 3 g) into the micronizer 
vessels with zirconia beads. Water with > 300 ppm of detergent (2 mL) was used as a 
fluid. Particle size was measured using Malvern Mastersizer 3000 at different time 
intervals until inhalable particle size was achieved by milling. Particles with the 
required size (~ 3 µm) were found after 12 hours of milling. Figure 3.15 shows the 
size of particles at different durations of milling. The samples were then dried in an 
oven overnight at 40 °C. 
 
Figure 3.15 Duration of IBP particle size reduction to inhalable size using 
micronizing mill. 
 
3.11 CRYSTAL IMAGE ANALYSIS  
Scanning electron microscope (SEM) and transmission electron microscope 
(TEM) were used for the image analysis of IBP raw powder, wet and dry particles. 
 Scanning electron microscope (SEM) 3.11.1
A Zeiss Sigma scanning electron microscope was used to investigate the 
morphological properties (shape, size and surface) of the IBP crystals.  
The sample preparation involved fixing the powder samples on to a metal stub with 
the aid of a double sided adhesive tape followed by coating for 180 seconds with a 
LEICA EM SCD005 gold coater. Scanning electron microscopy (SEM) was then 
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 Transmission electron microscope (TEM) 3.11.2
A Jeol 1400 transmission electron microscope was used to investigate the 
morphological properties (shape, size and surface) of the IBP crystals. 
Sample preparation for TEM involved deposition of a single drop of the sample 
suspension onto a 200 mesh copper grid coated with Formvar/Carbon (code no S162) 
followed by drying at ambient temperature. Images were then taken by loading the 
sample on the transmission electron microscope at 120 KV. 
3.12 DENSITY MEASUREMENTS 
Bulk density and tapped density of prepared powders were measured as 
described elsewhere [206]. IBP has a particle density of 1.110 g/cm3 [207, 208]. 
 Bulk density 3.12.1
The bulk density of a powder is defined as the ratio of the mass of an untapped 
powder sample to its volume, including the interparticulate void volume. Hence, 
the bulk density depends on both the density of powder particles and the spatial 
arrangement of particles in the powder bed [206]. 
The bulk density of the powder formulations was determined by measuring the 
volume of a known mass of powder sample in a dry, graduated cylinder (5 mL); the 
sample weighed with 0.1 per cent accuracy was gently introduced. Carefully the 
powder was levelled without compacting, and the unsettled apparent volume (V0) to 
the nearest graduated unit was recorded. Three replications for each formulation 
were performed. 
 Tapped density 3.12.2
The tapped density is an increased bulk density achieved after mechanically 
tapping a receptacle containing the powder sample. Mechanical tapping is achieved 
by raising the cylinder and allowing it to drop, under its own mass, in a distance of 
3.0 ± 0.2 mm using the Erweka tapped density tester [206]. After observing the 
initial powder volume and mass, the graduated (5 mL) measuring cylinder was 
mechanically tapped, and volume readings were taken until no further volume 
change was observed. 
A 5 mL graduated cylinder was filled with a mass of 1.3 ± 0.3 g of powder sample. 
The initial particle volume (Vo) and the initial weight of the samples were 
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determined. Then the cylinder was secured in the support of the tapping apparatus, 
100, 500 and 1250 taps on the same powder sample were carried out, and 
corresponding volumes V100, V500 and V1250 were recorded to the nearest graduated 
unit. If the difference between V500 and V1250 was less than or equal to 0.1 mL, V1250 
was considered as the tapped volume. If the difference between V500 and V1250 
exceeded 0.1 mL, the increments of 1250 taps were repeated until the difference 
between successive measurements was less than or equal to 0.1 mL. Three 
replications for each formulation were performed. 
3.13 POWDER COHESION AND FLOW MEASUREMENTS 
The effectiveness of the drug particle deposition depends on the particle flow 
behaviour during inspiration. Free flowing powders overcome the cohesion and 
adhesion forces and increase drug deposition into the deep lungs. To ensure drug 
delivery from the DPI formulation, flowability of the prepared IBP crystals was 
determined using the angle of repose, Carr‘s index and the Hausner ratio. 
 Angle of repose 3.13.1
To form the angle of repose on a fixed base, a 5 mL beaker was used as a base 
(10 mm diameter) to retain the powder (250 ± 0.5 mg). The powder was poured 
through a funnel (40 mm diameter and 65 mm height). The funnel height was 
maintained at approximately 2 – 4 cm from the top of the powder pile which is 
formed in order to minimise the impact of falling powder on the tip of the cone. The 
angle of repose was determined by measuring the height of the cone of powder and 
calculating the angle of repose, α, from the following equation: 
   ( )  
   𝑔 𝑡
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Table 3.3 Flow properties and corresponding angles of repose [209]. 
 
Flow Property Angle of repose (degree) 
Excellent 25-30 
Good 31-35 
Fair  36-40 
Passable 41-45 
Poor 46-55 
Very poor 56-65 
Very, very poor > 66 
 
 Carr’s index and Hausner ratio 3.13.2
In recent years the Carr‘s index and Hausner ratio have become the simple, 
fast, and most common methods of predicting powder flow properties. The Carr‘s 
index and the Hausner ratio are determined by measuring both the bulk volume and 
tapped volume of a powder (Section 3.12). 
Basic methods for Carr‘s compressibility index and Hausner ratio: The basic 
procedure is to measure the unsettled apparent volume (V0) and the final tapped 
volume, (Vf) of the powder after tapping the material until no further volume changes 
occur. The compressibility index and the Hausner ratio are calculated as follows:  









In this work, the Carr‘s compressibility index and Hausner ratio was calculated using 
measured values of bulk density (  𝑢  ) and tapped density ( 𝑡 𝑝𝑝 𝑑) as follows: 
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For the Carr‘s index and the Hausner ratio, the generally accepted scale of 
flowability is given in Table 3.4 [206, 209]. The two quantities are related, Carr‘s 
index = 1 – 1/Hausner ratio. 
 
 Table 3.4 Scale of flowability [206, 209]. 
 
Carr’s index (%) Flow character Hausner ratio 
≤ 10 Excellent 1.00-1.11 
11-15 Good 1.12-1.18 
16-20 Fair 1.19-1.25 
21-25 Passable 1.26-1.34 
26-31 Poor 1.35-1.45 
32-37 Very poor 1.46-1.59 
> 38 Very, very poor > 1.60 
 
3.14 CRYSTALLINITY TEST 
Crystallinity refers to the degree of structural order in a solid. In a crystal, the 
atoms or molecules are arranged in a regular, periodic manner. The degree of 
crystallinity of a drug has an effect on its bioavailability and on its physical and 
chemical stability. The experimental conditions (e.g. temperature, humidity) during 
the crystallization process might cause defects in the crystal lattice and decrease the 
degree of crystallinity, which could have a harmful effect on the drug‘s activity. 
 Differential scanning calorimetry (DSC) 3.14.1
Differential scanning calorimetry (DSC) experiments were carried out in a 
DSC Q100 from TA Instruments Explorer Q series. A small amount of sample (less 
than 6 mg) was enclosed in a hermetic aluminum pan. A liquid nitrogen cooling 
system was used in order to reach temperatures as low as - 42 °C. 
Processed and unprocessed IBP samples were scanned from 10 °C to 110 °C, using a 
heating rate of 10°C/min. All samples were analysed in triplicate. The percent 
crystallinity is then determined using the following equation [210]: 
% Crystallinity = [∆Hm – ∆Hc] / ∆Hm°× 100% 
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The heats of melting, ∆Hm, and cold crystallization, ∆Hc, are determined by 
integrating the areas (J/g) under the peaks using TA instrument Analysis 2000 
software. No cold crystallization exothermic peak was observed during the DSC 
experiment for IBP for both processed and unprocessed.  
The term ∆Hm° is a reference value and represents the heat of melting of the 100% 
crystalline IBP. Appendix A8 shows the DSC traces for determining the melting 
enthalpy of the raw IBP used in this work. It was found that the melting enthalpy of 
the raw IBP powder was 118.4 ± 7.3 J/g which is also in agreement with Nokhodchi 
and co-workers [194]. This value was used as the reference value to determine the 
percentage crystalline phase of IBP in the processed formulations with different 
compositions of additive. 
 Powder X-ray diffraction (XRD) 3.14.2
The crystallinities of the unprocessed and processed IBP were also evaluated 
using an X-ray powder diffractometer (XRD).  
Samples were front pressed into low background quartz holders. Diffraction patterns 
were collected in θ/2θ geometry on a PANalytical X‘Pert Pro diffractometer (Co Kα) 
using a W/Si parabolic mirror and 0.09° collimator before the point detector. A 0.25° 
fixed divergence slit, 10 mm mask, 1.4 mm incident antiscatter slit, and 0.04 rad pre 
and post diffraction Soller slits were used. Patterns were collected from 3 – 75°2θ at 
a step size of 0.02° for 1 hr. The sample was spun during data collection. An 
instrument function was determined from LaB6 (SRM 660a). Phase identification 
was performed with Highscore Plus (V4.5, PANalytical) using the PDF4+ database 
(ICDD) and confirmed via Rietveld refinement with TOPAS (V5, Bruker). 
Quantitative phase analysis was performed using TOPAS (v5, Bruker) via the 
Rietveld method. An instrument function determined from LaB6 (NIST SRM 660a) 
was used to model the profile shape. A Lorentzian crystallite size term was refined 
for each phase to account for profile broadening. Refined terms included specimen 
displacement, scale factor for each phase, and unit cell parameters for each phase. 
The amount of pluronic in some samples was estimated by the degree of crystallinity 
method where the numerical area of each phase is used to determine abundances. 
The pluronic was accounted for by modelling a peak at c.a. 27° 2θ (most obvious 
feature not modelled) and designating it as the amorphous phase. HPMC phase 
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abundance could not be quantified as its concentration in the formulation was too 
low to identify in the XRD curves. 
XRD patterns of both the processed and unprocessed IBP were compared to identify 
any alteration in their crystallinities. 
3.15 DRUG LOADING DETERMINATION 
Quantification of IBP content in the powder formulation was determined by 
UV spectrophotometer (Thermo Scientific Evolution Array) at a wavelength of 264 
nm. Samples were prepared by dissolving 10-15 mg of powder formulation in 50% 
aqueous ethanol solvent system. Complete solution of IBP in the selected solvent 
system was confirmed from the predetermined solubility results. The calibration plot 
shown in Section 3.4.2 was used to quantify the IBP concentration in the samples. 
IBP loading in the formulation was quantified from the ratio of determined total IBP 
amount to the weight of the powder formulation taken, in percentage. 
3.16 DRUG DISPERSIBILITY TESTING 
The prepared IBP microparticles were subjected to an aerosolization test using 
a device, Rotahaler®. 
 Evaluation of aerosolization and in vitro drug deposition 3.16.1
The efficiency of the prepared dry powder inhaler in terms of aerosolization 
and in vitro drug deposition was investigated by a Twin Stage Impinger (TSI, Copley 
Scientific, Nottingham, UK) (Figure 3.16), using methodology described in the 
British Pharmacopoeia (TSI apparatus, Apparatus A, Glass Impinger, British 
Pharmacopoeia, 2014). A Rotahaler® (Glaxo Wellcome) was used as the DPI device 
and 35% aqueous ethanol (determined from the solubility analysis) was used as the 
collection liquid in the upper and lower stages of the apparatus. 7 mL of collection 
liquid was placed in stage-1 (S-1) of the apparatus and 30 mL in stage-2 (S-2). The 
airflow through the TSI was controlled by a vacuum pump (ERWEKA) using a 
calibrated flow meter (ERWEKA). 
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Figure 3.16 Diagrammatic representation of Twin Stage Impinger [211]. 
 
For each actuation, a size 3 hard gelatin capsule (Fawns and McAllan Pty Ltd. 
Australia) loaded with about 32 ± 1 mg [146, 148] powder formulation was inserted 
into the Rotahaler®, which was placed into a moulded mouthpiece attached to the 
TSI and then twisted to release the powder into the body of the device. The amount 
of 32 mg of powder formulation was used to ensure the minimum IBP concentration 
within the limit of detection in UV spectrophotometry. The liberated powder was 
drawn through the TSI at a flow rate of 60 L/min for 5 seconds. This procedure was 
repeated five times for each preparation. 
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After each run, the two stages of the impinger and the powder inhaler were washed 
separately with an appropriate ethanol solvent into volumetric flasks and the volume 
was adjusted to 100 ml. The amount of drug deposited in each stage was analysed by 
UV spectrophotometer at 221 nm (Section 3.4.2). The total amount of drug collected 
from the inhaler device, stage-1 (S1) and stge-2 (S2) are termed as the recovered 
dose (RD). 
The emitted dose (ED) is defined as the fraction of recovered dose (RD) delivered 
from the inhalation device expressed as a percentage.  
 𝐷  
𝑆1  𝑆 
𝑅𝐷
 1   
The fine particle fraction (FPF) is defined as the fraction of recovered dose (RD) 
deposited in the stage-2 (S2) of TSI expressed as a percentage.  
     
𝑆 
𝑅𝐷
 1   
 
It was expected that DPI formulations of the prepared IBP crystals will be more 
efficient in delivering higher amount of drug (FPF%) into the deep lungs than the 
DPI formulations of the homogenised IBP drug particles. 
3.17 IN VITRO DISSOLUTION TEST 
A sample of pure IBP (12.5 mg) milled to 2.8 ± 0.1 µm volume median 
diameter (D[v,0.5]) and the processed formulations equivalent to 12.5 mg were 
subjected to dissolution studies. The USP paddle method (Pharma Test- DT 70) was 
adopted in 900 mL phosphate buffered saline (PBS) (pH 7.4) at 100 rpm and 37 °C 
for each sample. At the fixed time intervals of 2, 6, 10, 15, 20, 30, 60, 90 and 120 
minutes, 5 mL aliquots of the release medium were withdrawn and the same amount 
replaced with the fresh PBS. The drug content in the withdrawn aliquot was analyzed 
in UV spectrophotometer at 221 nm. Percentage drug release versus time data were 
plotted to establish drug release profiles from the formulations based on three 
replications. 
3.18 RAMAN SPECTROSCOPY 
WItec alpha 300 series (system ID: 100-1200-736, configuration: Raman 532 
nm) Raman instrument was used for spectral analysis of the individual components 
and scanning of the powder formulations. The purpose of the analysis was to identify 
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the additives and IBP drug component distinctively in the powder formulation from 
the Raman mapping. The samples were placed on a glass slide for running the 
spectrum of each of the components. A stainless-steel cup was filled with the 
formulation powder sample with a coverslip on the top for the confocal scans. The 
objective magnification of the lens was Zeiss 50×/0.7 and the laser power (THOR 
labs) used for each run was 10 mW.  The scans were done with a spot size of 20/20 
micron and step size of 41 with the integration time of 1s. The instrument was 
calibrated with pure silicon. IBP, Pl F127, HPMC and L-leucine spectrums were 
recorded using the commercial material as purchased. A D-mannitol spectrum was 
recorded after freeze drying the commercial material. The spectrum analysis and 
mapping of the powder components in the mixture were done using WITec control 
four and project four software. 
3.19 CONCLUSION 
Determination of IBP solubility by the dissolution method was validated by 
calibrating the UV spectrophotometer in the range of 0-50% aqueous ethanol 
solvents. The equilibrium of the IBP drug concentration was confirmed for each 
solvent system used. Method of preparing IBP particles in APC process was 
described. All the methods for the measurements of particle size, density, flow, 
crystallinity of prepared IBP particles and the milled IBP were demonstrated. A UV 
spectrophotometer was calibrated at 221 nm wavelength and the method was 
validated in duplicate to determine the drug dispersibility in the twin stage impinger. 
At least five capsules for each formulation were measured for the evaluation of in 
vitro aerosol performance of each formulation. Dissolution tests for the milled IBP 
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  Solubility of ibuprofen in Chapter 4:
aqueous ethanol with additives  
4.1 INTRODUCTION 
The solubility of a compound is important in understanding the design and 
optimization of crystallization processes and drug delivery systems [29, 92, 191], 
especially in pre-formulation studies of new drugs and dosage forms [193, 212-214]. 
Ibuprofen (IBP) is a non-steroidal anti-inflammatory drug and is classified as a water 
insoluble compound (BCS Class II) [192, 215]. The non-random two-liquid (NRTL) 
and universal quasichemical (UNIQUAC) models [216, 217] for solubility prediction 
of seven pharmaceuticals (lovastatin, valsartan, paracetamol, budesonide, 
allopurinol, furosemide and sulfadiazine) have been useful for determining the 
crystallization yield per mass of single, binary and ternary solvent mixtures and 
estimating the optimum solvent mixture [218, 219]. The solubility prediction models 
were also used to distinguish the difference between two polymorphs of buspirone 
hydrochloride, as the Gibbs free energy difference can be obtained from the 
solubility data of two polymorphs [220]. This chapter will correlate the recemic IBP 
solubility in aqueous ethanol at 10, 25 and 40oC by a single equation. Then the effect 
of the excipients on IBP solubility will be explained. 
4.2 SOLUBILITY MEASUREMENT METHOD  
Solubility studies were carried out using the method described in Chapter 3, 
section 3.5. For aqueous ethanol solvents, the IBP solubility was determined at 10, 
25 and 40oC. In Chapter 3, Figure 3.8 and Figure 3.9 show the approach to 
equilibrium for several experiments and indicated that solubility experiments should 
be continued for at least six hours to ensure equilibrium has been reached. Solubility 
by dissolution was performed by adding IBP to a chosen ethanol–water solvent (0 to 
50% E/(E+W) by weight where E = ethanol and W = water). Solubility by 
crystallization was determined by the addition of an IBP in ethanol solution (0.112 
g/g) into a stirred anti-solvent water making a chosen final ethanol composition 10 to 
50% E/(E+W). The effect of HPMC, Pluronic F127, leucine and mannitol excipients 
on IBP solubility was investigated at 25°C. The concentration ranges used were 0 to 
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2% w/w HPMC/(E+W), 0 to 1.85% w/w Pl F127/(E+W), 0 to 1.5% w/w 
leucine/(E+W), 0-9% mannitol/(E+W) in 0 to 20% w/w E/(E+W) aqueous ethanol. 
Drug solubilities were determined in triplicate under each condition and the results 
are reported as the mean with estimated 95% uncertainties.  
4.3 RESULTS AND DISCUSSIONS 
Rashid et al. [221] measured the solubility of IBP in aqueous ethanol at high 
ethanol contents (> 50%, w/w E/(E+W) (where E = ethanol and W = water)) at 10, 
25 and 40oC. The present work [222] extends the study to the lower ethanol contents 
and also explores the effect of four excipients Pluronic F127, HPMC, L-leucine and 
D-mannitol on IBP solubility in water ethanol co-solvents. All those experiments 
were performed at least with triplicate samples. The error bars in the figures of this 
chapter are smaller than the used markers. The raw data given in the Table 4.1 and 
4.2 and the appendixes (Appendix B1 and B2) corresponding to those figures 
includes the details of the sample number and the percentage errors. 
 Solubility in aqueous ethanol without excipients 4.3.1
Table 4.1 summarises the measured solubility results. Figure 4.1 shows the 
present results for IBP solubility in aqueous ethanol without excipients at 10, 25 and 
40 oC. Note that a log scale is used for the solubility. The majority were measured by 
the dissolution method, and those indicated (by a diamond) by the crystallization 
method. Figure 4.2 combines the present results with the prior data of Rashid et al. 
[31] (for higher ethanol contents), showing an apparent consistency with the earlier 
data. Solubility is still shown as a mass ratio. Figure 4.1 also shows solubility values 
obtained from crystallization (rather than dissolution) experiments. The 
crystallization results are in reasonable agreement, although, for unknown reasons, 
they are a little higher than the dissolution values. Note that the solubility in Figure 
4.2 covers nearly five orders of magnitude (from mass ratios of 3*10-5 in water to 
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Table 4.1 IBP solubility data in 0–50% aqueous ethanol solvents at 10, 25 and 40°C. 
The percentage errors are the estimated 95% uncertainties on the solubility values. 
 
10°C 25°C 40°C 
E/(E+W)

















0 41.1 0.4 0 45.5 2.6 0 88.4 5.9 
10.18 65.1 2.2 5.16 71.0 2.5 10.44 216.7 3.8 
20.16 124.4 4.7 10.07 102.4 1.5 20.57 1029 1.6 
29.36 403.0 4.3 15.28 159.8 2.4 
†
29.92  6525 5.4 
39.94 2165 3.9 19.94 284.7 0.7  
49.67 20410 2.8 20.85 367.3 1.8    
   30.1 1852 2.8    
   39.65 12470 3.6    
   50.19 67849.4 4    
   Solubility by crystallization  
   9.21 126.55 17.86    
   17.80 248.08 8.79    
   26.55 955.71 2.21    
   35.44 4934.75 0.64    
† Above 34%, phase separation occurred. 
 
Figure 4.1 .Results for the solubility of IBP in aqueous ethanol (0-50%, E/ (E+W)) at 
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Figure 4.2 IBP solubility in aqueous ethanol (filled symbols), compared with results 
of Rashid et al. [31] (unfilled symbols). 
 
The results in Figure 4.2 have been fitted by the sigmoid relation, 
       (   )    (    ( −   )) (      −(  − (    ( −   ))) 
  )      (  1) 
 
where sol = IBP solubility as mass ratio I*/(E+W) in ppm, t = temperature in oC and 
XE = E/(E+W) is the ethanol content of the solvent as a solute free mass ratio. Here 
I* = IBP at equilibrium, E = ethanol and W = water. The parameters of the sigmoid 
were taken to be linear functions of temperature but only the two shown as functions 
of temperature were significant. The values of the parameters are shown in Table 4.2 
with their percentage uncertainty. The correlation fits an estimated 95% of the 
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Table 4.2 Values of parameters in correlation. 
 
 Parameters Value % uncertainty1 
a -4.56 3 
b 4.63 4 
c 0.36 7 
d 0.12 20 
e 0.02 75 




1 95% uncertainty on parameter, as% . 
2 Goodness of fit to data, as%. 
 
Figure 4.3 shows the goodness of fit of the experimental data to the correlation. The 
42% error lines are shown. The biggest errors are those for Rashid et al. [31] for the 
lower ethanol contents where the evaporation to dryness measurement technique 
used becomes of limited accuracy. It is expected the correlation fits the true 
solubility within ± 10%. 
 
Figure 4.3 Goodness of fit of the solubility correlation to the data. 
 
0.5






























Chapter 4: Solubility of ibuprofen in aqueous ethanol with additives 78 
For low ethanol contents (< 50%) the data in Figure 4.2 approximately follow a 
straight line (on a log scale) so the effect of ethanol on solubility is near exponential, 
i.e. the solubility doubles for each ~ 3% increase in ethanol content. 
 
As demonstrated by Rashid et al. [31] and indicated on Figure 4.1 and Figure 4.2, 
there is phase separation (three phases) for a range of solution concentrations at 40 .oC 
(see section 4.3.2 below). 
 
This measured solubility data will be used to design the crystallization conditions to 
produce fine (<5 µm) IBP crystals for DPI formulations. This solubility trend will 
also be used to select a suitable aqueous ethanol solvent to wash the drug formulation 
after in vitro drug dispersion tests using the twin stage impinger. 
 Phase separation analysis at 40°C 4.3.2
 
Phase separation was confirmed by Rashid et al. [31] at 40 °C when the ethanol 
in water percentage used is above 34% and below 63%. This phenomena was also 
reported by other literature [191, 223]. A brief experiment was undertaken to confirm 
these values which are in approximate agreement with Rashid‘s values. Figure 4.4 
shows these two liquid layers. The 30% E/(W+E) (a) does not show any liquid phase 
separation but the other two do. The interface between the two liquid layers (40 and 
50% (E/E+W)) is clearly seen. IBP crystals are the densest species and they sink to 
sit in the bottom liquid layer.  
 
 Figure 4.4: IBP induced phase separation with 40 & 50% E/(W+E) solvents at 40 
ºC. 30% E/ (E+W) (a) does not show phase separation. 
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4.4 SOLUBILITY WITH ADDITIVES 
The purpose of determining IBP solubilities with the additives was to find out 
the maximum limit of saturation for the crystallization process. So, only three points 
were chosen for the determination. As the purpose of finding out the saturation limit 
of IBP with additives was achieved, we attempted to increase the experimental points 
in the later Figures 4.9 and 4.10. But due to the time limitation it couldn‘t be 
increased for the other experiments. So, we leave the experiments for the trends of 
solubilities for future work. 
 Effect of Pluronic F127 (Pl F127) 4.4.1
The growth rate inhibition effect of Pl F127 on IBP APC is a phenomenon that 
is well established in previous studies [28, 117, 124]. Hence, Pl F127 was chosen by 
Khan [28], and in the present study, as the additive for producing fine IBP crystals 
(<5 µm). The effect of the additive on IBP solubility at low ethanol aqueous solvents 
was investigated for the APC process. The IBP solubility increased linearly with the 
concentration of Pl F127 at each of the three ethanol contents (Figure 4.5). The raw 
data is given in Appendix B2. 
In ppm Pl F127 (% g/g solvent) units, the slopes of the lines in the units of Figure 
4.5 are 560 (± 4) for 0% E; 785 (± 5) for 10% E and 1520 (± 3) for 20% E. A 
correlation for the effect of Pl F127 on the solubility is  
          (   −                  
 )              (4.2) 
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Figure 4.5 . Effect of Pl F127 on IBP solubility in aqueous ethanol at 25oC. 
 
A possible explanation for the trend might be the effects of the ethylene oxide (EO) 
and propylene oxide (PO) blocks in Pl F127. The hydrophobic core (PO) block acts a 
reservoir for the drug and the hydrophilic portion (EO) functions as interface 
between the aqueous medium and the drug [136]. As a nonionic surfactant Pl F127 
molecules form monomolecular micelles with the drug at low concentration. 
However, these monomolecular micelles aggregate with each other at higher 
concentration (above the critical micelle concentration, typically ~ 0.7%  Pl  F127) 
[120, 136, 224]. Therefore, it was necessary to identify the optimum concentration of 
Pluronic F127 before using it in IBP precipitation.  
When ethanol is present, the solubility increases but the relative effect of  Pl F127 on 
the solubility falls slightly. A possible mechanism is that the proximate attraction of 
ethanol towards hydrophobic IBP suppresses the solubility enhancement effect of Pl 
F127. Verma et al., determined IBP solubility in 0.5%  Pl  F127 [117] and the value 
is in agreement with the linear correlation obtained in this work (Figure 4.6). In 
summary, the evidence from this study suggests that Pl F127 increases the IBP 
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Figure 4.6.Solubility of IBP with Pluronic F127 and HPMC in the concentration 
range 0-2%. The orange points were reported by Verma et al. [117]. 
 
 Effect of HPMC 4.4.2
Figure 4.7 shows the effect of HPMC on solubility in the absence of Pl F127. 
Again the results appear to be linear with the excipient concentration. At all ethanol 
contents the slope of the line is ~ 17 (± 4) ppm /HPMC (% g/g of solvent). This 
effect is far smaller (81 approx. one fiftieth) than the effect of Pl F127 (Figure 4.5). 























% w/w additives as ratio to solvent 
Sol = 48 + a*x 
Pl F127    a  = 560 
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Figure 4.7. Effect of HPMC on IBP solubility in aqueous ethanol. 
 
HPMCs are the substituted cellulosic polymers considered the most successful 
stabilizers for preparation of IBP suspensions [28]. Stabilization occurs by adsorbing 
onto the surface the IBP particles through the interaction of the hydrophobic 
methoxyl groups and hydrophilic hydroxypropyl groups present in the polymeric 
chain of HPMC [117]. It is also evident that the intermolecular hydrogen bonding 
between IBP and HPMC plays a role in prolonging supersaturation through 
nucleation inhibition, resulting in the stabilization of amorphous IBP particles [134]. 
Therefore, the APC process involving IBP suspension preparation requires using 
HPMC as a stabilizer to keep the fine IBP crystals non-aggregated in suspension 
during storage before drying. To identify the optimum quantity for use in 
precipitation, the effect of HPMC on IBP solubility was studied.  
As a first approximation it might be assumed the effect of both excipients is the sum 
of the single effects, i.e. 
          (   −                  
 )              
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where Sol is the IBP solubility (as I/(E+W) in ppm) in the presence of excipients, 
Sol0 is that in the absence of excipients (as given by equation 4.1) and [E], [Pl F127] 
and [HPMC] are the concentrations of ethanol, Pl F127 and HPMC as % g/g to 
solvent. 
Figure 4.8 plots the experimental solubility results against the Pl F127 concentration 
with ethanol HPMC contents as parameters. The results are grouped in terms of the 
nominal ethanol content. The lines show the values predicted by the correlation (Eqn. 
4.3) for 0 and 2% HPMC. The data is in reasonable agreement with the correlation 
although the amount of data is limited. The solubility data is given in Appendix B2. 
 
Figure 4.8. Solubility of IBP in mixtures of solvent and excipients. The solid lines are 
the predictions with no HPMC and the dotted lines with 2% HPMC. The first four 
entries in the legend are for 20% E. The last five are for HPMC and ethanol. 
 
The purpose of using polymeric stabilizers is to deliver stability for IBP 
nanosuspensions on short term storage and to achieve successful formation of 
nanocrystals during particle production. The literatures suggests that HPMC and Pl 
F127 serve these purposes effectively [28, 117, 120, 137]. In this work the effect of 
excipient combinations on solubility were investigated at three levels of aqueous 
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varied up to 2%, w/w as (Pl F127+HPMC)/(E+W). It has been reported that the 
polarity of the solvent decreases as the amount of organic solvent increases, which 
favors the solute-solvent interaction, especially in case of a nonpolar drug molecule 
like IBP, and affects the function of nonionic polar excipients like HPMC and Pl 
F127 on solubility enhancement [28, 225]. However, the effect of the excipients in 
this work was found to increase IBP solubility by a factor of fourteen compared to 
the solubility determined in water-ethanol co-solvents alone. 
 Effect of L-Leucine 4.4.3
The effect of leucine on IBP solubility was investigated for three 
concentrations of leucine (0.5, 1.0, & 1.5%) in the crystallization media, which 
comprised HPMC (0.4%), Pl F127 (1.4%) and mannitol (5.2%) in 10% aqueous 
ethanol (All additive + 0.1 E/(E+W)) (Figure 4.9). To investigate the effect of 
leucine alone, IBP solubility was determined at four different concentrations of 
leucine in water and 10% ethanol solutions (0.1 E/(E+W)). In the 10% aqueous 
ethanol solvents with all additives, the IBP solubility was increased linearly with 
leucine concentration. For all ethanol contents the slope of the line is ~55 (± 2). This 
value was approximately three-fold of the HPMC and one-seventeenth of the Pl F127 
effect on IBP solubility. The slope of the IBP solubility in the crystallization medium 
increased four times compared to that of leucine only solvents. It was also noticed 
that IBP solubility with ethanol compared to without ethanol did not increase 
significantly. The hydrophobic nature of both IBP and leucine [226] causes 
competition for the available ethanol. Thus, the drug solubility could not be 
enhanced as it was supposed to be in presence of ethanol in the solvent. Solubility 
data is given in Appendix B2. 
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Figure 4.9. Effect of L- leucine on IBP solubility. 
 
 Effect of Mannitol 4.4.4
To investigate the effect of mannitol alone, the IBP solubility was determined 
at four different concentrations of mannitol with aqueous and 10% ethanol solutions 
(Figure 4.10). For mannitol as the only excipient the IBP solubility trend was stable. 
For the 10% ethanol the IBP solubility follows no specific trend but increased 
slightly due to the ethanol. A similar effect was found in the crystallization medium 
(all additives); again IBP solubility increased significantly compared with the other 
two solvents (water and 10% aqueous ethanol). Thus, the increased concentration of 
mannitol does not affect the IBP solubility in any solvent composition with solubility 
expressed as a mass ratio of IBP to solvent (E+W). A similar effect was observed in 
the solubility of other water insoluble drugs (Ursodeoxycholic acid, rofecoxib) [227, 
228]. So, using this additive will not cause any fundamental change in the IBP mass 
ratio concentration during the APC. It will serve as an inert species to recover the 
prepared IBP fine particles after the freeze drying process. The effect of mannitol in 
IBP solubility was investigated using the crystallization media with three different 
concentrations of mannitol. Solubility data is given in Appendix B2. 
 
R² = 0.9962 
R² = 0.9886 




























Leucine, %,  w/w 
All additive+0.1E/(E+W) 0.1E/(E+W) Water
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Figure 4.10. Effect of mannitol on IBP solubility. 
 
4.5 CONCLUSIONS  
The experimental solubility data of IBP was determined in aqueous ethanol 
solutions at 10, 25 and 40 °C. The solubility of IBP increases considerably with 
increasing ethanol contents and also increases with temperature. The experimental 
data at 25 °C was in good agreement with the prior data of Rashid et al. [31]. A 
correlation is given to fit all the measured data (without excipients) (Figure 4.2). 
This correlation can be used to select a suitable solvent for washing the IBP drug 
during the in vitro drug dispersion test using a twin stage impinger. The effect of the 
four excipients HPMC, Pl F127, mannitol and L-leucine in solubility enhancement 
was investigated first as single component and then in combinations. Pl F127 raises 
the IBP solubility considerably, with the increases depending on the ethanol content. 
HPMC has a smaller effect. The combined effect of both excipients appears to be 
additive. The effect of leucine was positive in increasing the IBP solubility linearly 
with concentration. Mannitol did not show any effects on the IBP solubility. The 
results allowed calculation of the minimum amount of initial drug to be used to 
precipitate IBP during the antisolvent precipitation crystallization to produce fine (<5 






























Mannitol, %,  w/w 
All additive + 0.1 E/(E+W) 0.1E/ (E+W) Water
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 Investigation of variables Chapter 5:
affecting ibuprofen particle size 
and morphology 
5.1 INTRODUCTION 
Chapter 5 involves the investigation of variables affecting the size of the 
ibuprofen (IBP) drug particles from an anti-solvent precipitation crystallization 
(APC) process. The experimental methods of the APC process and a Plackett-
Burman design studying nine variables and screening for the most effective ones are 
discussed at the beginning of this chapter. Then the effects of individual excipients 
such as Pluronic F127 (Pl F127), HPMC (hydroxypropyl methyl cellulose), L-
leucine and D-mannitol on the size of the particles‘ are discussed. A comparative 
study of the particle morphology is made in the presence and absence of the HPMC 
and Pl F127 polymers, using scanning electron microscope images of IBP particles. 
Then a comparative study on the particle size is made between particles prepared 
with four additives and without the leucine and mannitol. Thus, an optimized method 
for preparing IBP particles (<5) µm is established by characterizing the particle size, 
using a Malvern Mastersizer 3000, SEM and TEM. 
5.2 EVALUATING THE SIGNIFICANT VARIABLES USING PLACKETT-
BURMAN DESIGN 
It was necessary to know which operating variables affected the product crystal 
size produced from the crash crystallization of IBP by the rapid addition of an 
ethanolic solution of IBP to an aqueous solution (containing excipients) in batch 
crystallizers. The product is desired to have an average size < 5 µm so the material 
can be used as an inhalable product. Table 5.1 shows the variables suggested as 
possibly having an effect. The ranges in Table 5.1 were chosen according to the 
Plackett-Burman design of experiments. These ranges were also chosen based on the 
trial and error experiments and the parameters were chosen from the references [28, 
124, 152, 200, 201]. 
The crystallizer used for this experiment was shown in Chapter 3 Figure 3.12. 
 
  









+ values (High) - Values (Low) 
X1 Stirring rate 2000 rpm 500 rpm 
X2 HPMC 1% 0.10% 
X3 Pluronic F127 2% 0.50% 
X4 Ethanol 10% 1% 
X5 Ibuprofen 0.005g/g E 1g/g E 
X6 Infusion rate 1000µl/s  100 µl/s  
X7 Ultrasound level  ON  OFF 
X8 Temperature 8-10°C 23-25°C 
X9 Batch size 100g 10g 
 
 Plackett–Burman design 5.2.1
A Plackett-Burman designed experiment [229] was considered appropriate as 
this gives a linear estimate of the effect of each variable with the smallest number of 
experiments. Each variable is investigated at a high (+) and low (-) level. Thus it is 
necessary to choose high and low levels for each variable. The choice should give 
values as far apart as possible to cover the near-full range of each variable, yet each 
condition should give a reasonable result (average product size say from 1 to 10 µm). 
Extreme size results will disturb the analysis. The high and low levels chosen are 
shown in Table 5.1. In retrospect some of the levels chosen were too extreme, but 
this was not known initially.  
 Results 5.2.2
An N = 16 Plackett-Burman pattern was chosen, so with the 9 variables above 
this results in 6 ―dummy‖ variables (A-F) which will be used as a measure of 
reproducibility. The Plackett–Burman design is shown in Table 5.2, where the level 
of each variable is indicated by a 1 (high) or –1 (low). The experiments were 
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undertaken using these levels and the results (the volume median size of the product 
(D[v,0.5]) and the size spread (Span) are also shown on Table 5.2. 
 
Table 5.2 Sixteen experiment Plackett–Burman design, with results. 
 
Trials X1 X2 X3 X4 X5 X6 X7 X8 X9 A B C D E F D[v,0.5]µm Span 
1 1 1 1 1 -1 1 -1 1 1 -1 -1 1 -1 -1 -1 18.1 1.6 
2 1 1 1 -1 1 -1 1 1 -1 -1 1 -1 -1 -1 1 12.4 2.9 
3 1 1 -1 1 -1 1 1 -1 -1 1 -1 -1 -1 1 1 8.0 1.3 
4 1 -1 1 -1 1 1 -1 -1 1 -1 -1 -1 1 1 1 7.8 1.3 
5 -1 1 -1 1 1 -1 -1 1 -1 -1 -1 1 1 1 1 66.7 1.4 
6 1 -1 1 1 -1 -1 1 -1 -1 -1 1 1 1 1 -1 9.2 1.5 
7 -1 1 1 -1 -1 1 -1 -1 -1 1 1 1 1 -1 1 7.1 26.3 
8 1 1 -1 -1 1 -1 -1 -1 1 1 1 1 -1 1 -1 7.1 17.0 
9 1 -1 -1 1 -1 -1 -1 1 1 1 1 -1 1 -1 1 15.1 1.5 
10 -1 -1 1 -1 -1 -1 1 1 1 1 -1 1 -1 1 1 223 0.8 
11 -1 1 -1 -1 -1 1 1 1 1 -1 1 -1 1 1 -1 205 0.7 
12 1 -1 -1 -1 1 1 1 1 -1 1 -1 1 1 -1 -1 5.6 3.2 
13 -1 -1 -1 1 1 1 1 -1 1 -1 1 1 -1 -1 1 345 2.0 
14 -1 -1 1 1 1 1 -1 1 -1 1 1 -1 -1 1 -1 8.8 4.2 
15 -1 1 1 1 1 -1 1 -1 1 1 -1 -1 1 -1 -1 26.7 8.2 
16 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 5.81 2.0 
 
The first point to note is that six of the experiments (nos 13, 10, 11, 5, 15, 9) gave 
average size results far outside the reasonable range. The first five of these results 
had a low level of stirring (500 rpm) which may not have been high enough to 
quickly mix in the added ethanolic solution or to keep the crystals suspended. Five of 
these six experiments (except for no. 5) also had the largest batch size, which 
reinforces the suggestion of inadequate mixing. Having an average size of 345 µm 
amongst other data around 5 µm will certainly greatly disturb the numerical analysis 
of the results. It is also noted that some of the product had multi-modal size 
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distributions resulting in large Spans (> 3) which would disrupt calculations for the 
effect of the variables on the size spread (Span). 
 Analysis of Plackett-Burman results 5.2.3
In spite of the above, it was decided to conclude the calculations for the 
Plackett–Burman results. Table 5.3 shows the calculated effect of each variable. The 
effect of each variable is calculated by summing the product of the result (D[v,0.5]) 
and the signs in the column for that variable (Table 5.2). This is divided by N, the 
total number of experiments (= 16). The effect is the predicted change in the result 
(D[v,0.5]) for a change in the variable equal to half the difference between the high 
and low values shown in Table 5.1, with all other variables held constant. The very 
large values for the effect (e.g. -50 µm for stirring rate) shown in Table 5.3 result 
from the very large sizes found in the experimental results, as described above. The 
sum of squares deviation for each variable (SSq) is the square of the effect multiplied 
by N. The degree of freedom (Dof) is 1 for each variable as there was only one 
change in its value. The numerical average of the sizes was 67.2 µm and its 
evaluation ‗consumed‘ one degree of freedom, leaving 15 for the variables. 
Table 5.3 Effect of variables and sum of squares. 
 
Variable Effect SSq Dof 
Stirring rate -50.31 40497 1 
HPMC -16.82 4526 1 
Pl F127 -21.58 7451 1 
Ethanol 1.49 35 1 
Ibuprofen -0.70 8 1 
Infusion rate 14.96 3582 1 
Ultrasound 43.65 30483 1 
Temperature 8.63 1192 1 
Batch size 45.26 32776 1 
A -23.03 8487 1 
B 15.50 3844 1 
C 24.51 9612 1 
D -17.82 5080 1 
E 6.23 621 1 
F 24.93 9941 1 
 
Since the effects for the dummy variable (A–F) are just a measure of error, their sum 
of squares was combined (Table 5.4). This is shown as an ANOVA (Analysis of 
Variance) table. The mean sum of squares (MSSq), an estimate of the variance, is 
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obtained by dividing SSq by Dof. F is the ratio of the MSSq to that estimated for the 
error. At the 95% confidence level the critical F value (F[1,6]) is 5.99, so only one 
result (stirring rate) exceeds this and is a significant effect. Very low F values are 
shown in red.  
Table 5.4 ANOVA table for all variables. 
 
Variable SSq Dof MSSq F 
Stirring rate 40497 1 40497 6.46 
HPMC 4526 1 4526 0.72 
Pl F127 7451 1 7451 1.19 
Ethanol 35 1 35 0.01 
Ibuprofen 8 1 8 0.00 
Infusion rate 3582 1 3582 0.57 
Ultrasound 30483 1 30483 4.87 
Temperature 1192 1 1192 0.19 
Batch size 32776 1 32776 5.23 
Error 37586 6 6264   
 
The least significant variable (Ibuprofen) was then eliminated and its SSq treated as 
error and the ANOVA re-calculated. This was continued until all non-significant 
variables were removed. Finally only stirring rate, batch size and ultrasound were left 
as variables significantly affecting the product size (Table 5.5). At the 95% 
confidence level, the critical F value (F[1,12]) is 4.75, so all three remaining 
variables have a significant effect on product size. 
Table 5.5 Final ANOVA. 
 
Variable SSq Dof MSSq F 
Stirring rate 40497 1 40497 8.94 
Ultrasound 30483 1 30483 6.73 
Batch size 32776 1 32776 7.23 
Error 54381 12 4532   
 
The same was confirmed from the Pareto graph (Figure 5.1) in which it shows 90% 
of the standardized effect on D[v,0.5] was from the variables‘ stirring rate (X1), batch 
size (X9) and ultrasound (X7). 
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Figure 5.1 Pareto chart showing the effect of different factors on the volume median 
diameter (D[v,0.5]) of IBP particle based on the observations of the Plackett-
Burman design. 
 
 Final equation 5.2.4
Finalising the Plackett–Burman analysis, the linear model fitting the data (in 
terms of -1, 1 coding for the variables) is, 
D[v,0.5]pr = 67 (± 37) - 45 (± 37) *St’ + 45 (± 37) *Ba’ + 44 (± 37) *Us’           (5.1) 
 
where D[v,0.5]pr is the predicted product size, St’ is the scaled stirring rate, Ba’ the 
scaled batch size and Us’ the scaled use of ultrasound. The value in brackets is the 
estimated 95% uncertainty on the coefficient. The dash symbol (‗) indicates scaled 
variables coded (-1, 1). This equation is readily coded into the variables with actual 
units using (from Table 5.1) St‘ = (St -1250)/750, Ba‘ = (Ba – 55)/45 and Us‘ = 2*Us 
-1, if ultrasound on = 1 and no ultrasound = 0, where the variables without dashes are 
in the original units shown in Table 1. Substituting gives,  
D[v,0.5]pr = 52 (± 40) - 0.067 (± 0.05) *St + 1.01 (± 08) Ba + 87.2 (± 75) *Us   (5.2) 
 
Thus a change in stirring rate from 500 to 1250 rpm would increase the volume 
median size of the product by 45 µm, which is not a useful result as the desired 
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This analysis used the volume median size of the product as the result. An analysis 
was also done using the log of this size as the result (to bring the larger sizes closer 
to the bulk of the results) but it gave similar conclusions. 
 Conclusions 5.2.5
Because of the range of variables chosen (particularly the stirring speed) a 
number of the results were out of range and the analysis was not very helpful.  
It was decided not to repeat the Plackett–Burman experiment as considerable 
experience had been obtained undertaking the exercise. Instead it was decided to 
explore a number of the variables individually. 
5.3 OPTIMIZATION OF THE PRECIPITATION PROCESS CONDITIONS 
 Temperature 5.3.1
The APC of IBP was undertaken in a constant temperature bath as described in 
Chapter 3, Section 3.8. The influence of the temperature on the resulting particle size 
was tested by increasing the temperature from 15 °C to 30 °C from individual batch 
crystallization. The smallest particle size was obtained at 25 °C temperature, as 
shown in Figure 5.2. The dried particles were resuspended in the saturated 
crystallization media for the size measurements in Malvern Mastersizer 3000. The 
investigation indicated 25 °C as the most suitable temperature to get inhalable size 
IBP particles. The raw data is given in Appendix C1. 
 
Figure 5.2 Effect of temperature of the precipitation process on particle size. Mean ± 
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 Ultrasound 5.3.2
The Plackett-Burman design indicated that longer ultrasound duration will 
cause a larger particle size of IBP in the APC process. The indicated result 
contradicts the available studies [230, 231] which state that ultrasound aids in the 
production of small pure crystals with uniform size. However, a further investigation 
was performed by varying the ultrasound duration for the precipitation process and 
the effect on size was observed. Figure 5.3 shows the particle size of IBP produced 
from individual batches using five different duration of ultrasound in the anti-solvent 
precipitation process. The raw data is given in Appendix C2. 
 
Figure 5.3 Effect of ultrasound duration on particle size in the APC process. Mean ± 
SD, n= 3. 
 
Initially the particle size increased with ultrasound duration, but after 30 minutes 
duration the size decreased. A possible reason could be the large volume ultrasonic 
bath unit used for the study. The explanation from the literature states that a fixed 
wave ultrasonic in a larger unit produces weaker penetrating and reflecting waves, so 
vibration and cavitation at some points in the liquid are lower [231]. This results in 
fewer nuclei, and hence in larger crystals being formed [231]. The literature also 
suggests that short duration of the ultrasonic wave fails to blend the solution, 
whereas longer duration reduces crystal size under continuous sonication. The 
production of small crystals via continuous sonication throughout the duration of the 
process can facilitate productive nucleation at higher levels of supersaturation at the 
expense of crystal growth [232, 233]. However, in any event the optimum ultrasound 
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maintained for 30 minutes throughout the process of the APC. Ultrasound causes 
uncontrolled increase of temperature in the longer duration like 60 minutes. The 
results of the investigation on the temperature (section 5.3.1) effect on particle size in 
APC process have shown that uncontrolled temperature during crystallization 
adversely affects the size of the particles. Constant temperature is also an utmost 
condition to control the particle size in the APC process. Though, in the investigation 
particles were smaller at 60 minutes of ultrasound duration to maintain the constant 
temperature of the bath at 25 °C it was decided to run the ultrasound for 30 minutes. 
 Mixing duration 5.3.3
The particle growth equilibrium was considered the deciding factor to finalize 
the solvent-antisolvent mixing duration in the APC process. A single batch run was 
performed to estimate the particle size equilibrium attainment duration. Samples 
were collected at 1, 2, 3, 4, 5, 10, 15 and 20 minutes of mixing, and particle size was 
measured in the Malvern Mastersizer 3000 immediately after sample collection. 
Figure 5.4 plots the particle size as volume median diameter against time in minutes. 
The raw data is given in Appendix C3. 
 
 
Figure 5.4 IBP Particle size vs time for a single batch in the APC process. Mean ± 
SD, n= 3. 
 
The plot shows that in the second minute of mixing the particle size is abruptly 
increased. A possible explanation for this might be that the addition of solvent phase 
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aggregation initially. However, after two minutes of mixing time the particle size 
dropped down to 5.4 ± 0.6 µm and it remained constant at about 6.1 ± 0.5 µm for 20 
minutes of mixing duration. Initial observation from this study suggests that the 
particle growth stopped after 5 minutes of solvent-antisolvent phase mixing. 
Therefore, the mixing duration for the APC process was considered to be a minimum 
of 20 minutes for preparing stable size IBP particles, as it should be continued 
fivefold the time taken for growth to stop. 
5.4 OPTIMIZATION OF THE CRYSTALLIZATION COMPONENTS 
 IBP concentration in the solvent system 5.4.1
An alteration of the IBP concentration in the system had an effect on the final 
particle size obtained in the APC process. Five different IBP concentrations were 
investigated, 1.0%, 0.9%, 0.8%, 0.7% and 0.5%. The largest particle size was 
obtained for 1.0% and 0.5% IBP concentration. However, the volume median 
diameter (D[v,0.5]) of the particle size was 4.88 µm, obtained with 0.8% IBP 
concentration. Change away from this optimum drug concentration increased the 
particle size (Figure 5.5). However, the range of drug concentration for the particle 
preparation was from 0.3 – 2 % IBP (w/w). Because in the final particle preparation 
ultrasound was used during the APC process, which has not been used in the 
investigation for identifying optimum IBP % (w/w). The raw data is given in 
Appendix C4. 
 
Figure 5.5 Effect of IBP concentration on the particle size obtained in the APC 
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 Solvent-antisolvent ratio (S/AS ratio) 5.4.2
The influence of the S/AS ratio on the resulting particle size was tested by 
increasing the ratio from 0.05, followed by 0.06, 0.08, and 0.09, up to 0.1 in 
individual batch crystallizations. The smallest particle size obtained was at a S/AS 
ratio of 0.08 (Figure 5.6). The volume median diameter (D[v,0.5]) of this sample 
was 4.88 µm (D[v,0.5]). A change in the S/AS ratio from this optimum level 
increased the particle size. The raw data is given in Appendix C5. 
 
Figure 5.6 Effect of solvent-antisolvent ratio on particle size of IBP produced in the 
APC process. Mean ± SD, n= 3. 
 
5.5 OPTIMIZATION OF THE ADDITIVE CONCENTRATION 
As mentioned above, Pluronic F127 (Pl F127) was used to restrict crystal 
growth, HPMC to minimise agglomeration, mannitol as a vehicle and a bulking 
agent for recovering freeze-dried IBP crystals [145], and L-leucine as a dispersive 
adjuvant for DPI formulations to enhance aerosol efficiency [158, 159]. Additive 
optimization was very critical due to the presence of four different materials 
(Pluronic F127, HPMC, L-leucine and D-mannitol). In the investigation by Knox and 
co-workers, the crystal growth of paracetamol was strongly influenced by the solvent 
composition used in the anti-solvent precipitation crystallization [234]. Hence, 
several experiments were performed to identify the effect of each additive on the IBP 
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 Hydroxypropylmethyl cellulose (HPMC) 5.5.1
The effect of HPMC on the particle size produced in an APC was investigated 
by running two series of experiments. Table 5.6 shows the formulation table 
including the additive, ethanol, IBP concentrations, batch size and the volume 
median diameter (D[v,0.5]) of prepared particles from the respective batches. 
Table 5.6 Formulation and results for the investigation of the HPMC effect on the 
























± SD, n=5 
H1 0 0 0.0 1.7 10.0 0.3 10 4.4 ± 0.4 
H2 0 0 0.2 1.7 10.0 0.3 10 3.7 ± 0.4 
H3 0.2 0.9 0.0 0.9 9.9 3.0 101.1 7.9± 0.8 
H4 0.2 0.9 0.5 0.9 9.9 3.0 101.7 7.5± 0.4 
 
Formulations H1 and H2 were compared with each other with respect to the mean 
particle size obtained, where H1 is the control batch and H2 has both HPMC and 
pluronic F127. The batch size for H1 and H2 was 10.0 g and the IBP concentration 
was 0.3%. The volume median diameter (D[v,0.5]) obtained from H1 and H2 
indicated a possible small reduction in particle size in the presence of HPMC. To 
ensure the same effect in presence of all other additives, Pl F127, L-leucine and D-
mannitol, H3 and H4 formulations were compared. H3 formulation is the control 
formulation with no HPMC but with the other three additives and H4 is the 
formulation with all additives. The batch size for H3 and H4 was 100.0 (±1) g and 
the IBP concentration used was 3.0%. The particle volume median diameter 
(D[v,0.5]) comparison between H3 and H4 also showed particle size reduction in the 
presence of HPMC. Thus, taken together these results suggest that HPMC is useful to 
keep the particle size smaller during the APC of IBP, which also supports the 
hypothesis suggested by Verma et al. [117]. 
Several experiments were done to optimise HPMC concentration. Figure 5.7 plots 
the volume median diameter (D[v,0.5]) of the particles produced in the APC process 
at different concentrations of HPMC. The raw data is given in Appendix C6. 
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Figure 5.7 Effect of HPMC concentration on IBP particle size produced in the APC 
process. Mean ± SD, n= 3. 
 
These results seem to indicate the optimum concentration would be 0.2% < HPMC < 
0.6% for the smallest particle size. The outliers at 0.09% and 0.9% HPMC resulted 
as the initial IBP load for those experiments were 0.5 g and 8.8 g respectively, which 
was too extreme (too low or too high) to optimize the particle size. The decrease of 
particle size might be because agglomeration was less likely to occur due to the non-
ionic nature of HPMC polymer. The probable mechanism might be the presence of a 
hydrodynamic boundary layer surrounding the crystal suspensions and the adsorption 
of the polymer molecules on the growing crystal faces, while HPMC also provides a 
steric hindrance to agglomeration and crystal growth [235, 236]. Hence, the drug-
polymer system can be explained by hydrogen bonding between the drug molecules 
and the polymer with a profusion of hydroxyl groups. However, the increases in 
particle size with increase in HPMC concentration can be explained by the enhanced 
viscosity of the solution hindering the penetration of ultrasonic wave. Thus, during 
precipitation the diffusion between the solvent and anti-solvent phase is impeded, 
which results in larger particles, and the concentric layers of HPMC also cause 
particle size enlargement [144]. However, for formulations the HPMC concentration 
of 0.2-0.6% was expected to be the optimal range to sufficiently cover the crystal 
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 Pluronic F127 (Pl F127) 5.5.2
The effect of Pl F127 on the particle size reduction of IBP particles in an APC 
has been reported by many researchers [28, 117, 124]. To determine the optimum 
concentration of Pl F127 for the lowest particles size, IBP particles were produced in 
an APC process by using Pl F127 concentrations of 0%, 0.7%, 1.3% and 2.0% in 
individual batches. All the other variables conditions and additive concentrations 
were maintained equally for all batches. Particles were prepared using the same 
method stated in Chapter 3, Section 3.8. Figure 5.8 plots the particle sizes at the four 
different concentrations of Pl F127 from four individual batches. The raw data is 
given in Appendix C7. 
 
Figure 5.8 Effect of Pl F127 concentration on the size of IBP particles produced in 
an APC process. Mean ± SD, n= 3. 
 
The particle size gradually decreases with an increase in Pl F127 concentrations up to 
1.3%. Then there was an increase in particle size at 2.0% Pl F127. An explanation for 
this effect could be that above the critical micelle concentration of Pl F127, it tends 
to form micelles with each other. Then the drug molecules might agglomerate and 
produce larger particles. However, the smallest particles were produced at 1.3% of Pl 
F127 and the volume median diameter was 3.5 ± 0.3 µm. From the results of these 
experiments it was concluded that 1.3% Pl F127 would be the optimum 
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 L-leucine 5.5.3
The effect of leucine concentration on the particle size was investigated by 
varying leucine concentrations (0%, 0.5%, 1.2% and 1.6%) with the same 
concentration of other additives and conditions in individual batches. Particles were 
prepared using the same method described in Chapter 3, Section 3.8. The dried 
particles were resuspended using crystallization medium before the size 
measurement in the Malvern Mastersizer 3000. Figure 5.9 shows the particle size 
results for each concentration of leucine. The raw data is given in Appendix C8. 
 
   
Figure 5.9 Effect of leucine concentration on the size of IBP produced in an APC 
process. Mean ± SD, n= 3. 
 
The volume median diameter (D[v,0.5]) of all the powder formulations was within 
the range of 5-10 µm (Leucine 0%: 7.6 ± 0.2 µm, Leucine 0.5%: 8.2 ± 0.3 µm, 
Leucine 1.2%: 5.9 ± 0.8 µm, Leucine 1.5%: 6.3 ± 0.6 µm). No specific trend was 
observed from this investigation. Another study investigating different leucine 
concentration effects on the particle size observed a similar pattern [158]. However, 
the smallest particle size (though it may not be significant) in our investigation was 
found from 1.2% leucine concentration. Thus, the optimum concentration of leucine 
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 D-mannitol 5.5.4
D-mannitol was used to recover the particles after freeze drying by acting as a 
bulking agent. After drying, the prepared IBP particles tend to form hard 
agglomerates which do not disperse easily while resuspended with a crystallization 
medium. To see the effect of mannitol on the size of prepared IBP particles, a control 
batch without mannitol was compared with a batch with mannitol. The particle size 
of the prepared particles from both batches was measured using the Malvern 
Mastersizer after drying and resuspending with crystallization medium. Figure 5.10 
shows the particle size distributions of the prepared IBP in both batches. 
 
 
Figure 5.10 Effect of mannitol of the particle size of prepared IBP in APC process. 
Mean ± SD, n= 3. 
 
The particle size distribution curve shown that D[v,0.5] of the prepared IBP particles 
in the absence of mannitol is larger than that of the particles prepared with mannitol. 
The size distribution curve for the no mannitol batch showed a small peak in the area 
of particles > 100 µm indicating the presence of large agglomerates. Therefore, it 
was confirmed that mannitol did not increase the IBP particle size during APC 
process and aids in particle dispersion after drying. 
The experiment on local degree of supersaturation was attempted to determine the 
nucleation rate by sampling every 5 seconds up to 30 minutes and the concentration 
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of adding the drug solution into the anti-solvent and the rate of nucleation could not 
be determined.  
In chapter 2 section 2.11.1 the theory of controlling the local supersaturation in the 
APC process was discussed as per the available literature. 
5.6 OPTIMIZED METHOD OF PRODUCING INHALABLE SIZE IBP 
USING HPMC AND PL F127 IN APC PROCESS 
An optimized method of producing inhalable size IBP particles was established 
by using HPMC (0.4%) and Pl F127 (1.4%) as agglomeration and growth inhibitors. 
In this case the solvent and antisolvent phase was mixed together using magnetic 
stirrer at 750 rpm and continued for 20 minutes. The IBP concentration was 0.3% 
and batch size was 10.0 g. This batch was run in triplicate and the particle size of the 
wet crystal suspension of each batch was measured in the Malvern Mastersizer 3000. 
Figure 5.11 presents the particle size distributions for three replicate batches. 
 
 
Figure 5.11 Reproducibility of particle size from three replicate batches of the 
optimized APC method of producing inhalable size IBP particles. Mean ± SD, n= 3. 
 
The particle size distributions of the three batches were found to be in good 
agreement with each other and the mean particle size of the three batches was 3.7 ± 
0.3 µm. This particle size was confirmed from the scanning electron microscope 
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of the images are shown. The images confirm the particle size obtained with the 
Malvern Mastersizer 3000. 
 
Figure 5.12 SEM image of the particles produced in an optimized APC process in 
presence of HPMC (0.4%) and Pl F127 (1.4%). 
 
5.7 EFFECT OF HPMC AND PL F127 ON PARTICLE MORPHOLOGY 
An experiment was executed to identify the effect of HPMC and Pl F127 on 
the particle morphology. Particles were prepared in an APC process using three 
different solvent-antisolvent ratios with and without HPMC and Pl F127 polymers. 
Then the prepared microparticle suspension samples were processed, as described in 
Chapter 3, Section 3.11.1, for the morphology investigation using a scanning electron 
microscope (SEM) after drying. It is seen from the SEM images in Figure 5.13 that 
IBP crystals produced without polymers are isolated from each other and have a 
sharp chunky crystal shape. The crystals produced in the presence of HPMC and Pl 
F127 were a loosely agglomerated form and the shape and morphology of the 
crystals were slightly roughened compared with the crystals produced without 
polymers. No significant difference in the crystal size or morphology was observed 
with the ethanol concentration change in batches both with and without polymer. The 
investigation indicated that the presence of polymers has a potential agglomeration 
effect for the dry crystals. To overcome this problem it was necessary to introduce D-
mannitol and L-leucine as additives during the APC process to acquire better particle 
flow and dispensability after drying.  
  




Figure 5.13 Scanning electron microscope images for the effect of HPMC and 
Pluronic F127 on the morphology of IBP particles produced in the APC process 
after drying. The SEM images 1(a),1(b) & 1(c) (on the left)  represent  particles 
produced without polymers at 5, 10 and 20 % w/w aqueous ethanol. The SEM 
images 2(a),2(b) & 2(c) (on the right)  represent particles produced with polymers 
(0.5% HPMC+0.5% Pl F127)  at 5, 10 and 20 % w/w aqueous ethanol. 
 
5.8 EFFECT OF LEUCINE AND MANNITOL ON PARTICLE SIZE AND 
MORPHOLOGY 
To overcome the particle aggregation and susceptible degradation of IBP 
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adjuvant were incorporated in the antisolvent phase of the APC process. Hence, it 
was important to ensure the presence of leucine and mannitol does not increase the 
particle size and determine if any effect on the particle morphology exists. To answer 
these questions, particles produced with HPMC and Pl F127 were compared with the 
particles produced with HPMC, Pl F127, leucine and mannitol in terms of size and 
morphology both before and after drying. Figure 5.14 shows the observations from 
the particle size measurements inform the Malvern Mastersizer 3000.  Figure 5.15 
and Figure 5.16 present the particle images from the scanning electron microscope 
and the transmission electron microscope.  
  
Figure 5.14 Effect of leucine and mannitol on the size of IBP particles produced in 




 Figure 5.15 Effect of leucine and mannitol on the morphology of IBP particles 
produced in the APC process from the scanning electron microscope images; a) All 
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Figure 5.16 Effect of leucine and mannitol on the morphology of IBP particles 
produced in the APC process from the transmission electron microscope images; a) 
All additives; b) No L-leucine and D-mannitol. 
  
The size distribution curves of the particles from both batches indicated no 
significant increase in particle size in the presence of leucine and mannitol. A 
parallel increase in the dried particle size distribution of both batches after one month 
of drying was observed. However, the particle size characteristics were found to be 
undisturbed due to the presence of leucine and mannitol with HPMC and Pl F127. 
The particle morphology characteristics were similar for both of the batches 
according to the images captured in SEM (Figure 5.15) and TEM (Figure 5.16). No 
size increase was observed from the image analysis either. The findings of the above 
investigation confirmed that leucine and mannitol did not interfere with the particle 
growth of morphology during the APC process. 
5.9 OPTIMIZED METHOD OF PRODUCING INHALABLE SIZE IBP 
USING HPMC, PL F127, L-LEUCINE AND D-MANNITOL IN APC 
PROCESS 
IBP particles were prepared by APC using HPMC (0.2%), Pl F127 (1.3%), 
leucine (1.2%) and mannitol (8.6%). The other method conditions and variables were 
maintained, as described in Section 5.6. The particle size of dried particles 
resuspended in the crystallization medium was measured using the nano zeta sizer 
(Figure 5.17) and the Malvern Mastersizer 3000 (Figure 5.18) with three replicate 
a b 
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batches. The particle size and morphology was also witnessed from the TEM images 
of the resuspended dried particles (Figure 5.19). 
 
Figure 5.17 IBP particle size distribution in Zetasizer from three replicate batches 





Figure 5.18 IBP particle size distribution in Malvern Mastersizer from three 























Mean size 409.5 ± 72.4 d.nm 
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Figure 5.19 TEM image of the particles produced from APC process using HPMC, 
Pl F127, leucine and mannitol. 
 
The particle size distribution curves from the nanoZetasizer showed multimodal 
distribution of particles. The peaks were found at approximate mean diameter of 
5560, 500, 40 and 20 nm. The mean size of three replicate batches from the 
nanosizer was 410 ± 72 nm, with an average polydisperse index (PDI) of 0.66 ± 0.1. 
The size measurement results from Malvern Mastersizer 3000 showed a unimodal 
curve with a small bump in the nano size range (Figure 5.18). The mean D[v,0.5] of 
three replicate batches was 3.9 ± 0.4 µm. The size distributions curves for the same 
particles in both the nano Zetasizer and the Malvern Mastersizer indicated that the 
prepared IBP crystals from the APC process are a mixture of nano and micron size. 
The particle size distributions were slightly different due to the presence of particles 
with the size of both nano-meter covering 1.7 (±1) % and micro-meter 7.5 (±2) % 
range. The nano size particles have 1 % error, which are estimated 95% uncertainties 
on the amount of nanometer size particles from three batches. Whereas the micron 
size particles with 2% error are estimated 95% uncertainties on the amount of 
microparticles prepared from three batches. Though the estimated errors are within 
the acceptable limit it is significant enough to cause the appeared differences 
between the particle distribution curves of the three replicate batches.  This 
phenomenon was supported from the particle images in the transmission electron 
microscope as well. However, the scale bar in the images also indicated that all the 
particles are below 5 µm in size (Figure 5.19). The results from the above findings 
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suggest that leucine and mannitol did not increase the particle size and morphology. 
The IBP particle size was within inhalable size range, as evident from the 
investigations above. Therefore, the optimized method for preparing inhalable size 
IBP particles by the APC process was validated. It was expected that the prepared 
IBP powder formulation will disperse successfully in the in vitro aerosolization test 
as the size requirements of the particles were fulfilled.  
5.10 CONCLUSION 
The Plackett-Burman design indicated ultrasound, stirring speed and the batch 
size as being the most significant variables for affecting the particle size of IBP 
produced in the APC process. Optimized level of temperature (25 °C), ultrasound (30 
minutes), stirring duration (>20 minutes), IBP concentration, solvent/antisolvent ratio 
and the additive concentrations were determined to produce the best inhalable size 
IBP particles. HPMC and Pl F127 agglomerated IBP particles after drying and 
leucine and mannitol improved the particle flow with no increase in particle size. IBP 
particles with the D[v,0.5] of 3.7 ± 0.3 µm were prepared by using HPMC and Pl 
F127 from three replicated batches in the APC process. Finally, a method of 
producing a mixture of nano size (410 ± 72 nm, PDI 0.66 ± 0.1) and micron size 
(3.91 ± 0.4 µm) IBP particles using four additives HPMC (0.2%), Pl F127(1.3%), 
leucine (1.2%) and mannitol (8.6%) was optimized and validated. Therefore, a 
method of producing inhalable size IBP in APC process was established. 
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 Ibuprofen dry powder inhaler Chapter 6:
formulation development, 
characterization and efficiency 
evaluation 
6.1 INTRODUCTION 
This chapter demonstrates the dry powder inhaler (DPI) formulations prepared 
with different compositions of ibuprofen (IBP), leucine, mannitol, HPMC and Pl 
F127 and batch size. The formulations were prepared to compare the effect of batch 
size, IBP concentration, leucine concentration and Pl F127 concentration on the 
aerodynamic diameter, density, flow property, crystallinity and morphology of the 
prepared IBP particles. Finally, the efficiency of the DPI formulations was evaluated 
by testing the drug dispersibility using a Twin Stage Impinger. The dissolution rates 
of the prepared powders and the milled IBP were investigated to understand their 
solubility behaviour. 
6.2 DPI FORMULATIONS OF THE PREPARED PARTICLES  
To evaluate the efficiency of the processed IBP powder in an APC process, 14 
DPI formulations were prepared based on different batch size of crystallization, 
initial IBP concentrations and the additive concentrations. The details of the 
methodology of preparing particles are given in Chapter 3 Section 3.8. Table 6.1 
represents the composition of all the DPI formulations. It is noted that the 
percentages of additives mentioned in the table are the percentages that were 
dissolved in the crystallization medium for the total batch size and are not the 
additive contents of the crystal product. The drug loading of each formulation was 
determined from the weighed amount of powder formulation (10-15 mg) dissolved in 
the suitable solvent system (50% aqueous ethanol).The concentrations of the drug in 
those formulations were measured using UV spectrophotometry at 264 nm 
wavelength. The method was described in Chapter 3, Section 3.15. 
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F1 10 1 1.3 4.5 0.4 1.8 72.7 
F2 30 1 0.9 4.5 0.7 1.3 77.9 
F3 100 1 0.9 4.5 0.7 1.3 90.3 
F4 50 2 1 8.4 0.1 0.9 99.8 
F5 50 2 0 0 0.1 0.9 100.0 
F6 10 1 0.9 4.5 0.6 1.2 83.3 
FPO 50 0.3 0.9 9.0 0.2 0 84.7 
F7 10 0.3 0.9 9.0 0.2 1.2 53.2 
F8 50 0.3 0.9 9.0 0.2 0.6 74.6 
F9 50 0.3 0.9 9.0 0.2 1.8 43.9 
FLO 50 0.3 0 9.0 0.2 1.2 83.9 
F10 50 0.3 1.2 9.0 0.2 1.2 73.5 
F11 50 0.3 1.5 9.0 0.2 1.2 52.7 
FMO 50 0.3 0.9 0 0.2 1.2 99.9 
*These are the percentages of drug/additives in total amount of crystallization 
batch size. 
Each of the products from these formulations was characterized for density, 
flowability, particle size distribution, morphology, crystallinity and in vitro drug 
dispersibility. F1, F2, F3, F6 and F7 formulations had different batch sizes from the 
50g. IBP concentration was varied from 0.3% in the formulations F1 to F6. The 
additive concentrations were 0.9% leucine, 9.0% mannitol, 0.2% HPMC and 1.2% 
Pluronic F127. These concentrations were varied as well. 
The characterizations of the formulations and the milled raw IBP were performed by 
determining the density and flowability, particle size, morphology and crystallinity. 
The obtained results were used to investigate the correlation of these properties of the 
particles on the aerosol and dissolution performance of the prepared DPI 
formulations. 
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6.3 CHARACTERIZATION OF THE FORMULATIONS 
Density measurements were done from the bulk and tapped density 
determinations, the flow property was measured by Carr‘s index, the Hausner ratio 
and angle of repose. Particle size was measured by dynamic light scattering in 
Malvern Mastersizer 3000. Particle morphology was investigated in SEM. 
Crystallinity of the formulations was investigated in DSC and XRD measurements. 
 Density, angle of repose & flowability 6.3.1
Powder bulk density and flowability are important parameters because they are 
closely related to the drug dispersibility. The estimation of the bulk density and 
tapped density (resulting in the Carr‘s index and Hausner ratio) and the angle of 
repose for estimating flowability are given in Table 6.2. The reference values and the 
scale of flowability of powders were discussed in Chapter 3, Section 3.13. 
Flowability of all the formulations given in Table 6.1 was determined and the effect 
of the additive and drug concentration on it was observed from the obtained results. 
The purpose of preparing these formulations was to identify those formulations with 
an inhalable particle size and with a better flow property. 
Table 6.2 Powder flow properties obtained from different formulations as 
[Mean ± SD, n=3] 






Hausner ratio Angle of 
Repose (°) 
Flowability 
F1 0.28 ± 0.02 0.36 ± 0.03 21.5 ± 0.3 1.27 ± 0.01 44.0 ± 0.1 Passable 
F2 0.24 ± 0.03  0.28 ± 0.01 23.7 ± 1.0 1.31 ± 0.02 42.0 ± 1.7 Passable 
F3 0.27 ± 0.04  0.35 ± 0.01 11.1 ± 1.0 1.12 ± 0.01 34.2 ± 1.8 Good 
F4 0.29 ± 0.01 0.34 ± 0.01 13.2 ± 0.8 1.15 ± 0.01 33.9 ± 1.1 Good 
F5 0.27 ± 0.03 0.35 ± 0.01 27.1 ± 0.8 1.37 ± 0.01 50.4 ± 0.2 Poor 
F6 0.26 ± 0.01 0.30 ± 0.02 13.9 ± 0.7 1.16 ± 0.01 36.5 ± 1.3 Good 
FPO 0.20 ± 0.02 0.29 ± 0.01 30.8 ± 0.7 1.44 ± 0.01 53.3 ± 0.4 Poor 
F7 0.18 ± 0.05 0.26 ± 0.02 30.1 ± 0.6 1.43 ± 0.01 53.7 ± 1.1 Poor 
F8 0.22 ± 0.03 0.34 ± 0.04 31.1 ± 0.4 1.45 ± 0.01 53.0 ± 0.7 Poor 
F9 0.21 ± 0.02  0.32 ± 0.01 37.5 ± 0.7 1.60 ± 0.02 60.3 ± 1.4 Very poor 
FLO 0.29 ± 0.001 0.36 ± 0.01 18.3 ± 0.6 1.22 ± 0.01 37.5 ± 0.4 Fair 
F10 0.14 ± 0.01 0.16 ± 0.02 13.1 ± 1.0 1.15 ± 0.01 33.9 ± 2.0 Good 
F11 0.18 ± 0.05 0.21 ± 0.03 26.9 ± 0.5 1.37 ± 0.01 53.3 ± 1.1 Poor 
FMO 0.11± 0.01 0.13 ± 0.02 13.7 ± 0.5 1.16 ± 0.01 34.7 ± 1.9 Good 
Milled IBP 0.13 ± 0.03 0.17 ± 0.05 22.7 ±1.0 1.29 ± 0.02 41.8 ± 0.5 Passable 
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Table 6.2 shows that formulations F3, F4, F6, F10 and FMO had good flow 
properties, F1, F2 and FLO were passable, and the rest were poor. Of those with 
good or passable flowabilities, F3, FPO and FMO formulations had a very large 
particle size (D[4,3] > 10 µm) which is not suitable for inhalation. F4, F5, F6, F7, F8, 
F9, F10, F11 and FLO formulations were suitable for inhalation as their aerodynamic 
diameter was smaller than 5 µm. However, the flow property for F5, F7, F8, F9 and 
F11 was not satisfactory for a DPI formulation. It was expected that the additive 
concentration might have a significant effect on the flow properties of the prepared 
IBP particles. The formulation F4 and F5 were prepared to compare the effect of L-
leucine and D-mannitol on the flow properties. Figure 6.1 presents the comparison 
between the flow properties of formulation F4 and F5, obtained from the Carr‘s 
index and angle of repose results. It is seen that the presence of L-leucine and D-
mannitol in the formulations had good flow property, whereas without them the flow 
properties of the formulations were poor.  
 
Figure 6.1 Effect of L-leucine and D-mannitol on the flow properties of the 
formulations. [Mean ± SD, n=3]. 
 
L-leucine is a well-accepted dispersive adjuvant for use in DPI formulations and it 
has been found to improve the powder flowability in several cases [133, 161, 164]. A 
recent study demonstrated that the enhanced dispersion of L-leucine conjugated 
chitosan nanoparticles was attributed to the amphiphilic environment of the L-
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leucine. The mechanism stated that the hydrophobic domain of L-leucine would be at 
the surface when the formulation is dispersed in air and the hydrophilic domain 
would be at the surface in water during the delivery of the drug [163]. Hence, to see 
the leucine effect on flowability, in this work its concentration was increased 
gradually from 0%, through 0.9%, 1.2% to 1.5% in FLO, F7, F10 and F11 
formulations respectively. However, no specific trend was observed in the 
flowability according to the values of Carr‘s index, Hausner ratio and angle of repose 
(as shown by the angle of repose plot Figure 6.2). Individually the F10 formulation 
shown the maximum flowability (lowest angle of repose) with 1.2% leucine and the 
lowest flowability were seen in F7 with 0.9% leucine.  
 
Figure 6.2 Effect of leucine concentration on particle flow. Here crystallization 
solution contains 0.3% IBP, 9.0% mannitol, 0.2% HPMC; 1.2% Pl F127; 50 g batch 
(except F7 at 10 g). [Mean ± SD, n=3, data from Table 6.2]. 
 
Surprisingly, FLO has no leucine but showed a better flowability than those of the 
formulations F7 and F11 (1.5% leucine). The literature suggests that, an optimal 
amount of leucine is critical to achieving the desired aerodynamic properties of the 
leucine coated particles, as excessive leucine decreases stability with no additional 
benefits [169]. Interestingly, an increase in the Pl F127 concentration in the 
formulations FPO, F8, F7 and F9, where concentration of PL F127 was increased 
from 0% to 0.6%, 1.2% and 1.8%, appeared to influence the flow ability negatively 
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Figure 6.3 Effect of Pl F127 concentration on particle flow. Here, the crystallization 
solution contains 0.3% IBP; 9.0% mannitol; 0.2% HPMC; 0.9% leucine; 50 g batch 
(except F7 at 10 g). [Mean ± SD, n=3, data from Table 6.2] 
The possible reason would be the decreased particle size with increasing Pl F127 
concentration, as the literature suggests that flowability increases significantly with 
increase in particle size [24]. The literature also shows that the drug particle owns a 
partial amorphous form due to the presence of Pl F127 [141], which might have 
influenced the powder flow negatively. This will be discussed in Section 6.3.4. 
Therefore, based on the flowability results, it was expected that F4, F6 and F10 
formulations would be more appropriate candidates for the drug dispersibility tests.  
 Particle size & aerodynamic diameter 6.3.2
The particle size distributions were measured from three replicate samples of 
each formulation. The volume mean diameter (D[4,3]) was used to determine the 
aerodynamic diameter (Dae) using the following equation: 
       √    
where ρp is the tapped densities as determined and given in Table 6.2 and χ is 
the dynamic shape factor, defined as the ratio of the drag force on the particle to the 
drag force on the spherical equivalent particle at the same velocity [22, 50, 55-57, 
156, 237-240]. The average Deq was the volume mean diameter (D[4,3]) as given 
Table 6.3 calculated from at least three replicate runs from the particle size 
distribution curves. The volume percentage (w/w) of particles < 6 µm (effective cut-
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undersize curves of the respective formulations using Malvern Mastersizer v3.10 
software. 
Table 6.3 Particle sizes for the various IBP DPI formulations (units µm [Mean ± SD, 
n=3). 
 
Formulation D[v,0.1],  D[v,0.5],  D[v,0.9],  D[4,3] Dae *<6 µm (%) 
F1 2.9 ± 0.1 6.9 ± 0.1 20.4 ± 2.9 9.6 ± 0.8 5.7 ± 0.1 8.2 ± 0.1 
F2 3.5 ± 0.1 8.5 ± 0.1 18.0 ± 0.2 9.7 ± 0.1 5.2 ± 0.1 6.9 ± 0.1 
F3 4.6 ± 0.1 17.1±0.5 47.9 ± 1.4 22.0 ± 0.4 13.1 ± 0.1 3.5 ± 0.1 
F4 3.3 ± 0.6 6.2 ± 0.2 9.3 ± 0.3 6.3 ± 0.2 3.7 ± 0.1 14 ± 0.3 
F5 4.2 ± 0.3 7.2 ± 0.5 11.3 ± 1.5 7.5 ± 0.5 4.4 ± 0.1 15.4 ± 0.4 
F6 2.9 ± 0.5 5.9 ± 0.8 10.7 ± 1.6 6.5 ± 1.1 3.6 ± 0.1 9.6 ± 0.1 
FPO 6.1 ± 0.1 11 ± 0.6 18.7 ± 1.3 12.34 ± 1.2 6.7 ± 0.1 6.1 ± 0.1 
F7 1.1 ± 0.1 3.9 ± 0.4 9.0 ± 0.9 5.1 ± 0.9 2.6 ± 0.1 4.8 ± 0.1 
F8 3.7 ± 0.1 6.8 ± 0.1 11.9 ± 0.1 7.4 ± 0.1 4.3 ± 0.1 10.5 ± 0.1 
F9 1.3 ± 0.1 6.1 ± 0.1 12.8 ± 0.3 6.7 ± 0.1 3.8 ± 0.1 7.8 ± 0.2 
FLO 3.2 ± 0.1 6.1 ± 0.1 10.1 ± 0.3 6.6 ± 0.6 4.0 ± 0.1 12.6 ± 0.4 
F10 1.4 ± 0.2 6.4 ± 0.3 12.9 ± 0.5 7.1 ± 0.2 2.9 ± 0.1 8.1 ± 0.1 
F11 1.2 ± 0.0 5.4 ± 0.6 11.8 ± 0.7 6.4 ± 0.4 2.9 ± 0.1 7.8 ± 0.2 
FMO 3.7 ± 0.1 8.7 ± 0.1 28.2 ± 1.2 20.9 ± 1.3 7.4 ± 0.2 26.1 ± 1.2 
Milled IBP 1.2 ± 0.1 2.8 ± 0.1 4.45 ± 0.2 2.8 ± 0.1 1.2 ± 0.1 99.7 ± 0.5 
* Effective cut-off diameter (ECD), 6.4 µm [211] 
 
The effect of batch size was noticeable (Figure 6.4) in the F6 (10g), F2 (30 g) 
and F3 (100g) formulations. It shows an increase of D[4,3] from 6.52 ± 1.07 µm 
(F6), 9.73 ± 0.11 µm (F2) and 22.0 ± 0.41 (F3) µm of the particles prepared in 10, 30 
g and 100 g batch sizes respectively. It means increased particle size was observed 
with increased batch size.  Figure 6.4 limits only three points because we were not 
interested to proceed with the experiments where particle size was more than 6.4 µm. 
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Figure 6.4 Effect of batch size on particle size produced in APC process. 
Crystallizaton solution contains 1.0% IBP; 4.5% mannitol; 0.7% HPMC; 1.3% Pl 
F127;0.9% leucine. [Mean ± SD, n=3, data from Table 6.3] 
 
This effect of batch size on particle size was also identified in the Plackett-Burman 
investigation (demonstrated in Chapter 5 Section 5.2). Usually the batch size makes 
no difference and is fundamental in scaling up to industrial scale. It may be the 
mechanics of addition of the alcohol solution which does not scale [99, 241]. 
The concentration of leucine and Pl F127 did not show any specific trend on the 
particle size of the formulations. Figure 6.5 shows the plot of particle aerodynamic 
diameter of the formulations with increasing concentration of Pl F127.  
 
Figure 6.5 Effect of Pl F127 concentration on particle aerodynamic diameter. Here, 
the crystallization solution contains 0.3% IBP; 9.0% mannitol; 0.2% HPMC; 0.9% 
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The aerodynamic diameter of the particles decreased linearly until 1.2% Pl F127 (F7) 
concentration in the formulations. But for an unknown reason, the aerodynamic 
diameter increased in the formulation F9, having 1.8% of Pl F127 concentration. It 
was seen (see Section 5.5) that mannitol and PL F127 aids in reducing particle size. 
FPO and FMO are the formulations without Pl F127 and D-mannitol respectively, 
and particles grew larger in these formulations due to their absence. It has been 
explained in Chapter 2, Section 2.14.3, that mannitol prevents nanoparticle 
aggregation during the drying process. The hypothesis of nanoparticle stabilization 
during the freeze drying step proposes that sugars isolate individual particles in the 
unfrozen fraction, thereby preventing aggregation during freezing above glass 
transition temperature, Tg. In this case, the transition of the substance into a glass is 
not required for this effect and the spatial separation of particles within the unfrozen 
fraction is sufficient to prevent aggregation [153]. As a result, the particle size 
remains stable with no further growth due to aggregation after the drying step. 
Therefore, bearing in mind the limit of an aerodynamic diameter of 1-5 μm for 
successful lung delivery [16-18, 49, 50], the formulations F4, F5, F6, F7, F8, F9, 
F10, F11 and FLO were chosen to be tested for the aerosol performance. 
 Particle Morphology 6.3.3
The particle morphology of the formulations was investigated by scanning with the 
electron microscope (SEM). Figure 6.6 represents the SEM images of raw IBP, 
milled raw IBP and all the formulations. The dried powder formulation was sprinkled 
on an aluminium metal stub and gold coated, following the method described in 
Section 3.11.1. 
  
Raw IBP Milled IBP 
  















Figure 6.6 Particle morphology of the raw and milled IBP and formulations F1, F2, 
F3, F4, F5, F6, F7, F8, F9, F10, F11, FLO, FMO and FPO in scanning electron 
microscopy (Magnification: 5.00 K X). 
 
The crystal habit of IBP depends on the crystallization conditions such as the solvent 
type and presence of additives [133, 207, 242]. Figure 6.6 shows that the commercial 
raw IBP is needle-shaped, whereas the formulation particles crystallized in presence 
of additives are platelike ( Figure 6.6 : F2 & F3), chunky (FMO) or irregular shapes 
(milled IBP, F1, F4, F5,F6, F7, F8, F9, F10, F11, FPO and FLO). The different 
crystal habits and shapes could be the function of the different IBP concentration and 
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shape were mostly with high IBP concentrations, which was 1% for F2 & F3 
formulations. Leucine and Pl F127 concentrations during the crystallization process 
of F1 particles were higher than for the others which may have had more additives on 
the surface of IBP particles causing shape irregularity and roughness. In the case of 
formulation F5, the crystallization was carried out in the absence of leucine and 
mannitol, which resulted in different morphology, with the crystals having rough 
surfaces comprising flat-shaped IBP particles sticking together to make bigger 
particles. As the SEM images here represent the dried form of formulation, it is very 
likely the particles in F5 formulation aggregated and agglomerated into large 
irregular shapes due to drying without the presence of leucine and mannitol. The 
morphology of the formulations F6, F7, F9, F10, F11, FPO and FLO with low IBP 
concentration (0.3%) seems to be the loose agglomerate of IBP particles adhering to 
each other. As the drug concentration was comparatively low during crystallization 
in the presence of all additives, there was no distinguishable difference. The particle 
size also appears to be changed in the formulations with low IBP and high additive 
concentrations. However, in the case of FMO, the IBP particles are seen clearly in 
the tight agglomerated form of chunky shaped crystals. This indicates that mannitol 
influences the particles to be agglomerated either tightly or loosely after drying. The 
needle shaped crystal habit of the particles with no Pl F127 formulation (FPO) 
indicated that Pl F127 does influence the crystal habit of the treated IBP particles. 
However, the IBP particle morphology was significantly influenced by both the 
additive composition and concentration. Hence, the best additive concentration and 
composition would possibly be identified from the aerosol performance of the 
respective formulations. 
 Crystallinity 6.3.4
Particles of the same organic compound that have different shapes could have 
different polymorphic forms [133]. Therefore, crystallinity of the raw IBP powder, 
milled IBP powder, additives and the DPI formulations was examined using 
differential scanning calorimetry (DSC) and X-ray diffraction (XRD). Table 6.4 
shows the melting peak temperature, enthalpy and the percentage of crystalline 
material present in the formulations obtained from DSC runs. The percentage of 
crystallinity is then determined using the following equation [210]: 
% Crystallinity = ∆Hm / ∆Hm°× 100% 
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The heat of melting, ∆Hm, was determined by integrating the areas (J/g) under the 
peaks using TA instrument Analysis 2000 software. The term ∆Hm° is a reference 
value and represents the heat of melting of 100% crystalline IBP. It was found that 
the melting enthalpy of the raw IBP powder was 118.4 ± 7.3 J/g which is also in 
agreement with Nokhodchi and co-workers [194]. This value was used as the 
reference value to determine the percentage crystalline phase of IBP in the processed 
formulations with different compositions of additive. 
Table 6.4 DSC data obtained for various formulations [mean ± SD, n=3] 
 
Formulation Peak (°C) Enthalpy (jg
-1) *Crystalline IBP 
(%) 
*Pure IBP 77.1 ± 0.5 118.4 ± 7.3 100 
Milled IBP 74.2 ± 0.7 111.8 ± 0.9 94.7 ± 0.9 
F1 74.6 ± 0.3 40.02 ± 6.8 33.8 ± 5.7 
F2 76 ± 1.4 75.4 ± 6.5 63.7 ± 5.5 
F3 77.1 ± 0.1 84.8 ± 3.3 71.6 ± 2.8 
F4 76.3 ± 0.4 117.4 ± 2.0 99.1 ± 1.7 
F5 76.5 ± 0.8 113.3 ± 4.7 95.7 ± 4.0 
F6 76.0 ± 0.5 61.2 ± 5.2 51.7 ± 4.4 
FPO 77.1 ± 0.9 63.7 ± 4.6 53.7 ± 3.9 
F7 75.0 ± 0.4 30.6 ± 2.8 25.8 ± 2.4 
F8 76.3 ± 1.3 75.6 ± 4.1 63.7 ± 3.4 
F9 74.6 ± 0.3 13.0 ± 1.1 11.0 ± 1.0 
FLO 75.4 ± 1.2 65.1 ± 2.4 55.0 ± 2.1 
F10 75.6 ± 0.4 47.4 ± 1.5 40.0 ± 1.3 
F11 75.3 ± 0.3 34.5 ±1.4 29.1 ± 1.2 
FMO 78.0 ± 3.8 83.2 ± 7.4 70.3 ± 6.2 
HPMC 55.5 ± 0.8 243.8 ± 1.2 0 
Pl F127 77.5 ± 0.4 134.1 ± 2.3 0 
Mannitol 165.9 ± 0.5 303.3 ± 1.4 0 
Leucine  >300 Not determined 0 
  
DSC can be used to determine the polymorphic composition of pharmaceutical 
powders, if two or more polymorphs are present and if the transition temperatures are 
known. As can be seen in Table 6.4, in all the formulations (including the milled 
IBP) an endothermic peak commenced in the range of 74–78 °C. These transition 
temperature results are in agreement (within ± 2.0 °C) with the previous reports 
which suggest that IBP exists as a stable crystalline solid exhibiting a typical melting 
range of 75–77 °C [242]. Figure 6.7 (a) shows the melting point for pure IBP, 
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HPMC, Pl F127, mannitol and leucine.  Figure 6.7 (b) shows the DSC curves for raw 
and milled IBP and all the prepared formulations. 
 
 
Figure 6.7 DSC curves for (a) Pluronic F127, HPMC, L-leucine, D-mannitol, raw 
IBP; (b) milled IBP, F1, F2, F3, F4, F5. F6, F7, F8, F9, F10, F11, FPO, FLO, FMO 
and raw IBP. 
 
In Figure 6.7 (a) only HPMC had shown a sharp peak before the melting point of the 
pure IBP drug. Pl F127 also shows a small peak at a similar melting range to pure 
IBP. The melting point for mannitol was much higher than for pure IBP. The leucine 
melting point could not be detected as it was out of the range of the instrument 
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mannitol and leucine would not interfere with the pure IBP melting peak 
identification in DSC, but HPMC and Pl F127 could. Figure 6.7 (b) shows the 
endothermic peaks for all the formulations, within the melting point range for 
crystalline IBP. The height of the peak was changed with respect to the IBP content 
present in the formulation. The low IBP concentration formulations have shown a 
smaller peak than the formulations containing high IBP concentration.  For certain 
formulations with a low concentration of IBP and high HPMC, the melting peak for 
HPMC also appeared at 55 °C. The peak for Pl F127 might have overlapped with 
IBP, as both have a similar melting point (Table 6.4). However, to ensure IBP does 
not exist in other polymorphs, all the formulations and additives were examined by 
XRD. Figure 6.8 presents the XRD patterns of pure IBP and all the additives. Figure 
6.9 presents the XRD patterns for all the formulations compared with the raw IBP 



























Figure 6.8. XRD patterns of raw IBP, pluronic F127, HPMC, leucine and mannitol. 
 
The XRD patterns of the raw additives (Figure 6.8) shows that HPMC is an 
amorphous compound showing one small intensity peak at around 13° two theta 
angles, and Pl F127 shows two peaks though it was partly in an amorphous phase. 
Leucine and mannitol show complete crystalline phases with sharp peaks on several 
angles. The XRD patterns of the independent additives will help to identify the peaks 
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Figure 6.9 XRD of raw IBP, milled IBP and DPI formulations of crystallized IBP. 
 
Figure 6.9 presents XRD patterns for all the formulation compared with the XRD 
pattern of pure IBP. It can be seen that all the formulations show peaks in the similar 
angle point as to the pure IBP. The concern about the polymorphic change in the 
milled IBP due to the high energy milling process could be addressed from the DSC 
and XRD analysis results. As can be seen in Table 6.4, for the milled IBP powder, 
endothermic peak commenced at 74.2 ± 0.7 °C and for the raw IBP it was at 77.1 ± 
0.5 °C. These transition temperature results are in agreement (within ± 2.0 °C) with 
the previous reports which suggest that IBP exists as a stable crystalline solid  with 
no polymorphic change exhibiting a typical melting range of 75–77 °C [242]. Figure 
6.10 shows the comparison between the XRD patterns of raw and milled IBP. The 
micronized IBP had shown peaks at the same angle points to that of the raw IBP. 
This investigation confirmed that micronized particles did not produce polymorphs 
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Figure 6.10 XRD patterns for raw and milled IBP showing no polymorphic change 
due to the milling process.  
 
The peaks other than the IBP points were due to the presence of mannitol which can 
be confirmed by looking at the XRD pattern of the FMO formulation (Figure 6.13). 
Figure 6.11 presents the XRD patterns of formulations FLO, F7 and F11 where L-
leucine concentration is increased from 0- 1.5%. The XRD pattern of F11 shows that 
higher concentration of L-leucine produces a higher amorphous phase. Figure 6.12 
presents the XRD patterns of formulations with increasing concentration of Pl F127. 
The smallest peak intensity was seen for the formulation F9 with the highest Pl F127 
concentration. The possible reason could be due to the small particle size or the 
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Angle, 2θ 
Figure 6.11 XRD patterns of formulations with increasing concentration of L-
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Angle, 2θ 
Figure 6.12 XRD patterns of formulations with increasing concentration of Pl F127 














Figure 6.13 XRD patterns of raw IBP, mannitol, formulation with mannitol (F7) and 
formulation without mannitol (FMO). Mannitol was encountered with a signature 
peak at angle 52° 2θ (shown in red circle), which was absent for the formulation 
FMO but present in the formulation F7. 
 
FMO does not contain mannitol in its formulation composition and did not show any 
peaks on the points raw mannitol has shown in Figure 6.13. This indicates that 
mannitol was present in the final formulations in crystalline form. Table 6.5 shows 
that mannitol exists in two polymorphic forms (alpha and delta). It is to be noted that 
although mannitol crystallizes in different polymorphic forms (α, β or δ) depending 
on the concentration (relative to other component in the formulation) and freezing 
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drying/processing characteristics or product stability has been reported so far [145, 
155]. However, XRD profiles for all the formulations of treated IBP were similar to 
the untreated raw IBP powder (shown with diamond markers in Figure 6.9) at the 
same angles, demonstrating that the crystal structure of treated IBP had not changed. 
The DSC curves of all the treated IBP formulations also demonstrated sharp peaks in 
the melting point range of raw IBP particles. Therefore, it could be confirmed that 
IBP remain isomorphic in the formulations after being treated in the APC process, 
but the amorphous content of the drug increased due to the presence of the additives. 
The interaction between the IBP particles and the additives in the APC process 
caused no change in the crystal structure of the IBP drug. Moreover, the XRD 
patterns of milled IBP were similar with the raw IBP powder indicating that no 
polymorphic change caused by the milling process. 
The amount of Pl F127 in some samples was estimated by the degree of crystallinity 
method, where the numerical area of each phase is used to determine abundances. 
The Pl F127 was accounted for by modelling a peak at about 27 °2θ (most obvious 
feature not modelled) and designating it as the amorphous phase. HPMC phase 
abundance could not be quantified, as its concentration in the formulation was too 
low to identify in the XRD curves. Table 6.5 presents the data calculated from the  
XRD curves of the dry powder formulations. The results could be used to get an 
approximate percentage of the IBP and the additive concentration in the crystalline 
phase in the dry powder formulations. 
Table 6.5 IBP and the additive phase abundance from area and weight percentages 
from XRD curves of the DPI formulations.  
 















F9 29.1 4.0 36.2 19.6 11.2 30.8 39.7 21.5 8.0 
F11 29.1 4.0 36.2 19.6 11.2 48.6 20.1 21.1 10.3 
F7 37.0 1.9 40.5 11.6 9.0 37.9 44.4 11.5 6.2 
F10 46.6 1.7 18.5 18.9 14.3 56.8 32.9 4.5 5.8 
FLO 68.7 1.0 13.7 16.6  69.3 14.1 16.6 - 
F6 73.0 1.6 19.4 - 6.0 74.8 21.1 - 4.1 
FMO 94.8 1.3 - - 3.9 97.7 - - 2.3 
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Figure 6.14 presents the comparison of the IBP content percentage from XRD and 
DSC data. It shows that F9 and F11 contain the lowest IBP content due to the 
presence of a high percentage of Pl F127 and L-leucine during the particle 
preparation. Pl F127 and L-leucine increase the dissolution of IBP linearly 
(demonstrated in Chapter 4, Sections 4.4.1 & 4.4.3) causing loss of IBP particles 
with the discarded solution after crystallization, during the isolation of the particles 
by centrifugation. The maximum IBP content in FMO also shows that absence of 




Figure 6.14 IBP crystalline content percentage comparison between the formulations 
obtained from the XRD and DSC data. 
 
Interestingly, the DSC data for IBP content percentage was lower but in a reasonable 
parallel trend with the results obtained from XRD data. This relationship indicates 
that the calculated results might be useful to estimate relative drug percentages in the 
crystalline phase of the dry formulations.  
6.4 AEROSOL PERFORMANCE IN TWIN STAGE IMPINGER (TSI) 
The aerosol performances of the formulations of the milled and prepared IBP 
particles were investigated using the TSI (details in Chapter 3, Section 3.16). The 
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the mean particle size to 2.8 ± 0.1 µm (details of procedure in Chapter 3, Section 
3.10) which was used as control, to compare the dispersibility behaviour with the 
prepared formulations. Table 6.6 shows the TSI results of all the formulations tested. 
The amount of IBP per capsule that is deposited in the lower stage of the TSI after 
aerosolization at 60 l/min (effective cut-off diameter (ECD), 6.4 µm [211]) was 
considered to be the fine particle dose (FPD). The recovered dose (RD) was defined 
as the total quantity of drug recovered per capsule after each actuation, while the 
emitted dose (ED) was that emitted from the inhaler device into the TSI (by loss of 
weight of inhaler). The percentage emission was calculated as the percentage of 
emitted dose to total recovered dose. Fine particle fraction (FPF) was the ratio of 
FPD to RD, while dispersibility was the percentage of FPD to ED [146]. 
Table 6.6 Deposition of IBP in a TSI after aerosolization from dry powder 
formulations containing additives via a Rotahaler® at 60 ± 5 l/min [Mean ± SD, 
n=5] 
 
Formulation RD (% ) ED (% ) Dispersibility (% ) FPF (% ) FPD (µg) 
Milled IBP 89.0 ± 3.9 73.8 ± 1.2 16.0 ± 1.2 11.8 ± 0.9 3424.8 ± 346.6 
F4 80.1 ± 3.2 51.1 ± 1.3 4.2 ± 0.4 2.1 ± 0.2 553.8 ± 42.3 
F5 76.3± 1.6 39.3 ± 0.4 4.0 ± 0.1 1.6 ± 0.04 387.3 ± 6.3 
F6 64.2± 2.3 69.4 ± 2.4 4.0 ± 0.4 2.8 ± 0.1 574.0 ± 15.4 
F7 65.3± 1.7 50.4 ± 1.5 2.5 ± 0.2 1.6 ± 0.1 332.3 ± 16.0 
F8 69.3± 3.0 58.5 ± 0.1 2.1 ± 2.0 1.2 ± 0.1 272.1 ± 11.8 
F9 33.6± 1.1 68.6 ± 2.7 0.5 ± 0.1 0.4 ± 0.1 38.7 ± 10.3 
FLO 60.7± 1.8 67.7 ± 1.4 2.1 ± 0.1 1.4 ± 0.1 283.4 ± 11.2 
F10 55.9± 2.8 67.1 ± 2.9 3.4 ± 0.1 2.3 ± 0.1 413.8 ± 9.8 
F11 44.2± 2.7 62.9 ± 2.5 1.6 ± 0.2 1.0 ± 0.1 140.2 ± 8.1 
  
Formulations F4 and F5 were prepared to investigate the contribution of leucine and 
mannitol to the overall physicochemical properties of the formulation. Formulation 
F5 was prepared without leucine and mannitol and characterized for its 
aerosolization efficiency. The flowability of F4 (good) was better than F5 (poor) 
(Figure 6.2); the aerodynamic diameter of the F4 particles was smaller than that of 
F5, and the percentage of crystalline IBP in F4 was higher than the F5 formulation. 
All these results indicated that presence of leucine and mannitol in the F4 
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formulation lowered the aerodynamic diameter of the particle and improved the flow 
properties, resulting in better FPF. The aerosolization test results of F4 and F5 show 
2.1% and 1.6% FPF respectively, indicating increase of drug dispersibility due to the 
presence of leucine and mannitol in F4. A study by Feng et. al. revealed that the 
crystallinity of leucine in the microparticles relates to a change in particle 
morphology which decreases powder density and enhances the dispersibility [165]. 
L-leucine possess the ability to form hollow particles, and a change in particle 
morphology from solid spheres to hollow, rugose particles leads to the formation of 
low density particles and enhanced dispersibility of the DPI formulations [159, 166-
168]. The hollow particles were observed from SEM images of the formulations (F4, 
F6, F9, F10, F11) shown in Figure 6.6. On the other hand, the particles in the the 
SEM image of formulation F5 (no L-leucine) did not show the hollow feature in their 
appearance. Figure 6.15 plots the FPF % of the formulations F4 and F5 against their 
aerodynamic diameter, which clearly supports the above statements. However, to 
determine the significance of the results, errors were estimated as the 95% 
uncertainties on the mean values of the FPF% of F4 and F5. Using the t-test the 95% 
uncertainties of F4 was 13.1 % and F5 was 3.9% which indicated the significance of 
the increase in FPF% of F4 is negligible. 
 
Figure 6.15 Aerodynamic diameter vs fine particle fraction (FPF) comparison 
between formulations with (F4) and without (F5) L-leucine and D-mannitol. [Mean 
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Maximum drug dispersibility was achieved from the F6 formulation, which is 2.8%. 
The particles of F6 formulation achieved a good flow property with an aerodynamic 
diameter of 3.6 ± 0.05 µm. However, the percentage of IBP crystalline of F6 was 
lower than for F4 and F5. A possible explanation would be the higher drug and lower 
Pl F127 concentration used in F4 and F5 compared to F6. As was seen earlier, Pl 
F127 influences the production of more amorphous particles in the APC process. 
Hence, a better controlled aerodynamic diameter and flowability of the F6 
formulation increased the percentage of FPF. The FPF percentage of the 
formulations was increased with the increase in crystalline content percentage 
obtained from the XRD and DSC results. Figure 6.16 presents the nearly linear trend 
of FPF % increase with the IBP crystalline content in the formulations.  
 
Figure 6.16 Relationship between IBP crystalline content (determined in XRD and 
DSC) and fine particle fraction (TSI) percentage of the formulations. [Mean ± SD, 
n=5, data from Table 6.6] 
 
  
Figure 6.17 Linear relationship between the % particles < 6 µm and the % FPF in 
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A linear trend was observed between the percentage of particle < 6 µm size and FPF 
% in the formulations F5, FLO, F8 and F11 (Figure 6.17). The lowest FPF % of the 
formulation F9 indicated that a high concentration of Pl F127 resulted in very poor 
particle properties leading to a very low drug dispersibility. It is also to be noted that 
F9 had shown the lowest percentage of IBP crystalline particles in the DSC 
investigation. It has been reported by many researchers that a higher loss in the 
capsule and device retention for a DPI formulation occurs due to the cohesive nature 
of amorphous powders, lower Gibbs free energy [86, 243, 244] or electrostatic 
charges [245]. Pl F127 is a non-ionic surfactant widely used as a growth inhibitor in 
the APC process which integrates onto the surface of IBP particles. Pl F127 also 
enhances IBP solubility significantly (discussed in Section 4.4.1) thus slowing IBP 
precipitation and perhaps resulting in the production of low crystalline and highly 
amorphous IBP particles in the APC process. Therefore, increased Pl F127 
concentration decreased the percentage of crystalline IBP in the formulations, 
perhaps resulting in a low percentage of FPF. The second lowest drug dispersion was 
from the formulation with highest leucine concentration (F11), having an 
aerodynamic diameter of 2.95 ± 0.02 µm but a poor flow property and a low 
percentage of crystalline IBP present in the formulation. This also might have 
lowered the percentage of FPF. Taking all the results together, the composition of 
formulation F6 showed best aerosol performance among all formulations prepared in 
the APC process. The percentage of FPF from the milled IBP powder was much 
higher than that of the formulations prepared in the APC process. For pulmonary 
drug delivery, the drug powder should have a narrow particle size distribution and a 
mean particle size of 5 µm with almost no particles larger than 10 µm [76]. The 
particle size distribution of milled IBP (Table 6.3) achieved the above criteria, which 
caused high IBP dispersibility in the aerosolization test. Another possible explanation 
for this might be that the absence of additives and no antisolvent precipitation 
produced a low amorphous content of IBP (as seen in the crystallinity results from 
the DSC), eventually increasing the FPF compared to the formulation prepared in the 
APC process using the additives. Moreover, the rough and corrugated surface of the 
milled IBP might have aided in the higher dispersibility [246, 247]. This 
phenomenon was evidenced in a study of enhancing powder aerosol performance of 
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particles with corrugated surfaces [248], due to the reduction of contact area and 
increasing the separation distance between the particles [249].  
Finally, it should be noted that, although it is quite feasible to achieve particles with 
narrow size distribution with controlled solution crystallization process, some key 
disadvantages are to eliminate the residual solvents and absolute drying of the 
material which may result powder caking and declined powder dispersibility [22, 
99].  
6.5 DISSOLUTION STUDIES 
Dissolution studies for the milled raw IBP powder and the prepared 
formulation powders F4, F6 and F10 were performed to compare drug release rates 
in phosphate buffer saline at 37°C. The first three formulations ranking on the drug 
dispersibility performance test were selected for the dissolution studies and 
compared with the performance of milled raw IBP powder. Figure 6.18 presents the 
dissolution release profiles of the milled raw IBP powder and the formulations F4, 
F6 and F10, respectively. The formulation compositions for F4, F6 and F10 are 
different with respect to the initial drug load and the additive concentration. F4 
contains 2% initial IBP and the additive concentrations are 1% L-leucine, 8.4% D-
mannitol, 0.1% HPMC and 0.9% Pl F127. The composition of F6 includes 1% initial 
IBP and the additive concentrations are 1.2% L-leucine, 4.5% D-mannitol, 0.6% 
HPMC and 1.2% Pl F127. Finally, F10 contains 0.3% initial IBP and the additive 
concentrations are 1.2% L-leucine, 9% D-mannitol, 0.2% HPMC and 1.2% Pl F127. 
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Figure 6.18 In vitro dissolution of milled raw IBP powder and formulations prepared 




Table 6.7 Dissolution release data for milled pure IBP powder and formulations (F4, 




Cumulative % IBP release (%) 
Milled IBP F4 F6 F10 
0 0 0 0 0 
2 46.2 ± 1.7 55.4 ± 1.4 63.6 ± 1.7 96.1 ± 3.7 
6 59.1 ± 1.4 68.7 ± 2.5 67.9 ± 2.0 76.6 ± 2.1 
10 66.6 ± 1.9 75.4 ± 2.6 72.0 ± 2.1 81.0 ± 2.5 
15 71.5 ± 1.8 78.8 ± 2.1 80.4 ± 2.9 78.8 ± 2.5 
20 73.3 ± 2.4 88.6 ± 3.0 82.4 ± 2.9 85.1 ± 1.8 
30 75.0 ± 2.1 89.8 ± 2.7 85.3 ± 2.9 83.8 ± 2.1 
60 80.2 ± 2.3 96.2 ± 3.7 86.6 ± 3.0 90.8 ± 2.7 
90 80.9 ± 2.3 100.9 ± 3.0 86.9 ± 2.7 86.7 ± 2.6 
120 79.0 ± 2.6 102.7 ± 3.4 84.6 ± 2.2 89.3 ± 2.4 
 
Dissolution studies revealed that the milled pure IBP release rate was slower than the 
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milled IBP, F4, F6 and F10 were 46.2 ± 1.7%, 55.4 ± 1.4%, 63.6 ± 1.7% and 96.1 ± 
3.7% respectively. The results indicated that the prepared formulation dissolution 
rate is faster than the milled pure IBP. Among the prepared formulations, F10 
released the maximum percentage of drug content (96.1 ± 3.7%) in the first two 
minutes. The possible reason could be the presence of a higher content of additives 
(Pl F127 1.2%, L-leucine 1.2%, D-mannitol 9.0% and HPMC 0.2%) and very low 
initial drug load (0.3%) in the composition of the formulation F10. The formulations 
with the higher initial IBP and lower additive concentrations have shown a 
comparatively lower dissolution rate in the first two minutes. The dissolution profiles 
of the pure milled IBP and the prepared formulations indicated that the presence of 
the hydrophilic polymeric additives in the formulations strongly promotes drug 
wettability by reducing the interaction among the hydrophobic IBP particles. On the 
other hand, the relatively higher cohesive forces with the milled pure IBP could 
potentially influence the overall dissolution negatively [250]. The maximum release 
from milled pure IBP was 81 ± 2.3%, whereas from the prepared formulations F4, F6 
and F10 were 102 ± 3.4%, 87 ± 2.7% and 96 ± 3.7% respectively. In Chapter 4 we 
demonstrated that the solubility profile of IBP with additives was significantly higher 
than the solubility of raw IBP in water. Therefore, it can be concluded that the 
prepared formulations are better than the milled IBP in terms of the dissolution 
release rate. A faster dissolution rate of the formulations is expected to provide a 
better bioavailability than that of milled IBP powder.  
A recent in vivo study for IBP after inhalation revealed that the inhalation dose is 
four to five orders of magnitude less than the orally delivered one that gives the same 
analgesic action [251]. Hence, the peak plasma level of IBP is found in the literature 
to be within 17-36 µg/mL (typically from 400 mg tablet administered orally after ~1 
hour) [179-182]. The dissolution test results and the FPD of the prepared 
formulations (554 µg, 574.0 µg & 413.8 µg from the formulations F4, F6 and F10, 
respectively) indicate the future potential to improve the IBP drug delivery by 
lowering the dose and increasing the bioavailability. Our predicted calculation 
indicates the available IBP plasma concentration would be approximately 17 µg/mL 
(predicted from the obtained FPD and dissolution rate of the prepared formulations 
(F4, F6 & F10)) from a single puff of a 32 mg dose of the prepared DPI 
formulations. If the prediction is proven true in future (from an in vivo study), the 
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prepared formulations are expected to provide the same analgesic effect as a 400 mg 
tablet but with approximately a 10 times smaller dose. 
6.6 RAMAN MAPPING FOR POWDER FORMULATION 
The particle morphology was investigated using Raman spectroscopy to 
identify each component individually and the arrangements of the drug particle with 
the additives materials in the powder formulation mixture of F6. Figure 6.19 shows 
the images extracted by mapping each component from their Raman spectrum and 
analysed by the WItec Project four software. The images revealed that IBP drug 
particles are covered by the additives used specially the Pl F127 was mostly seen on 
the surface of IBP drug particles. It was also visible that the IBP drug particles are 
surrounded by the D-mannitol extensively. The Raman images also showed presence 
of very trace amount of HPMC and L-leucine. Figure 6.19 (a) shows the usual 
appearance of F6 powder formulation whereas Figure 6.19 (b) presents the 
appearance of the F6 powder formulation in the second stage of TSI after in vitro 
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Figure 6.19 Raman images of F6 powder formulation mixture (a) Before in vitro 
aerosolization test, (b) in stage 2 of TSI after in vitro aerosolization test. 
 
The difference between two images indicated that IBP drug particles are 
deagglomerated from the mixture of additives after impaction in TSI though the 
additives are still present. The interaction between IBP and Pl F127, HPMC and L-
leucine found similar in both images whereas the attachment of the IBP particles 
with the D-mannitol shown to be apart slightly. The Raman investigation also 
confirmed that presence of the additives with the IBP particle will have a significant 
effect on the drug dispersibility test of the powder formulations. 
6.7 CONCLUSION 
This chapter has compared the characteristics of the formulations with respect 
to the composition, batch size and additive concentrations in their preparation. The 
presence of leucine and mannitol in the formulations improved the flowability, 
lowered the particle aerodynamic diameter, and showed higher FPF of IBP from DPI 
formulations. Among all the parameters, a narrow aerodynamic diameter of particles 
and high percentage of crystalline IBP phase in the formulation positively influenced 
the drug dispersibility. The FPF % of the milled IBP was much higher than that of 
the prepared formulations due to achieving narrow particle size distribution, high 
IBP content, and rough and corrugated particle surface. However, the dissolution 
tests revealed that the rate of dissolution of milled IBP is slower than that of the 
prepared formulations (as compared with F4, F6 and F10) which indicates that the 
prepared powders would provide better bioavailability of IBP. 
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 Conclusion and future directions Chapter 7:
7.1 SUMMARY & CONCLUSION 
This research proposes a new approach to developing IBP DPI formulation 
using regular size particles produced by a controlled crystallization process. So far 
there is no work reported in the literature on IBP microcrystal to produce a DPI 
formulation, and thus the outcome of this project is expected to enable the 
development of a non-invasive DPI formulation with reduced cost and with better 
therapeutic benefit. The limited literature shows some attempts have been made at a 
direct crystallization technique using additives for producing respirable size crystals, 
but it appears that this technique has never been applied successfully. The present 
PhD project proposes to develop a new method of controlled crystallization process 
for producing IBP small size (~5 μm) crystals for pulmonary delivery. 
IBP solubility determination by the dissolution method was undertaken in the range 
of 0-50% aqueous ethanol solvents. Attainment of equilibrium of the IBP drug 
concentration was confirmed for each solvent system used.  
The UV spectrophotometer was calibrated at 264 nm for the solubility measurements 
and at 221 nm wavelength to measure the drug dispersibility in the twin stage 
impinger. The experimental solubility data of IBP in aqueous ethanol solutions was 
determined at 10, 25 and 40 °C. The solubility of IBP increases considerably with 
increasing ethanol contents and also increases with temperature. The experimental 
data at 25 °C was in good agreement with the prior data of Rashid et al. [31]. A 
correlation is given to fit all the measured data. This correlation was used to select a 
suitable solvent for washing the IBP drug during the in vitro drug dispersion test 
using the twin stage impinger. The effectiveness of the four excipients HPMC, Pl 
F127, mannitol and leucine in solubility enhancement was investigated first as single 
component and then in combinations. Pl F127 raises the IBP solubility considerably, 
with the increases depending on the ethanol content. HPMC has a smaller effect. The 
effect of leucine was certainly positive in increasing the IBP solubility linearly with 
concentration. Mannitol did not show any trend of affecting the IBP solubility. The 
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combined effect of all excipients appears to be additive. The results allowed 
calculation of the minimum amount of initial drug to be used to precipitate IBP 
during particle preparation in precipitation crystallization in order to produce fine (<5 
µm) IBP crystals for dry powder inhaler formulations.  
A Plackett-Burman design was used to attempt to optimize the variables for the anti-
solvent precipitation crystallization (APC) process of producing inhalable IBP 
particle. The experiment indicated ultrasound, stirring speed and batch size as most 
significant variables for the particle size of IBP produced in the APC process. 
However, optimization of the variables was not successful in the Plackett-Burman 
design and the effect of individual variables was studied. Optimized level of 
temperature (25 °C), ultrasound (30 minutes), stirring duration (>20 minutes), IBP 
concentration, solvent/antisolvent ratio and the additive concentrations needed to 
produce inhalable size IBP particles were determined. HPMC and Pl F127 
agglomerated IBP particles after drying, and leucine and mannitol, improve the 
particle flow with no increase in particle size. IBP particles with the volume median 
diameter (D[v,0.5]) of 3.7 ± 0.3 µm were prepared by using HPMC and Pl F127. 
Finally, a method of producing a mixture of nano size (410 ± 72 nm, PDI 0.66 ± 
0.10) and micron size (3.9 ± 0.4 µm) IBP particles using four additives—HPMC 
(0.2%), Pl F127(1.3%), leucine (1.2%) and mannitol (8.6%)—was optimized and 
validated. A method of producing inhalable size IBP by an APC process was 
established. 
DPI formulations were developed with respect to the composition, batch size and 
drug and additive concentrations, and characterized for the density, size, flow and 
crystallinity. It was seen that the presence of leucine and mannitol in the formulation 
improved the flowability, lowered the particle aerodynamic diameter, and showed a 
higher percentage of FPF in the drug dispersibility test. A trend of decrease in the 
percentage of crystalline IBP phase was observed, with an increase in Pl F127 
concentration in the formulations, which also decreased the drug dispersibility in the 
TSI test. Among all the parameters, the narrow aerodynamic diameter of particles 
and high percentage of crystalline IBP phase in the formulation positively influenced 
the drug dispersibility in the aerosolization test. The milled IBP had shown higher 
dispersibility than the prepared IBP particles in the APC process. It is assumed that 
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the surface roughness and corrugation of the milled IBP particles, narrow particle 
size distribution and the 100% drug content delivery increased the FPF significantly. 
The dissolution tests results revealed that the dissolution rate of the prepared powder 
is faster than the milled IBP powder. The prepared particles (F10) achieved 96% of 
dissolution in the first two minutes of drug delivery. On the other hand, the 
maximum dissolution of milled IBP was 80% after two hours of drug delivery. The 
faster dissolution rate of the prepared particles is expected to provide better 
bioavailability than the raw milled IBP. A recent in vivo study for IBP after 
inhalation revealed that the inhalation dose is four to five orders of magnitude less 
than the orally delivered one that gives the same analgesic action [251]. Hence, the 
peak plasma level of IBP from the literature is found to be within 17-36 µg/mL [179-
182]. The dissolution test results and the FPD of the prepared formulations (554 µg, 
574.0 µg & 413.8 µg from the formulations F4, F6 and F10, respectively) indicate 
the future potential to improve IBP drug delivery by lowering the dose and also 
increasing the bioavailability.  
The solubility correlation of IBP in aqueous ethanol systems developed in this work 
would be very useful for the pre-formulation investigation of IBP in other dosage 
forms as well. Solubility enhancement in the presence of the additives (especially Pl 
F127) certainly has the potential to overcome the bioavailability issues caused by the 
poor water solubility of IBP. The IBP solubility trend in aqueous ethanol with Pl 
F1127, HPMC, L-leucine and D-mannitol is the first novelty of this research. It is 
expected that this work would contribute to advancing new technological 
possibilities in the enhancement of the drug‘s solubility for any dosage formulation.  
The second novelty of this research is the one step process of producing inhalable 
size IBP particles without further high shear milling. This outcome is expected to 
contribute to precise and predictive control of vital physicochemical properties like 
solubility of the active pharmaceutical ingredients (APIs) and pharmaceutical 
excipients in pharmaceutical formulation development for improving the in vivo 
delivery, storage stability, and manufacturability of drug substances. 
The effects of Pl F127, HPMC, L-leucine and D-mannitol on the crystallinity of the 
IBP and their relationship to the drug‘s dispersibility have not been investigated prior 
to this study. The knowledge obtained from this work will contribute to further 
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studies on the use of these excipients in the formulation and for the prediction of 
possible stability problems during storage.   
7.2 LIMITATIONS AND FUTURE DIRECTION 
IBP is usually administered as tablets. This project looks at the feasibility of 
administering IBP pneumatically into the lungs, which is expected to be more 
effective and efficient in terms of bioavailability. Our work was limited to in vitro 
studies of the drug dispersibility into the lungs. To achieve the actual effectiveness of 
the prepared formulations, in vivo lung dispersibility tests would be an important 
future approach. This is a very general recommendation for the future direction of 
this research.  
The solubility studies of IBP in water ethanol co-solvents produced correlations 
which can calculate the IBP solubility in water-ethanol co-solvents at different 
temperatures (10, 25 and 40 °C). However, in the case of the solubility studies of IBP 
with additives, the experimental points were limited to the required conditions to 
produce inhalable IBP particles. IBP solubility investigations with the selected 
additives at a wider range of concentrations would be useful to establish a correlation 
for further pre-formulation studies for developing new IBP dosage forms.  
The DPI formulations prepared in this work have shown a considerably low fine 
particle fraction, though the fine particle dose amount was at a satisfactory level. 
However, developing interactive mixtures of the prepared IBP particles in an APC 
process with lactose or any other suitable carrier might enhance the fine particle 
fraction of the DPI formulations.  
Finally, performing a stability test of the developed formulations would be a valuable 
added feature to this research work in the future. As seen from the crystallinity 
characterizaization, Pl F127 and L-leucine caused loss of IBP from the dry powder 
formulations. Though mannitol is a very useful additive for pharmaceutical 
formulations, its hygroscopicity often creates problems of stability. Thus, a long term 









1. Ballester M, Nembrini C, Dhar N, Titta A, Piano C, Pasquier M, et al. Nanoparticle conjugation 
and pulmonary delivery enhance the protective efficacy of ag85b and cpg against 
tuberculosis. Vaccine. 2011;29:6959-66. 
2. Alhanout K, Brunel JM, Dubus JC, Rolain JM, Andrieu V. Suitability of a new antimicrobial 
aminosterol formulation for aerosol delivery in cystic fibrosis. Journal of Antimicrobial 
Chemotherapy. 2011;66:2797-800. 
3. Forman JP, Stampfer MJ, Curhan GC. Non-narcotic analgesic dose and risk of incident 
hypertension in us women. Hypertension. 2005;46:500-7. 
4. Chan AT, Manson JE, Albert CM, Chae CU, Rexrode KM, Curhan GC, et al. Nonsteroidal 
antiinflammatory drugs, acetaminophen, and the risk of cardiovascular events. Circulation. 
2006;113:1578-87. 
5. Daugherty SE, Berndt SI, Purdue M, Huang W-y. Abstract b93: Nonsteroidal anti-
inflammatory drugs and all-cause mortality, cancer mortality, and cardiovascular mortality in 
the prostate, lung, colorectal, and ovarian cancer screening trial. Cancer Prevention 
Research. 2012;5:B93. 
6. Gradon L, Sosnowski TR. Formation of particles for dry powder inhalers. Advanced Powder 
Technology. 2013. 
7. Shoyele SA, Slowey A. Prospects of formulating proteins/peptides as aerosols for pulmonary 
drug delivery. International Journal of Pharmaceutics. 2006;314:1-8. 
8. Timsina MP, Martin GP, Marriott C, Ganderton D, Yianneskis M. Drug delivery to the 
respiratory tract using dry powder inhalers. International Journal of Pharmaceutics. 
1994;101:1-13. 
9. Weibel E. Morphometry of the human lung: The state of the art after two decades. Bulletin 
européen de physiopathologie respiratoire. 1979;15:999. 
10. Lee H-K, Kwon J-H, Park S-H, Kim C-W. Insulin microcrystals prepared by the seed zone 
method. Journal of Crystal Growth. 2006;293:447-51. 
11. Wolff RK, Dorato MA. Toxicologic testing of inhaled pharmaceutical aerosols. Critical Reviews 
in Toxicology. 1993;23:343-69. 
12. Emami J, Hamishehkar H, Najafabadi AR, Gilani K, Minaiyan M, Mahdavi H, et al. Particle size 
design of PLGA microspheres for potential pulmonary drug delivery using response surface 
methodology. Journal of Microencapsulation. 2009;26:1-8. 
13. Sakagami M. In vivo, in vitro and ex vivo models to assess pulmonary absorption and 
disposition of inhaled therapeutics for systemic delivery. Advanced Drug Delivery Reviews. 
2006;58:1030-60. 
14. Kho K, Hadinoto K. Optimizing aerosolization efficiency of dry-powder aggregates of 
thermally-sensitive polymeric nanoparticles produced by spray-freeze-drying. Powder 
Technology. 2011;214:169-76. 
15. Tsapis N, Bennett D, Jackson B, Weitz DA, Edwards DA. Trojan particles: Large porous carriers 
of nanoparticles for drug delivery. Proceedings of the National Academy of Sciences of the 
United States of America. 2002;99:12001-5. 
16. Rasenack N, Steckel H, Müller BW. Preparation of microcrystals by in situ micronization. 
Powder Technology. 2004;143-144:291-6. 
17. Service RF. Hijacking a cell's chemical paths to make new antibiotics. Science. 1997.  
  
Bibliography 148 
18. Shoyele SA, Cawthorne S. Particle engineering techniques for inhaled biopharmaceuticals. 
Advanced Drug Delivery Reviews. 2006;58:1009-29. 
19. Islam N, Gladki E. Dry powder inhalers (DPIs)—a review of device reliability and innovation. 
International Journal of Pharmaceutics. 2008;360:1-11. 
20. Islam N, Stewart P, Larson I, Hartley P. Effect of carrier size on the dispersion of salmeterol 
xinafoate from interactive mixtures. Journal of Pharmaceutical Sciences. 2004;93:1030-8. 
21. Steckel H, Mueller BW. In vitro evaluation of dry powder i nhalers i: Drug deposition of 
commonly used devices. International Journal of Pharmaceutics. 1997;154:19-29. 
22. Ragab DM, Rohani S. Particle engineering strategies via crystallization for pulmonary drug 
delivery. Organic Process Research and Development. 2009;13:1215-23. 
23. Andreou J, Stewart P, Morton D. Short-term changes in drug agglomeration within 
interactive mixtures following blending. International Journal of Pharmaceutics. 2009;372:1-
11. 
24. Liu LX, Marziano I, Bentham AC, Litster JD, White ET, Howes T. Effect of particle properties on 
the flowability of ibuprofen powders. International Journal of Pharmaceutics. 2008;362:109-
17. 
25. Muzzio FJ, Shinbrot T, Glasser BJ. Powder technology in the pharmaceutical industry: The 
need to catch up fast. Powder Technology. 2002;124:1-7. 
26. Rashid MA. Crystallization engineering of ibuprofen for pharmaceutical formulation [PhD 
Thesis]. Brisbane, Australia: University of Queensland; 2011. 
27. Waltersson J, Lundgren P. The effect of mechanical comminution on drug stability. Acta 
Pharmaceutica Suecica. 1985;22:291-300. 
28. Khan S, Matas Md, Zhang J, Anwar J. Nanocrystal preparation: Low-energy precipitation 
method revisited. Crystal Growth Design. 2013;13:2766-77. 
29. Bhattamishra S, Padhy R. Estimation of ibuprofen solubilization in cationic and anionic 
surfactant media: Application of the micelle binding model. Indian Journal of Chemical 
Technology. 2009;16:426-30. 
30. Newman SP, Busse WW. Evolution of dry powder inhaler design, formulation, and 
performance. Respiratory medicine 2002;96:293-304. 
31. Rashid A, White ET, Howes T, Litster JD, Marziano I. Effect of solvent composition and 
temperature on the solubility of ibuprofen in aqueous ethanol. Journal of Chemical & 
Engineering Data. 2014;59:2699-703. 
32. Reid DJ, Pham NT. Emerging therapeutic options for the management of copd. Clinical 
Medicine Insights: Circulatory. 2013;7:7-15, 9 pp. 
33. Behara SRB, Longest PW, Farkas DR, Hindle M. Development and comparison of new high-
efficiency dry powder inhalers for carrier-free formulations. Journal of Pharmaceutical 
Sciences. 2014;103:465-77. 
34. Patton JS. Mechanisms of macromolecule absorption by the lungs. Advanced Drug Delivery 
Reviews. 1996;19:3-36. 
35. Haghi M, Ong HX, Traini D, Young P. Across the pulmonary epithelial barrier: Integration of 
physicochemical properties and human cell models to study pulmonary drug formulations. 
Pharmacology & therapeutics. 2014;144:235-52. 
36. Fehrenbach H. Alveolar epithelial type ii cell: Defender of the alveolus revisited. Respiratory 
Research. 2001;2:1-20. 
37. Thiriet M. Cell and tissue organization in the circulatory and ventilatory systems: Springer; 
2011. 
38. Nicod LP. Lung defences: An overview. European Respiratory Review. 2005;14:45-50. 
  
Bibliography 149 
39. Hamm H, Fabel H, Bartsch W. The surfactant system of the adult lung: Physiology and clinical 
perspectives. The Clinical Investigator. 1992;70:637-57. 
40. Samet JM, Cheng PW. The role of airway mucus in pulmonary toxicology. Environmental 
Health Perspectives. 1994;102:89-103. 
41. Effros RM, Mason GR. Measurements of pulmonary epithelial permeability in vivo. American 
Review of Respiratory Disease. 1983;127:S59-S65. 
42. Schneeberger EE, Lynch RD. The tight junction: A multifunctional complex. American Journal 
of Physiology - Cell Physiology. 2004;286:C1213-C28. 
43. Chandar N, Viselli S. Cell and molecular biology: Lippincott Williams & Wilkins; 2012. 
44. Foth H. Role of the lung in accumulation and metabolism of xenobiotic compounds — 
implications for chemically induced toxicity. Critical Reviews in Toxicology. 1995;25:165-205. 
45. Rejman J, Oberle V, Zuhorn IS, Hoekstra D. Size-dependent internalization of particles via the 
pathways of clathrin- and caveolae-mediated endocytosis. Biochemical Journal. 
2004;377:159-69. 
46. Matsukawa Y, Lee VHL, Crandall ED, Kim K-J. Size-dependent dextran transport across rat 
alveolar epithelial cell monolayers. Journal of Pharmaceutical Sciences. 1997;86:305-9. 
47. Hastings RH, Folkesson HG, Matthay MA. Mechanisms of alveolar protein clearance in the 
intact lung. American Journal of Physiology - Lung Cellular and Molecular Physiology. 
2004;286:L679-L89. 
48. Adjei A, Garren J. Pulmonary delivery of peptide drugs: Effect of particle size on 
bioavailability of leuprolide acetate in healthy male volunteers. Pharm Res. 1990;7:565-9. 
49. Fernández Tena A, Casan Clarà P. Deposition of inhaled particles in the lungs. Archivos de 
Bronconeumología (English Edition). 2012;48:240-6. 
50. Carvalho TC, Peters JI, Williams RO, III. Influence of particle size on regional lung deposition: 
What evidence is there? International Journal of Pharmaceutics. 2011;406:1-10. 
51. Gonda I. Targeting by deposition. Drugs and the pharmaceutical sciences. 1992;54:61-82. 
52. Gonda I. Particulate interactions in dry powder formulations for inhalation. Elsevier B.V; 
2004. p. 509-. 
53. Newman S, Anderson P. Respiratory drug delivery: Essential theory and practice: Respiratory 
Drug Delivery Online; 2009. 
54. Azhdarzadeh M, Olfert JS, Vehring R, Finlay WH. Effect of electrostatic charge on oral -
extrathoracic deposition for uniformly charged monodisperse aerosols. Journal of Aerosol 
Science. 2014;68:38-45. 
55. Telko MJ, Hickey AJ. Dry powder inhaler formulation. Respiratory Care. 2005;50:1209-27. 
56. El-Sherbiny IM, Smyth HDC. Biodegradable nano-micro carrier systems for sustained 
pulmonary drug delivery: (i) self-assembled nanoparticles encapsulated in 
respirable/swellable semi-ipn microspheres. International Journal of Pharmaceutics. 
2010;395:132-41. 
57. Du J, El-Sherbiny IM, Smyth HD. Swellable ciprofloxacin-loaded nano-in-micro hydrogel 
particles for local lung drug delivery. AAPS PharmSciTech. 2014;15:1535-44. 
58. De Boer AH, Gjaltema D, Hagedoorn P, Frijlink HW. Characterization of inhalation aerosols: A 
critical evaluation of cascade impactor analysis and laser diffraction technique. International 
Journal of Pharmaceutics. 2002;249:219-31. 
59. Yang Y, Cheow WS, Hadinoto K. Dry powder inhaler formulation of lipid-polymer hybrid 
nanoparticles via electrostatically-driven nanoparticle assembly onto microscale carrier 
particles. International Journal of Pharmaceutics. 2012;434:49-58. 
  
Bibliography 150 
60. Tuli R, . Studies on the surface properties of biodegradable polymer carriers in respiratory 
delivery of drug from dry powder inhaler formulations [PhD Thesis]. Brisbane, Australia: 
Queensland University of Technology.; 2012. 
61. Jaafar-Maalej C, Andrieu V, Elaissari A, Fessi H. Assessment methods of inhaled aerosols: 
Technical aspects and applications. Expert Opinion on Drug Delivery. 2009;6:941-59. 
62. Pilcer G, Vanderbist F, Amighi K. Correlations between cascade impactor analysis and laser 
diffraction techniques for the determination of the particle size of aerosolised pow der 
formulations. International Journal of Pharmaceutics. 2008;358:75-81. 
63. Freedman T. Medihaler therapy for bronchial asthma; a new type of aerosol therapy. 
Postgraduate Medicine. 1956;20:667-73. 
64. Stegemann S, Kopp S, Borchard G, Shah VP, Senel S, Dubey R, et al. Developing and 
advancing dry powder inhalation towards enhanced therapeutics. European Journal of 
Pharmaceutical Sciences. 2013;48:181-94. 
65. Labiris NR, Dolovich MB. Pulmonary drug delivery. Part ii: The role of inhalant delivery 
devices and drug formulations in therapeutic effectiveness of aerosolized medications: 
Physiological factors affecting the effectiveness of inhaled drugs. British Journal of Clinical 
Pharmacology. 2003;56:600-12. 
66. de KJP, van dMTW, Coenegracht PMJ, Tromp TFJ, Frijlink HW. Effect of an external resistance 
to airflow on the inspiratory flow curve. International Journal of Pharmaceutics. 
2002;234:257-66. 
67. Janssens W, VandenBrande P, Hardeman E, De LE, Philps T, Troosters T, et al. Inspiratory flow 
rates at different levels of resistance in elderly copd patients. European Respiratory Journal. 
2008;31:78-83. 
68. Virchow JC, Crompton GK, Dal NR, Pedersen S, Magnan A, Seidenberg J, et al. Importance of 
inhaler devices in the management of airway disease. Respiratory Medicine. 2008;102:10-9. 
69. Hammerlein A, Muller U, Schulz M. Pharmacist-led intervention study to improve inhalation 
technique in asthma and copd patients. Journal of Evaluation in Clinical Practice,. 
2011;17:61-70. 
70. Taburet A-M, Schmit B. Pharmacokinetic optimization of asthma treatment. Clinical 
Pharmacokinetics. 1994;26:396-418. 
71. Israelachvili JN. Intermolecular and surface forces. San Diego: Academic Press; 1991.  
72. Kaialy W, Alhalaweh A, Velaga SP, Nokhodchi A. Effect of carrier particle shape on dry 
powder inhaler performance. International Journal of Pharmaceutics. 2011;421:12-23. 
73. Wong J, Kwok PCL, Noakes T, Fathi A, Dehghani F, Chan H-K. Effect of crystallinity on 
electrostatic charging in dry powder inhaler formulations. Pharmaceutical Research. 
2014;31:1656-64. 
74. Briggner LE, Buckton G, Bystrom K, Darcy P. The use of isothermal microcalorimetry in the 
study of changes in crystallinity induced during the processing of powders. International 
Journal of Pharmaceutics. 1994;105:125-35. 
75. Ticehurst MD, Basford PA, Dallman CI, Lukas TM, Marshall PV, Nichols G, et al. 
Characterization of the influence of micronization on the crystallinity and physical stability of 
revatropate hydrobromide. International Journal of Pharmaceutics. 2000;193:247-59. 
76. Rohani S. Applications of the crystallization process in the pharmaceutical industry. From 
Frontiers of Chemical Engineering in China 2010;4:2-9. 
77. Kubavat HA, Shur J, Ruecroft G, Hipkiss D, Price R. Influence of primary crystallisation 
conditions on the mechanical and interfacial properties of micronise d budesonide for dry 
powder inhalation. International Journal of Pharmaceutics. 2012;430:26-33. 
  
Bibliography 151 
78. Shur J, Kubavat HA, Ruecroft G, Hipkiss D, Price R. Influence of crystal form of ipratropium 
bromide on micronisation and aerosolisation behaviour in dry powder inhaler formulations. 
Journal of pharmacy and pharmacology. 2012;64:1326-36. 
79. Kaialy W, Nokhodchi A. Treating mannitol in a saturated solution of mannitol: A novel 
approach to modify mannitol crystals for improved drug delivery to the lungs. International 
Journal of Pharmaceutics. 2013;448:58-70. 
80. Kaialy W, Larhrib H, Ticehurst M, Nokhodchi A. Influence of batch cooling crystallization on 
mannitol physical properties and drug dispersion from dry powder inhalers. Crystal Growth 
Design. 2012;12:3006-17. 
81. Kaialy W, Larhrib H, Martin GP, Nokhodchi A. The effect of engineered mannitol -lactose 
mixture on dry powder inhaler performance. Pharmaceutical Research. 2012;29:2139-56. 
82. Zeng XM, Martin GP, Marriott C, Pritchard J. The use of lactose recrystallised from carbopol 
gels as a carrier for aerosolised salbutamol sulphate. European Journal of Pharmaceutics and 
Biopharmaceutics. 2001;51:55-62. 
83. Tuli RA, Dargaville TR, George GA, Islam N. Polycaprolactone microspheres as carriers for dry 
powder inhalers: Effect of surface coating on aerosolization of salbutamol sulfate. Journal of 
Pharmaceutical Sciences. 2012;101:733-45. 
84. Kaialy W, Hussain T, Alhalaweh A, Nokhodchi A. Towards a more desirable dry powder 
inhaler formulation: Large spray-dried mannitol microspheres outperform small 
microspheres. Pharmaceutical Research. 2014;31:60-76. 
85. Chawla A, Taylor KMG, Newton JM, Johnson MCR. Production of spray-dried salbutamol 
sulfate for use in dry powder aerosol formulation . International Journal of Pharmaceutics. 
1994;108:233-40. 
86. Buckton G, Darcy P, Greenleaf D, Holbrook P. The use of isothermal microcalorimetry in the 
study of changes in crystallinity of spray-dried salbutamol sulphate. International Journal of 
Pharmaceutics. 1995;116:113-8. 
87. Kaerger JS, Price R. Processing of spherical crystalline particles via a novel solution 
atomization and crystallization by sonication (saxs) technique. Pharmaceutical Research. 
2004;21:372-81. 
88. Manish M, Harshal J, Anant P. Melt sonocrystallization of ibuprofen: Effect on crystal 
properties. European Journal of Pharmaceutical Sciences. 2005;25:41-8. 
89. Lee M-J, Kwon J-H, Shin J-S, Kim C-W. Microcrystallization of α-lactalbumin. Journal of Crystal 
Growth. 2005;282:434-7. 
90. Kwon J-H, Lee B-H, Lee J-J, Kim C-W. Insulin microcrystal suspension as a long-acting 
formulation for pulmonary delivery. European Journal of Pharmaceutical Sciences. 
2004;22:107-16. 
91. Murnane D, Martin GP, Marriott C. Dry powder formulations for inhalation of fluticasone 
propionate and salmeterol xinafoate microcrystals. Journal of Pharmaceutical Sciences. 
2009;98:503-15. 
92. Rasenack N, Steckel H, Muller BW. Micronization of anti-inflammatory drugs for pulmonary 
delivery by a controlled crystallization process. Journal of Pharmaceutical Sciences. 
2003;92:35-44. 
93. Steckel H, Rasenack N, Muller BW. In-situ-micronization of disodium cromoglycate for 
pulmonary delivery. European Journal of Pharmaceutics and Biopharmaceutics. 2003;55:173-
80. 
94. Bakhbakhi Y, Charpentier PA, Rohani S. Experimental study of the gas process for producing 
microparticles of beclomethasone-17,21-dipropionate suitable for pulmonary delivery. 
International Journal of Pharmaceutics. 2006;309:71-80. 
  
Bibliography 152 
95. Ikegami K, Kawashima Y, Takeuchi H, Yamamoto H, Momose D-I, Saito N, et al. In vitro 
inhalation behavior of spherically agglomerated steroid particles with carrier lactose. 
Advanced Powder Technology. 2000;11:323-32. 
96. Yang Z, Hu T, Le Y, Liu M, Shen Z, Chen J. Preparation of ultrafine sumatriptan succinate for 
dry powder inhalation via reactive crystallization and its evaluation. Huagong Jinzhan. 
2008;27:1412-6. 
97. Chiou H, Li L, Hu T, Chan H-K, Chen J-F, Yun J. Production of salbutamol sulfate for inhalation 
by high-gravity controlled antisolvent precipitation. International Journal of Pharmaceutics. 
2007;331:93-8. 
98. Balducci AG, Cagnani S, Sonvico F, Rossi A, Barata P, Colombo G, et al. Pure insulin highly 
respirable powders for inhalation. European Journal of Pharmaceutical Sciences. 
2014;51:110-7. 
99. Ragab D, Rohani S, Samaha MW, El-Khawas FM, El-Maradny HA. Crystallization of 
progesterone for pulmonary drug delivery. Journal of Pharmaceutical Sciences. 
2010;99:1123-37. 
100.  Chen J-F, Wang Y-H, Guo F, Wang X-M, Zheng C. Synthesis of nanoparticles with novel  
technology:  High-gravity reactive precipitation. Industrial & Engineering Chemistry Research. 
2000;39:948-54. 
101.  Hu T, Chiou H, Chan H-K, Chen J-F, Yun J. Preparation of inhalable salbutamol sulphate using 
reactive high gravity controlled precipitation. Journal of Pharmaceutical Sciences. 
2008;97:944-9. 
102.  Muhammad SAFS, Oubani H, Abbas A, Chan HK, Kwok PCL, Dehghani F. The production of 
dry powder by the sonocrystallisation for inhalation drug delivery. Powder Technology. 
2013;246:337-44. 
103.  Ter Horst JH, Schmidt C, Ulrich J. 32 - fundamentals of industrial crystallization a2 - rudolph, 
peter.  Handbook of crystal growth (second edition). Boston: Elsevier; 2015. p. 1317-49. 
104.  Dirksen JA, Ring TA. Fundamentals of crystallization: Kinetic effects on particle size 
distributions and morphology. Chemical Engineering Science  1991;46:2389-427. 
105.  Chan H-K, Kwok PCL. Production methods for nanodrug particles using the bottom-up 
approach. Advanced Drug Delivery Reviews. 2011;63:406-16. 
106.  Mullin JW. Crystallization (4th edition). Elsevier. 
107.  Myerson A. Handbook of industrial crystallization: Butterworth-Heinemann; 2002. 
108.  Ostrowska K, Kropidlowska M, Katrusiak A. High-pressure crystallization and structural 
transformations in compressed r,s-ibuprofen. Crystal Growth Design. 2015;15:1512-7. 
109.  Shankland N, Florence AJ, Cox PJ, Sheen DB, Love SW, Stewart NS, et al. Crystal morphology 
of ibuprofen predicted from single-crystal pulsed neutron diffraction data. Chemical 
Communications. 1996:855-6. 
110.  Cano H, Gabas N, Canselier JP. Experimental study on the ibuprofen crystal growth 
morphology in solution. Journal of Crystal Growth. 2001;224:335-41. 
111.  McConnell JF. The 2-(4-isobutylphenyl) propionic acid. Ibuprofen or prufen. Crystal 
Structure Communications 1974;3:73-5. 
112.  Leising G, Resel R, Stelzer F, Tasch S, Lanziner A, Hantich G. Physical aspects of dexibuprofen 
and racemic ibuprofen. Journal of Clinical Pharmacology. 1996;36:3S-6S. 
113.  Freer AA, Bunyan JM, Shankland N, Sheen DB. Structure of (s) -(+)-ibuprofen. Acta 
Crystallogr, Sect C: Crystal Structure Communications. 1993;C49:1378-80. 
114.  Montes A, Litwinowicz AA, Gradl U, Gordillo MD, Pereyra C, Martinez de la Ossa EJ. 
Exploring  high operating conditions in the ibuprofen precipitation by rapid expansion of 
supercritical solutions process. Industrial & Engineering Chemistry Research. 2014;53:474-80. 
  
Bibliography 153 
115.  Sinha B, Müller RH, Möschwitzer JP. Systematic investigation of the cavi-precipitation 
process for the production of ibuprofen nanocrystals. International Journal of Pharmaceutics. 
2013;458:315-23. 
116.  Kocbek P, Baumgartner S, Kristl J. Preparation and evaluation of nanosuspensions for 
enhancing the dissolution of poorly soluble drugs. International Journal of Pharmaceutics. 
2006;312:179-86. 
117.  Verma S, Gokhale R, Burgess DJ. A comparative study of top-down and bottom-up 
approaches for the preparation of micro/nanosuspensions. International Journal of 
Pharmaceutics. 2009;380:216-22. 
118.  Onischuk AA, Tolstikova TG, Sorokina IV, Zhukova NA, Baklanov AM, Karasev VV, et al. 
Analgesic effect from ibuprofen nanoparticles inhaled by male mice. Journal of Aerosol 
Medicine and Pulmonary Drug Delivery. 2009;22:245-53. 
119.  Nesamony J, Shah IS, Kalra A, Jung R. Nebulized oil -in-water nanoemulsion mists for 
pulmonary delivery: Development, physico-chemical characterization and in vitro evaluation. 
Drug Development and Industrial Pharmacy. 2014;40:1253-63. 
120.  Wu L, Zhang J, Watanabe W. Physical and chemical stability of drug nanoparticles. 
Advanced Drug Delivery Reviews. 2011;63:456-69. 
121.  Montes A, Gordillo MD, Pereyra C, De los Santos DM, Martínez de la Ossa EJ. Ibuprofen–
polymer precipitation using supercritical co2 at low temperature. The Journal of Supercritical 
Fluids. 2014;94:91-101. 
122.  Matteucci ME, Hotze MA, Johnston KP, Williams RO. Drug nanoparticles by antisolvent 
precipitation:  Mixing energy versus surfactant stabilization. Langmuir. 2006;22:8951-9. 
123.  Rasenack N, Mueller BW. Dissolution rate enhancement by in situ micronization of poorly 
water-soluble drugs. Pharmaceutical Research. 2002;19:1894-900. 
124.  Vetter T, Mazzotti M, Brozio J. Slowing the growth rate of ibuprofen crystals using the 
polymeric additive pluronic f127. Crystal Growth Design. 2011;11:3813-21. 
125.  Gao L, Zhang D, Chen M. Drug nanocrystals for the formulation of poorly soluble drugs and 
its application as a potential drug delivery system. Journal of Nanoparticle Research. 
2008;10:845-62. 
126.  Douroumis D, Fahr A. Nano- and micro-particulate formulations of poorly water-soluble 
drugs by using a novel optimized technique. European Journal of Pharmaceutics and 
Biopharmaceutics. 2006;63:173-5. 
127.  Zhang J-Y, Shen Z-G, Zhong J, Hu T-T, Chen J-F, Ma Z-Q, et al. Preparation of amorphous 
cefuroxime axetil nanoparticles by controlled nanoprecipitation method without surfactants. 
International Journal of Pharmaceutics. 2006;323:153-60. 
128.  Zhong J, Shen Z, Yang Y, Chen J. Preparation and characterization of uniform nanosized 
cephradine by combination of reactive precipitation and liquid anti-solvent precipitation 
under high gravity environment. International Journal of Pharmaceutics. 2005;301:286-93. 
129.  Kipp JE. The role of solid nanoparticle technology in the parenteral delivery of poorly water-
soluble drugs. International Journal of Pharmaceutics. 2004;284:109-22. 
130.  Xie S, Poornachary SK, Chow PS, Tan RBH. Direct precipitation of micron-size salbutamol 
sulfate: New insights into the action of surfactants and polymeric additives. Crystal Growth 
Design. 2010;10:3363-71. 
131.  Zhang X-Y, Fevotte G, Zhong L, Qian G, Zhou X-G, Yuan W-K. Crystallization of zinc lactate in 
presence of malic acid. Journal of Crystal Growth. 2010;312:2747-55. 
132.  Kestur US, Lee H, Santiago D, Rinaldi C, Won Y-Y, Taylor LS. Effects of the molecular weight 
and concentration of polymer additives, and temperature on the melt crystallization kinetics 
of a small drug molecule. Crystal Growth Design. 2010;10:3585-95. 
  
Bibliography 154 
133.  Kaialy W, Nokhodchi A. The use of freeze-dried mannitol to enhance the in vitro 
aerosolization behaviour of budesonide from the aerolizer®. Powder Technology. 
2016;288:291-302. 
134.  Terebetski JL, Michniak-Kohn B. Combining ibuprofen sodium with cellulosic polymers: A 
deep dive into mechanisms of prolonged supersaturation. International Journal of 
Pharmaceutics. 2014;475:536-46. 
135.  Basalious EB, El-Sebaie W, El-Gazayerly O. Application of pharmaceutical qbd for 
enhancement of the solubility and dissolution of a class ii bcs drug using polymeric 
surfactants and crystallization inhibitors: Development of controlled-release tablets. AAPS 
PharmSciTech. 2011;12:799-810. 
136.  Newa M, Bhandari KH, Li DX, Kwon T-H, Kim JA, Yoo BK, et al. Preparation, characterization 
and in vivo evaluation of ibuprofen binary solid dispersions with poloxamer 188. 
International Journal of Pharmaceutics. 2007;343:228-37. 
137.  Park Y-J, Kwon R, Quan QZ, Oh DH, Kim JO, Hwang MR, et al. Development of novel 
ibuprofen-loaded solid dispersion with improved bioavailability using aqueous solution. 
Archives of Pharmacal Research. 2009;32:767-72. 
138.  Vasil'ev MV. Classification of diagrams of state of binary metallic systems by the force of 
interatomic reactions. Zh Fiz Khim. 1964;38:871-7. 
139.  Passerini N, Albertini B, Gonzalez-Rodriguez ML, Cavallari C, Rodriguez L. Preparation and 
characterization of ibuprofen-poloxamer 188 granules obtained by melt granulation. 
European Journal of Pharmaceutical Sciences. 2002;15:71-8. 
140.  Seo A, Holm P, Kristensen HG, Schaefer T. The preparation of agglomerates containing solid 
dispersions of diazepam by melt agglomeration in a high shear mixer. International Journal of 
Pharmaceutics. 2003;259:161-71. 
141.  Newa M, Bhandari KH, Oh DH, Kim YR, Sung JH, Kim JO, et al. Enhanced dissolution of 
ibuprofen using solid dispersion with poloxamer 407. Archives of Pharmacal Research. 
2008;31:1497-507. 
142.  Raghavan S, Trividic A, Davis A, Hadgraft J. Crystallization of hydrocortisone acetate: 
Influence of polymers. International Journal of Pharmaceutics. 2001;212:213-21. 
143.  Iervolino M, Raghavan SL, Hadgraft J. Membrane penetration enhancement of ibuprofen 
using supersaturation. Journal of Pharmaceutical Sciences. 2000;198:229-38. 
144.  Mishra B, Sahoo J, Dixit PK. Formulation and process optimization of naproxen 
nanosuspensions stabilized by hydroxy propyl methyl cellulose. Carbohydrate Polymers. 
2015;127:300-8. 
145.  Schwegman JJ, Hardwick LM, Akers MJ. Practical formulation and process development of 
freeze-dried products. Pharmaceutical Development and Technology. 2005;10:151-73. 
146.  Tee SK, Marriott C, Zeng XM, Martin GP. The use of different sugars as fine and coarse 
carriers for aerosolised salbutamol sulphate. International Journal of Pharmaceutics. 
2000;208:111-23. 
147.  Steckel H, Bolzen N. Alternative sugars as potential carriers for dry powder inhalations. 
International Journal of Pharmaceutics. 2004;270:297-306. 
148.  Saint-Lorant G, Leterme P, Gayot A, Flament MP. Influence of carrier on the performance of 
dry powder inhalers. International Journal of Pharmaceutics. 2007;334:85-91. 
149.  Lee MK, Kim MY, Kim S, Lee J. Cryoprotectants for freeze drying of drug nano-suspensions: 
Effect of freezing rate. Journal of Pharmaceutical Sciences.98:4808-17. 
150.  Abdelwahed W, Degobert G, Stainmesse S, Fessi H. Freeze-drying of nanoparticles: 




151.  Flume PA, Aitken ML, Bilton D, Agent P, Charlton B, Forster E, et al. Optimising inhaled 
mannitol for cystic fibrosis in an adult population. Breathe. 2015;11:39-48. 
152.  Yadollahi R, Vasilev K, Prestidge CA, Simovic S. Polymeric nanosuspensions for enhanced 
dissolution of water insoluble drugs. Journal of Nanomaterials. 2013:170201, 11 pp.  
153.  Allison SD, Molina MC, Anchordoquy TJ. Stabilization of lipid/DNA complexes during the 
freezing step of the lyophilization process: The particle isolation hypothesis. Biochim Biophys 
Acta. 2000;1468:127-38. 
154.  Abdelwahed W, Degobert G, Fessi H. Investigation of nanocapsules stabilization by 
amorphous excipients during freeze-drying and storage. European Journal of Pharmaceutics 
and Biopharmaceutics. 2006;63:87-94. 
155.  de Waard H, Grasmeijer N, Hinrichs WLJ, Eissens AC, Pfaffenbach PPF, Frijlink HW. 
Preparation of drug nanocrystals by controlled crystallization: Application of a 3-way nozzle 
to prevent premature crystallization for large scale production. European Journal of  
Pharmaceutical Sciences. 2009;38:224-9. 
156.  Yu H, Teo J, Chew JW, Hadinoto K. Dry powder inhaler formulation of high-payload 
antibiotic nanoparticle complex intended for bronchiectasis therapy: Spray drying versus 
spray freeze drying preparation. International Journal of Pharmaceutics. 2016;499:38-46. 
157.  Liang W, Kwok PCL, Chow MYT, Tang P, Mason AJ, Chan H-K, et al. Formulation of ph 
responsive peptides as inhalable dry powders for pulmonary delivery of nucleic acids. 
European Journal of Pharmaceutics and Biopharmaceutics. 2014;86:64-73. 
158.  Otake H, Okuda T, Hira D, Kojima H, Shimada Y, Okamoto H. Inhalable spray-freeze-dried 
powder with l-leucine that delivers particles independent of inspiratory flow pattern and 
inhalation device. Pharm Res. 2016;33:922-31. 
159.  Lechuga-Ballesteros D, Charan C, Stults CLM, Stevenson CL, Miller DP, Vehring R, et al. 
Trileucine improves aerosol performance and stability of spray-dried powders for inhalation. 
Journal of Pharmaceutical Sciences. 2008;97:287-302. 
160.  Begat P, Price R, Harris H, Morton DAV, Staniforth JN. The influence of force control agents 
on the cohesive-adhesive balance in dry powder inhaler formulations. KONA Powder and 
Particle Journal. 2005;23:109-21. 
161.  Chew NYK, Shekunov BY, Tong HHY, Chow AHL, Savage C, Wu J, et al. Effect of amino acids 
on the dispersion of disodium cromoglycate powders. Journal of Pharmaceutical Sciences. 
2005;94:2289-300. 
162.  Begat P, Morton DAV, Shur J, Kippax P, Staniforth JN, Price R. The role of force control 
agents in high-dose dry powder inhaler formulations. Journal of Pharmaceutical Sciences. 
2009;98:2770-83. 
163.  Muhsin MD, George G, Beagley K, Ferro V, Wang H, Islam N. Effects of chemical conjugation 
of l-leucine to chitosan on dispersibility and controlled release of drug from a 
nanoparticulate dry powder inhaler formulation. Molecular Pharmaceutics. 2016;13:1455-66. 
164.  Qu L, Zhou Q, Denman JA, Stewart PJ, Hapgood KP, Morton DAV. Influence of coating 
material on the flowability and dissolution of dry-coated fine ibuprofen powders. European 
Journal of Pharmaceutical Sciences. 2015;78:264-72. 
165.  Feng AL, Boraey MA, Gwin MA, Finlay PR, Kuehl PJ, Vehring R. Mechanistic models facilitate 
efficient development of leucine containing microparticles for pulmonary drug delivery. 
International Journal of Pharmaceutics. 2011;409:156-63. 
166.  Lucas P, Anderson K, Potter UJ, Staniforth JN. Enhancement of small particle size dry 




167.  Lähde A, Raula J, Kauppinen EI. Simultaneous synthesis and coating of salbutamol sulphate 
nanoparticles with l-leucine in the gas phase. International Journal of Pharmaceutics. 
2008;358:256-62. 
168.  Wang L, Zhang Y, Tang X. Characterization of a new inhalable thymopentin formulation. 
International Journal of Pharmaceutics. 2009;375:1-7. 
169.  Ibrahim BM, Jun SW, Lee MY, Kang SH, Yeo Y. Development of inhalable dry powder 
formulation of basic fibroblast growth factor. International Journal of Pharmaceutics. 
2010;385:66-72. 
170.  Islam N, Tuli RA, George GA, Dargaville TR. Colloidal drug probe: Method development and 
validation for adhesion force measurement using atomic force microscopy. Advanced 
Powder Technology. 2014;25:1240-8. 
171.  Boraey MA, Hoe S, Sharif H, Miller DP, Lechuga-Ballesteros D, Vehring R. Improvement of 
the dispersibility of spray-dried budesonide powders using leucine in an ethanol -water 
cosolvent system. Powder Technology. 2013;236:171-8. 
172.  Bolten D, Lietzow R, Tuerk M. Solubility of ibuprofen, phytosterol, salicylic acid, and 
naproxen in aqueous solutions. Chemical Engineering & Technology. 2013;36:426-34. 
173.  Bakhbakhi Y, Alfadul S, Ajbar A. Precipitation of ibuprofen sodium using compressed carbon 
dioxide as antisolvent. European Journal of Pharmaceutical Sciences. 2013;48:30-9. 
174.  Yang J, inventor; Hubei South Ocean Medicine Products Co., Ltd., Peop. Rep. China . 
assignee. Ibuprofen medical formulation and its preparation method patent CN1919188A. 
2007. 
175.  Adams SS, Bresloff P, Mason CG. Pharmacological differences between the optical isomers 
of ibuprofen: Evidence for metabolic inversion of the (-)-isomer. Journal of Pharmacy and 
Pharmacology 1976;28:256-7. 
176.  Rainsford KD. Ibuprofen: A critical bibliographic review: CRC Press; 2003.  
177.  Gee CM, Watkinson AC, Nicolazzo JA, Finnin BC. The effect of formulation excipients  on the 
penetration and lateral diffusion of ibuprofen on and within the stratum corneum following 
topical application to humans. Journal of Pharmaceutical Sciences. 2014:Ahead of Print.  
178.  Mehlisch DR, Sykes J. Ibuprofen blood plasma levels and onset of anal gesia. International 
Journal of Clinical Practice. 2013;67:3-8. 
179.  Albert KS, Gernaat CM. Pharmacokinetics of ibuprofen. The American Journal of Medicine. 
1984;77:40-6. 
180.  Jones K, Seymour RA, Hawkesford JE. Are the pharmacokinetics of ibuprofen important 
determinants for the drug's efficacy in postoperative pain after third molar surgery? British 
Journal of Oral and Maxillofacial Surgery. 1997;35:173-6. 
181.  Wood DM, Monaghan J, Streete P, Jones AL, Dargan PI. Fatality after deliberate ingestion of 
sustained-release ibuprofen: A case report. Critical Care. 2006;10:R44. 
182.  Collier PS, D'Arcy PF, Harron DW, Morrow N. Pharmacokinetic modelling of ibuprofen. 
British Journal of Clinical Pharmacology. 1978;5:528-30. 
183.  Cohen B, Shefy-Peleg A, Zilberman M. Novel gelatin/alginate soft tissue adhesives loaded 
with drugs for pain management: Structure and properties. Journal Of Biomaterials Science -
Polymer Edition. 2014;25:224-40. 
184.  Obidchenko YA, Khuchua NS, Abramovich RA, Savochkina AY, Karamyan AS, Barsegyan SS, 
et al. Preparation of micronized ibuprofen substance and assessment of its bioavailability. 
Pharmaceutical Chemistry Journal. 2013;47:382-6. 
185.  Jachowicz R, Nürnberg E, Pieszczek B, Kluczykowska B, Maciejewska A. Solid dispersion of 
ketoprofen in pellets. International Journal of  Pharmaceutics. 2000;206:13-21. 
  
Bibliography 157 
186.  Bolten D, Lietzow R, Türk M. Solubility of ibuprofen, phytosterol, salicylic acid, and 
naproxen in aqueous solutions. Chemical Engineering & Technology. 2013;36:426-34. 
187.  Fini A, Fazio G, Feroci G. Solubility and solubilization properties of non-steroidal anti-
inflammatory drugs. International Journal of Pharmaceutics. 1995;126:95-102. 
188.  Rytting E, Lentz K, Chen X-Q, Qian F, Venkatesh S. Aqueous and cosolvent solubility data for 
drug-like organic compounds. The AAPS Journal. 2005;7:E78-E105. 
189.  Watkinson RM, Herkenne C, Guy RH, Hadgraft J, Oliveira G, Lane ME. Influence of ethanol 
on the solubility, ionization and permeation characteristics of ibuprofen in silicone and 
human skin. Skin Pharmacology and Physiology. 2009;22:15-21. 
190.  Yalkowsky SH, Valvani SC, Roseman TJ. Solubility and partitioning vi: Octanol solubility and 
octanol–water partition coefficients. Journal of Pharmaceutical Sciences. 1983;72:866-70. 
191.  Manrique J, Martinez F. Solubility of ibuprofen in some ethanol + water cosolvent mixtures 
at several temperatures. Latin American Journal of Pharmacy. 2007;26:344-54. 
192.  Jouyban A, Soltanpour S, Acree WE, Jr. Solubility of acetaminophen and ibuprofen in the 
mixtures of polyethylene glycol 200 or 400 with ethanol and water and the density of solute-
free mixed solvents at 298.2 k. Journal of Chemical & Engineering Data. 2010;55:5252-7. 
193.  Garzon LC, Martinez F. Temperature dependence of solubility for ibuprofen in some organic 
and aqueous solvents. Journal of Solution Chemistry. 2004;33:1379-95. 
194.  Nokhodchi A, Homayouni A, Araya R, Kaialy W, Obeidat W, Asare -Addo K. Crystal 
engineering of ibuprofen using starch derivatives in crystallization medium to produce 
promising ibuprofen with improved pharmaceutical performance. RSC Advances. 
2015;5:46119-31. 
195.  Wahbi AA, Hassan E, Hamdy D, Khamis E, Barary M. Spectrophotometric methods for the 
determination of ibuprofen in tablets. Pakistan Journal of Pharmaceutical Sciences. 
2005;18:1-6. 
196.  Silva KGH, Xavier FH, Jr., Farias IEG, Silva AKA, Caldas NJA, Souza LCA, et al. Stationary 
cuvette: A new approach to obtaining analytical curves by uv-vis spectrophotometry. 
Phytochemical Analysis. 2009;20:265-71. 
197.  Bajwa GS, Sammon C, Timmins P, Melia CD. Molecular and mechanical properties of 
hydroxypropyl methylcellulose solutions during the sol:Gel transition. Polymer. 
2009;50:4571-6. 
198.  Vannucci M, Sha N, Brown PJ. Nir and mass spectra classification: Bayesian methods for 
wavelet-based feature selection. Chemometrics and Intelligent Laboratory Systems. 
2005;77:139-48. 
199.  Campbell FC. Theorem of le châtelier and the clausius-clapeyron equation.  Phase diagrams 
- understanding the basics. USA: ASM International; 2012. 
200.  Thorat AA, Dalvi SV. Liquid antisolvent precipitation and stabilization of nanoparticles of 
poorly water soluble drugs in aqueous suspensions: Recent developments and future 
perspective. Chemical Engineering Journal. 2012;181–182:1-34. 
201.  Dalvi SV, Dave RN. Analysis of nucleation kinetics of poorly water-soluble drugs in presence 
of ultrasound and hydroxypropyl methyl cellulose during antisolvent precipitation. 
International Journal of Pharmaceutics. 2010;387:172-9. 
202.  Bs iso 13320-1:1999: Particle size analysis. Laser diffraction methods. General principles. 
British Standards Institute; 2000. 
203.  Malvern. Increased dynamic range and resolution with the mastersizer 3000 particle size 
analyzer In: Malvern, editor. Extending the capabilities of laser diffraction particle size and 
size distribution measurements: Malvern Instruments Limited; 2016. 
  
Bibliography 158 
204.  Malvern. Sample dispersion and refractive index guide [User Manual]. England: Malvern 
Instruments Limited 2007 [April 2007:[1-44]. Available from: 
http://www.malvern.com/en/support/resource-center/user-manuals/MAN0396EN.aspx. 
205.  Saritha D, Bose PSC, Nagaraju R. Formulation and evaluation of self emulsifying drug 
delivery system (sedds) of ibuprofen. International Journal of Pharmaceutical Sciences and 
Research. 2014;5:3511+. 
206.  Pharmacopoeia B. Bulk density and tapped density of powders.  British pharmacopoeia. 
Appendix XVII S.2016. 
207.  Nokhodchi A, Amire O, Jelvehgari M. Physico-mechanical and dissolution behaviours of 
ibuprofen crystals crystallized in the presence of various additives. Daru: journal of Faculty of 
Pharmacy, Tehran University of Medical Sciences. 2010;18:74. 
208.  Adeleke I, Okafor I, Alebiowu G. Studies on the micromeritic properties of ibuprofen 
microcapsules. The Pacific Journal of Science and Technology. 2012;13:469-72. 
209.  Lakshmi MGP, Prabha MS, Manikiran SS, Rao NR. Formulation and evaluation of pulsatile 
salubutamol sulphate tablet in capsule pulsatile release device for asthma. European Journal 
of Biomedical and Pharmaceutical Sciences 2014;1:125-48. 
210.  Sichina WJ. Dsc as problem solving tool: Measurement of percent crystallinity of 
thermoplastics. wwwperkinelmercom. 
211.  Hallworth G, Westmoreland D. The twin impinger: A simple device for assessing the 
delivery of drugs from metered dose pressurized aerosol inhalers. Journal of pharmacy and 
pharmacology. 1987;39:966-72. 
212.  Machatha SG, Bustamante P, Yalkowsky SH. Deviation from linearity of drug solubility in 
ethanol/water mixtures. International Journal of Pharmaceutics. 2004;283:83-8. 
213.  Ojha N, Prabhakar B. Advances in solubility enhancement techniques. International Journal 
of Pharmaceutical Sciences Review and Research. 2013;21:351-8. 
214.  Wang S, Zhang P, Song Z, Du Y, Qu Y. Solution thermodynamics of s-ibuprofen n-octyl-d-
glucamine salt in ethanol-water cosolvent mixtures. Fluid Phase Equilibria. 2014;372:69-75. 
215.  Kawabata Y, Wada K, Nakatani M, Yamada S, Onoue S. Formulation design for poorly water-
soluble drugs based on biopharmaceutics classification system: Basic approaches and 
practical applications. International Journal of Pharmaceutics. 2011;420:1-10. 
216.  Fang Z, Zhang L, Mao S, Rohani S, Ulrich J, Lu J. Solubility measurement and pre diction of 
clopidogrel hydrogen sulfate polymorphs in isopropanol and ethyl acetate. The Journal of 
Chemical Thermodynamics. 2015;90:71-8. 
217.  Mirmehrabi M, Rohani S, Perry L. Thermodynamic modeling of activity coefficient and 
prediction of solubility: Part 2. Semipredictive or semiempirical models. Journal of 
Pharmaceutical Sciences. 2006;95:798-809. 
218.  Sheikholeslamzadeh E, Chen C-C, Rohani S. Optimal solvent screening for the crystallization 
of pharmaceutical compounds from multisolvent systems. Industrial & Engineering Chemistry 
Research. 2012;51:13792-802. 
219.  Sheikholeslamzadeh E, Rohani S. Solubility prediction of pharmaceutical and chemical 
compounds in pure and mixed solvents using predictive models. Industrial & Engineering 
Chemistry Research. 2012;51:464-73. 
220.  Sheikhzadeh M, Rohani S, Taffish M, Murad S. Solubility analysis of buspirone hydrochloride 
polymorphs: Measurements and prediction. International Journal of Pharmaceutics. 
2007;338:55-63. 
221.  Rashid A, White T, Howes T, Litster J, Marziano I. Racemic ibuprofen solubility in ethanol 




222.  Afrose A, White T, Howes T, George G, Rashid A, Islam N, editors. A controlled 
crystallization technique for producing ibuprofen fine crystals for developing an efficient dry 
powder inhaler (DPI) formulation. IHBI  Inspires 2014 19-20 November 2014; Gold Coast, Qld. 
223.  Jbilou M, Ettabia A, Guyot-Hermann AM, Guyot JC. Ibuprofen agglomerates preparation by 
phase separation. Drug Development and Industrial Pharmacy. 1999;25:297-305. 
224.  Jones M-C, Leroux J-C. Polymeric micelles – a new generation of colloidal drug carriers. 
European Journal of Pharmaceutics and Biopharmaceutics. 1999;48:101-11. 
225.  Filippa MA, Gasull EI. Ibuprofen solubility in pure organic solvents and aqueous mixtures of 
cosolvents: Interactions and thermodynamic parameters relating to the solvation process. 
Fluid Phase Equilibria. 2013;354:185-90. 
226.  Nozaki Y, Tanford C. Solubility of amino acids and two glycine peptides in aqueous ethanol 
and dioxane solutions. Establishment of a hydrophobicity scale. The Journal of biological 
chemistry. 1971;246:2211-17. 
227.  Okonogi S, Yonemochi E, Oguchi T, Puttipipatkhachorn S, Yamamoto K. Enhanced 
dissolution of ursodeoxycholic acid from the solid dispersion. Drug Development and 
Industrial Pharmacy. 1997;23:1115-21. 
228.  Desai KH, Kulkarni AR, Agnihotri SA, Gudasi KB, Aminabhavi TM. Solubility enhancement of 
rofecoxib in water in the presence of hydrophilic polymers, surfactants, co-solvents, and 
small molecules at 310.15 k. Indian Journal of Chemistry. 2006;45A:1667-9. 
229.  Plackett RL, Burman JP. The design of optimum multifactorial experiments. Biometrika. 
1946;33:305-25. 
230.  Gandhi P, Patil S, Aher S, Paradkar A. Ultrasound-assisted preparation of novel ibuprofen-
loaded excipient with improved compression and dissolution properties. Drug Development 
and Industrial Pharmacy. 2016:1-11. 
231.  Luque de Castro MD, Priego-Capote F. Ultrasound-assisted crystallization 
(sonocrystallization). Ultrasonics Sonochemistry. 2007;14:717-24. 
232.  Li H, Wang J, Bao Y, Guo Z, Zhang M. Rapid sonocrystallization in the salting-out process. 
Journal of Crystal Growth. 2003;247:192-8. 
233.  Ruecroft G, Hipkiss D, Ly T, Maxted N, Cains PW. Sonocrystallization:  The use of ultrasound 
for improved industrial crystallization. Organic Process Research & Development. 
2005;9:923-32. 
234.  Knox M, Trifkovic M, Rohani S. Combining anti-solvent and cooling crystallization: Effect of 
solvent composition on yield and meta stable zone width. Chemical Engineering Science. 
2009;64:3555-63. 
235.  Raghavan SL, Trividic A, Davis AF, Hadgraft J. Crystallization of hydrocortisone acetate: 
Influence of polymers. International Journal of Pharmaceutics. 2001;212:213-21. 
236.  Zimmermann A, Millqvist-Fureby A, Elema MR, Hansen T, Müllertz A, Hovgaard L. 
Adsorption of pharmaceutical excipients onto microcrystals of siramesine hydrochloride: 
Effects on physicochemical properties. European Journal of Pharmaceutics and 
Biopharmaceutics. 2009;71:109-16. 
237.  Hassan M, Lau R. Effect of particle shape on dry particle inhalation: Study of flowability, 
aerosolization, and deposition properties. AAPS PharmSciTech. 2009;10:1252-62. 
238.  Chow AHL, Tong HHY, Chattopadhyay P, Shekunov BY. Particle engineering for pulmonary 
drug delivery. Pharmaceutical Research. 2007;24:411-37. 
239.  Gradon L, Sosnowski TR. Formation of particles for dry powder inhalers. Advanced Powder 
Technology. 2014;25:43-55. 
240.  Yang Z-Y, Le Y, Hu T-T, Shen Z, Chen J-F, Yun J. Production of ultrafine sumatriptan succinate 
particles for pulmonary delivery. Pharmaceutical Research. 2008;25:2012-8. 
  
Bibliography 160 
241.  Bakhbakhi Y, Charpentier PA, Rohani S. Experimental study of the gas process for producing 
microparticles of beclomethasone-17,21-dipropionate suitable for pulmonary delivery. 
Journal of Pharmaceutical Sciences. 2006;309:71-80. 
242.  Garekani HA, Sadeghi F, Badiee A, Mostafa SA, Rajabi -Siahboomi AR. Crystal habit 
modifications of ibuprofen and their physicomechanical characteristics. Drug Development 
and Industrial Pharmacy. 2001;27:803-9. 
243.  Ward GH, Schultz RK. Process-induced crystallinity changes in albuterol sulfate and its effect 
on powder physical stability. Pharmaceutical Research. 1995;12:773-9. 
244.  Raula J, Thielmann F, Kansikas J, Hietala S, Annala M, Seppälä J, et al. Investigations on the 
humidity-induced transformations of salbutamol sulphate particles coated with l -leucine. 
Pharmaceutical Research. 2008;25:2250-61. 
245.  Elajnaf A, Carter P, Rowley G. The effect of relative humidity on electrostatic charge decay 
of drugs and excipient used in dry powder inhaler formulation. Drug Development and 
Industrial Pharmacy. 2007;33:967-74. 
246.  Adi H, Traini D, Chan H-K, Young PM. The influence of drug morphology on the 
aerosolisation efficiency of dry powder inhaler formulations. Journal of Pharmaceutical 
Sciences. 2008;97:2780-8. 
247.  Tan BMJ, Chan LW, Heng PWS. Improving dry powder inhaler performance by surface 
roughening of lactose carrier particles. Pharmaceutical Research. 2016;33:1923-35. 
248.  Chew NYK, Chan H-K. Use of solid corrugated particles to enhance powder aerosol 
performance. Pharmaceutical Research. 2001;18:1570-7. 
249.  Chew NYK, Tang P, Chan H-K, Raper JA. How much particle surface corrugation is sufficient 
to improve aerosol performance of powders? Pharmaceutical Research. 2005;22:148-52. 
250.  Pattnaik S, Swain K, Rao JV, Talla V, Prusty KB, Subudhi SK. Polymer co-processing of 
ibuprofen through compaction for improved oral absorption. RSC Advances. 2015;5:74720-5. 
251.  Onischuk AA, Tolstikova TG, An’kov SV, Baklanov AM, Valiulin SV, Khvostov MV, et al. 
Ibuprofen, indomethacin and diclofenac sodium nanoaerosol: Generation, inhalation delivery 







Appendix A1: Shows the concentration and absorbance data of IBP in different composition 
of water and ethanol mixture from three trials at a wavelength of 264 nm (Refer to Figure 


































49.7 0.1 63.7 0.1 647.7 0.9 313.5 0.4 166.1 0.2 
59.9 0.2 97.3 0.1 1258.2 1.7 626.3 0.8 341.7 0.5 
95.8 0.2 125.6 0.2 1590.3 2.2 939.2 1.3 636.0 0.9 
119.0 0.3 51.3 0.1 976.7 1.4 1236.9 1.7 1013.8 1.4 
305.9 0.3 97.3 0.2 1291.0 1.8 1568.5 2.1 1333.7 1.8 
48.5 0.1 188.6 0.3 1649.9 2.3 82.7 0.1 1642.6 2.2 
59.9 0.2 218.8 0.3 86.8 0.1 169.9 0.2 181.1 0.2 
97.1 0.2 245.9 0.4 173.0 0.2 342.6 0.5 341.0 0.5 
121.6 0.3 99.4 0.2 340.0 0.5 635.0 0.9 674.4 0.9 
307.7 0.3 147.5 0.2 668.3 0.9 940.0 1.3 963.5 1.3 
48.8 0.1 194.4 0.3 978.3 1.4 1247.1 1.7 1346.8 1.8 
60.8 0.1 221.3 0.3 1315.9 1.8 623.7 0.9 373.7 0.5 
96.8 0.2 244.9 0.4 1643.7 2.2 934.8 1.3 736.5 1.0 
122.0 0.3 199.0 0.3 1610.1 2.2 1244.8 1.7 1056.8 1.4 
52.0 0.1 223.4 0.3 599.4 0.8 86.9 0.1 1413.9 1.9 
  244.1 0.4 900.0 1.2 179.8 0.3 166.1 0.2 
    148.5 0.2 315.9 0.4 341.7 0.5 
      1262.5 1.7 636.0 0.9 
      305.2 0.4 1013.8 1.4 
      611.2 0.9 1333.7 1.8 
      909.2 1.3 1642.6 2.2 
      1212.7 1.7 315.7 0.4 
      907.8 1.3 616.3 0.8 
      1212.6 1.7 920.8 1.2 



































      158.6 0.2 317.7 0.4 
      310.8 0.4 636.0 0.8 
      608.9 0.8 939.1 1.2 
      914.9 1.4 1242.5 1.6 
        317.5 0.4 








Appendix A2: Slopes of calibration lines with error estimates (Refer to Figure 3.5). 
 
% E slope 95% 
error 
as% 
10.15 0.00142 0.00027 19 
20.13 0.001380 0.000038 2.8 
30.10 0.001321 0.000016 1.2 
30.10 0.001389 0.000006 0.5 
39.94 0.001270 0.000007 0.5 
39.94 0.001307 0.000024 1.9 
49.85 0.001258 0.000017 1.3 
















Appendix A3: Shows the concentration and absorbance data of IBP in 35% w/w ethanol 
solution from two trials at a wavelength of 221 nm (Refer to Figure 3.6). 
 
Trial 1 Trial 2 
IBP conc, µg/mL Absorbance IBP conc, µg/mL Absorbance 
0.3 0.03 0.4 0.03 
0.8 0.05 0.8 0.05 
1.6 0.08 1.6 0.08 
3.1 0.15 3.1 0.15 
4.7 0.20 4.7 0.21 
6.2 0.26 6.2 0.25 
7.8 0.32 7.8 0.32 
12.4 0.51 12.5 0.51 
15.5 0.64 15.6 0.64 
18.6 0.77 18.7 0.77 




Appendix A4: Shows time and concentration data of IBP in water, 10% and 20% aqueous 
ethanol for equilibrium investigation at 25 °C. (Refer to Figure 3.8) 
 













IBP conc, I/I+E+W, 
ppm 
0 47.52 0 0 0 0 
2 47.17 2 103.4 2 263 
4 46.34 4 103.1 4 384 
6 45.93 6 104.1 6 378 
8 45.79 8 105.5 8 364 
10 45.79 10 103.6 10 367 
12 45.79 20 103.6 12 370 
25 47.17 22 102.2 24 379 
26 48.28 24 103.1 25 362 
27 46.97 25 100.5 26 369 
  26 98.8 27 349 





Appendix A5: Shows time and concentration data of IBP in water, 10% and 20% aqueous 
ethanol for equilibrium investigation at 25°C. (Refer to Figure 3.9) 
 
5% ethanol, .0005% 
excipients 
10% ethanol, 0.1% 
excipients 
















0 0 0.08 372.72 0.08 3471.06 
1 76.62 0.17 413.25 0.25 2967.53 
2 101.8 0.25 435.45 0.5 3567.19 
3 72.93 0.33 454.55 0.75 3438.75 
4 73.7 0.42 387.04 1 3252.73 
5 75.23 0.50 388.25 1.25 2861 
10 73.07 0.58 407.14 3 1077.17 
15 71.05 0.67 407.28 5 1323.93 
20 74.04 0.75 414.66 10 1255.36 
25 73.49 0.83 422.77 15 858.44 
30 70.91 0.92 490.34 30 847.03 
40 70.63 1.00 640.23 60 822.95 
50 70.84 60.00 483.38   
60 71.54     
 
Appendix A6: NIR spectrophotometer wavelength scan with eleven different concentrations of 






Appendix A7: Shows the concentration and absorbance data of water in ethanol solution from 
at least two trials at a wavelength of 1932 nm (Refer to Figure 3.10). 
Water conc.  
W/(E+W), g/g 
Absorbance 
Water conc.  
W/(E+W), g/g 
Absorbance 
0.00 0.00 0.39 0.20 
0.06 0.03 0.42 0.21 
0.11 0.06 0.55 0.30 
0.16 0.08 0.65 0.37 
0.20 0.11 0.73 0.41 
0.28 0.15 0.81 0.47 
0.10 0.05 0.91 0.52 



























Appendix B1: Shows IBP solubility raw data in 0- 50% aqueous ethanol solvents at 10, 25 
and 40°C. Here XE represents the percentage of ethanol in water in weight basis of the 


















0 1 0.06 40.9 0.07 46.3 0.13 84.7 
2 0.06 40.6 0.07 45.9 0.13 86.7 
3 0.06 40.7 0.07 45.8 0.14 91.6 
4 0.06 40.8 0.07 45.8 0.13 90.6 
5   0.06 42.3   
6   0.07 47.2   
7   0.07 48.3   
8   0.07 47.0   
9   0.07 46.3   
5.16 1   0.10 67.6   
2   0.10 69.0   
3   0.11 72.7   
4   0.11 72.5   
5   0.10 71.6   
6   0.10 71.4   
7   0.11 72.3   
10 1 0.09 65.3 0.15 103.3 0.32 223.7 
2 0.09 64.9 0.15 103.1 0.31 215.7 
3 0.09 66.3 0.15 104.1 0.31 216.1 
4 0.09 62.9 0.15 105.5 0.30 211.2 
5 0.09 63.0 0.15 103.6   
6 0.09 65.7 0.15 103.6   
7   0.15 102.2   
8   0.15 103.1   
9   0.14 100.5   
10   0.14 98.8   
11   0.14 98.7   
15 1   0.22 155.3   
2   0.23 161.4   
3   0.23 164.0   
4   0.24 169.3   
5   0.22 156.4   
6   0.22 156.2   
7   0.22 155.9   
8   0.23 159.9   


















19.94 1   0.40 285.6   
2   0.40 287.2   
3   0.39 283.5   
4   0.40 286.4   
5   0.39 284.2   
6   0.39 283.0   
7   0.40 287.8   
8   0.39 280.0   
20 1 0.17 125.8 0.53 375.9 1.41 1013.8 
2 0.17 125.7 0.52 375.9 1.44 1034.7 
3 0.17 125.8 0.50 361.9 1.44 1037.3 
4 0.16 118.4 0.51 364.7 1.43 1031.4 
5   0.51 368.2   
6   0.52 376.9   
7   0.50 360.2   
8   0.51 366.9   
9   0.48 347.3   
10   0.52 375.3   
30 1 0.53 392.8 1.51 1804.0 2.82 17845.2 
2 0.53 394.5 1.47 1747.5 2.92 20400.7 
3 0.54 404.7 1.46 1848.9 2.72 19263.0 
4 0.56 416.5 1.59 1897.8 2.43 18775.1 
5   1.58 1883.9   
6   1.58 1880.1   
7   1.50 1899.3   
40 1 2.76 2126.9 1.73 13022.4 0.99 59938.2 
2 2.62 2017.5 1.71 12913.9 0.77 55603.5 
3 2.73 2100.4 1.74 12208.5 0.86 60725.5 
4 2.86 2200.8 1.72 12447.5 0.87 54349.5 
5 3.00 2305.7 1.70 11912.3   
6 2.85 2195.0 1.67 12326.8   
7 2.87 2206.6     
50 1 0.51 20125.5 0.99 65248.4 2.1 241494.5 
2 0.63 20530.2 1.05 69578.9 2.1 302580.8 
3 0.66 20251.5 1.07 69307.9 2.1 283079.7 
4 0.64 20931.4 1.01 65687.5 1.5 275315.5 






Appendix B2: IBP solubility in 0%, 10% and 20% aqueous ethanol solvents at 25°C. The 
errors shown for the solubility values are the 95% probable for the mean (Refer to Figure 
4.5,Figure 4.6,Figure 4.7,Figure 4.8, Figure 4.9 & Figure 4.10). 














Intrinsic solubility (water) 45.55 ± 0.05 
0.51 5.32 0.42 1.43 11.15 1496.17 ± 0.05 
1.02 5.20 0.43 1.41 11.12 1599.04 ± 0.08 
1.52 5.22 0.42 1.55 10.75 1725.76 ± 0.04 
0.11 0.00 0.00 0.00 11.21 164.34 ± 0.07 
0.52 0.00 0.00 0.00 11.21 185.32 ± 0.05 
1.02 0.00 0.00 0.00 11.21 221.62 ± 0.10 
1.54 0.00 0.00 0.00 11.21 243.19 ± 0.12 
0.13 0.00 0.00 0.00 0.00 74.52 ± 0.11 
0.67 0.00 0.00 0.00 0.00 112.99 ± 0.04 
1.03 0.00 0.00 0.00 0.00 129.56 ± 0.02 
1.60 0.00 0.00 0.00 0.00 155.19 ± 0.06 
0.98 0.98 0.39 1.37 0.00 1007.21 ± 0.05 
0.98 5.04 0.39 1.37 0.00 1173.15 ± 0.03 
1.00 11.04 0.40 1.40 0.00 1124.01 ± 0.02 
0.00 1.08 0.00 0.00 10.02 59.65 ± 0.08 
0.00 5.51 0.00 0.00 10.02 127.95 ± 0.08 
0.00 10.14 0.00 0.00 10.02 166.54 ± 0.06 
0.00 13.95 0.00 0.00 10.02 88.47 ± 0.03 
0.00 1.30 0.00 0.00 0.00 55.32 ± 0.11 
0.00 5.44 0.00 0.00 0.00 65.81 ± 0.04 
0.00 12.66 0.00 0.00 0.00 60.69 ± 0.06 
0.00 17.82 0.00 0.00 0.00 58.40 ± 0.06 
0.49 0.51 0.00 0.00 0 330.46 ± 0.01 
0.46 0.45 0.00 0.00 9.40 562.42 ± 0.06 
0.39 0.42 0.00 0.00 20.23 1195.52 ± 0.04 
0.22 0.26 0.00 0.00 0 161.32 ± 0.01 
0.22 0.23 0.00 0.00 9.95 321.42 ± 0.03 
0.21 0.21 0.00 0.00 17.84 658.23 ± 0.07 
0.96 0.99 0.00 0.00 0 663.80 ± 0.04 
0.85 0.92 0.00 0.00 10.11 1260.58 ± 0.04 
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0.77 0.80 0.00 0.00 19.85 1859.76 ± 0.01 
0 1.03 0.00 0.00 0 680.58 ± 0.05 
0 0.93 0.00 0.00 10.06 857.49 ± 0.06 
0 0.82 0.00 0.00 20.07 1662.20 ± 0.01 
0 2.02 0.00 0.00 0 1152.19 ± 0.01 
0 1.85 0.00 0.00 10.06 1534.14 ± 0.07 
0 1.68 0.00 0.00 19.6 2847.70 ± 0.06 
0.99 0 0.00 0.00 0 55.09 ± 0.06 
0.88 0 0.00 0.00 9.17 112.37 ± 0.02 
0.81 0 0.00 0.00 19.66 355.96 ± 0.05 
1.99 0 0.00 0.00 0 92.66 ± 0.07 
1.78 0 0.00 0.00 10.52 119.48 ± 0.01 



























Appendix C1: Data representing the effect of temperature of the precipitation process on 




15°C 20°C 25°C 30°C 
D[v,0.1] 4.93 ± 0.01 3.65 ± 0.03 3.72 ± 0.01 4.92 ± 0.07 
D[v,0.5] 12.6 ± 0.05 7.61 ± 0.02 7.14 ± 0.01 9.77 ± 0.04 
D[v,0.9] 37.3 ± 0.97 14.9 ± 0.32 13.4 ± 0.10 17.4 ± 0.17 
 
Appendix C2: Data representing the effect of ultrasound duration on particle size in the APC 
process, Mean ± SD, n= 3 (Refer to Figure 5.3). 
Particle size 
(µm) 
Ultrasound duration (Minutes)  
0 5 15 30 60 
D[v,0.1] 2.92 ± 0.01 2.86 ± 0.01 4.44 ± 0.06 3.93 ± 0.02 2.62 ± 0.07 
D[v,0.5] 6.11 ± 0.02 6.27 ± 0.01 8.8 ± 0.01 8.4 ± 0.04 6.4 ± 0.12 
D[v,0.9] 11.3 ± 0.08 13.8 ± 0.07 15.9 ± 0.08 16.1 ± 0.05 14 ± 0.39 
 
Appendix C3: Data representing IBP Particle size vs time for a single batch in the APC 
process, Mean ± SD, n= 3 (Refer to Figure 5.4). 
Time, 
Minutes 
Particle size, µm, 
(D[v,0.5])( ± SD) 
1 5.47 ± 0.38 
2 99.1 ± 11.30 
3 5.39 ± 0.59 
4 6.55 ± 0.03 
5 6.78 ± 0.03 
10 5.6 ± 0.46 
15 5.95 ± 0.26 




Appendix C4: Data representing the effect of IBP concentration on the particle size obtained 
in the APC process, Mean ± SD, n= 3 (Refer to Figure 5.5). 
Particle size 
(µm) 
IBP concentration, %, (w/w)  
1.0 0.9 0.8 0.7 0.5 
D[v,0.1] 3.82 ± 0.04 2.39 ± 0.04 2.47± 0.01 2.79 ± 0.03 3.76 ± 0.06 
D[v,0.5] 7.13± 0.03 4.92 ± 0.03 4.88 ± 0.01 5.39 ± 0.01 7.05 ± 0.02 
D[v,0.9] 12.7 ± 0.36 9.43 ± 0.25 8.86 ± 0.07 9.56 ± 0.10 12 ± 0.13 
 
Appendix C5: Data representing the effect of IBP concentration on the particle size obtained 
in the APC process, Mean ± SD, n= 3 (Refer to Figure 5.6). 
Particle size 
(µm) 
Solvent-antisolvent ratio  
0.10 0.09 0.08 0.06 0.05 
D[v,0.1] 3.82 ± 0.04 2.39 ± 0.04 2.47± 0.01 2.79 ± 0.03 3.76 ± 0.06 
D[v,0.5] 7.13± 0.03 4.92 ± 0.03 4.88 ± 0.01 5.39 ± 0.01 7.05 ± 0.02 
D[v,0.9] 12.7 ± 0.36 9.43 ± 0.25 8.86 ± 0.07 9.56 ± 0.10 12 ± 0.13 
 
Appendix C6: Data representing the effect of HPMC concentration on IBP particle size 
produced in the APC process, Mean ± SD, n= 3 (Refer to Figure 5.7). 
HPMC, % (w/w) Particle size, D[v,0.5], (µm) 
0.9 16 ± 5.3 
0.1 19 ± 6.9 
0.1 6 ± 1.8 
0.1 8 ± 0.8 
0.2 11 ± 0.3 
0.6 10 ± 0.9 
0.3 9 ± 0.3 
0.5 7 ± 0.4 
0.0 10 ± 2.6 






Appendix C7: Data representing the effect of Pl F127 concentration on the size of IBP 
particles produced in an APC process, Mean ± SD, n= 3 (Refer to Figure 5.8). 
Particle size 
(µm) 
Pluronic F127 concentration, %, (w/w) 
0.0 0.7 1.3 2.0 
D[v,0.1] 6.06 ± 0.05 3.59 ± 0.03 1.22 ± 0.03 1.29 ± 0.01 
D[v,0.5] 10.5 ± 0.04 6.77 ± 0.01 3.49 ± 0.01 6.14 ± 0.02 
D[v,0.9] 17.3 ± 0.16 12 ± 0.08 8.19 ± 0.28 12.7 ± 0.41 
 
Appendix C8: Data representing the effect of leucine concentration on the size of IBP 
produced in an APC process, Mean ± SD, n= 3 (Refer to Figure 5.9). 
Particle size 
(µm) 
L-leucine concentration, %, (w/w) 
0.0 0.5 1.2 1.6 
D[v,0.1] 3.82 ± 0.01 3.66 ± 0.01 2.9 ± 0.01 2.86 ± 0.02 
D[v,0.5] 7.62 ± 0.01 8.16 ± 0.02 5.94 ± 0.05 6.3 ± 0.04 
D[v,0.9] 14.2 ± 0.07 17.5 ± 0.17 11.4 ± 0.13 12.8 ± 0.06 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
